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 II
”Discovery is about exposing the mysteries of the nature, of what already exists. 
Invention is about creating something that never existed before (…) Discovery is about 
the excitement of travelling. Invention is about satisfaction of arriving when it becomes 
‘fit for purpose’.” 
                                                                                                        Sir James Whyte Black 
 III
Abstract 
 
1. Vascular tone is a key determinant of blood pressure and tissue blood flow. In 
this study I investigated local and distant modulation of arterial tone by the 
endothelium during activation of endothelium-dependent and -independent 
signalling pathways.  
2. The results obtained confirm that in rat small mesenteric arteries the 
endothelium modulates the tone of the underlying smooth muscle cells (SMCs) 
via release of relaxing and contracting factors (EDRFs and EDCFs, 
respectively). EDRF involved signalling of nitric oxide synthase (NOS) that 
produced nitric oxide (NO) in two forms: free radical (NO•) and nitroxyl anion 
(NO-). The latter but not the former stimulated both big conductance Ca2+-
activated potassium (BKCa) and voltage-gated potassium (Kv) channels via 
guanylyl cyclase signalling and was able to evoke conducted dilatation. 
3. Physiological adrenergic agonists, adrenaline or noradrenaline (NA), suppressed 
local dilatation to the endothelium-dependent agonist acetylcholine (ACh). The 
main role belonged to β-adrenoceptors, which via cAMP signalling suppressed 
NO signalling, probably by inhibiting eNOS, and intermediate conductance 
Ca2+-activated potassium (IKCa) channel components of the dilatation, whilst 
enhancing the conducted response. 
4. The endothelium did not directly participate in the local dilatation to β-
adrenoceptor stimulation by release of EDRFs. Rather it served to create a semi-
permeable barrier that reduced the potency of luminal adrenergic agonists to act 
on the underlying smooth muscle cells. Moreover, stimulation of β-adrenergic 
receptors, especially in old and hypertensive animals, was associated with 
endothelial cell COX signalling, which attenuated the local dilatation.  
 IV
 
5. β-adrenoceptors were also able to evoke conducted dilatation that spread along 
the vessel wall in a similar way to the dilatation evoked by ACh. Smooth muscle 
KATP channels did not contribute much to the local response, but were essential 
for the conducted dilatation. The conducted response to both agonists was 
enhanced by stimulation with a thromboxane (TP) receptor agonist. 
6.  Taken together, this study demonstrates that the endothelium does not directly 
participate in β-adrenoceptor-mediated vasodilatation, and stimulation of the 
receptor leads to the inhibition of endothelium-derived dilatation. However, the 
endothelium appears crucial for establishing conducted vasodilatation, providing 
a pathway for the hyperpolarization evoked locally by either β-adrenergic 
stimulation or endogenous NO- production.  
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Chapter 1. Introduction 
 
 2
1.1 Principles of blood flow development and structure of resistance 
arteries 
Live tissue metabolism requires a continual supply of oxygen and nutrients in the 
amounts sufficient to cover its current needs. The ultimate source of such nutrients is 
the blood, transported by arteries feeding the tissue. The blood flow is driven by the 
difference in the arterial and venal pressures created by the cardiac output and vascular 
resistance to the flowing blood. This can be expressed as (Levy, 1979): 
R
PQ Δ= ,                                   (Equation 1.1) 
where Q is the rate of blood flow, ∆P is the pressure gradient and R is the resistance of 
the artery. Vascular resistance occurs due to the friction of the passing blood against the 
vessel wall, and can be calculated by means of the modified Hagen-Poiseuille equation:  
4
128
d
lR π
μ=  ,                                 (Equation 1.2) 
where µ is viscosity, l is vessel length and d is the vessel diameter. Therefore the blood 
flow can be determined as: 
l
dPQ μ
π
128
4Δ=  ,                                (Equation 1.3) 
It can be seen from the equation that the blood flow depends on the arterial diameter 
raised to the power of four. Such a high dependency provides an important mechanism 
of regulation of the circulation by a fine modulation of the arterial diameter with 
numerous physicochemical stimuli. Small resistance arteries, in contrast to the big 
conduit vessels, are able to considerably change their diameter, thus enabling the fine 
control of blood pressure and tissue blood flow.  
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Due to the large amount of blood that flows through the mesenteric artery, this 
vascular bed significantly contributes to the regulation of arterial pressure. Mesenteric 
arteries being a part of the splanchnic circulation system supply blood to the duodenum 
and transverse colon. The main (superior) mesenteric artery arises from the abdominal 
aorta, then separates to multiple branches and forms a mesenteric arcade (Figure 2.1B). 
Small mesenteric arteries from the arcade are recognised as resistance arteries. Their 
wall, as with all blood vessels, consists of three main layers: tunica adventitia, tunica 
media and tunica intima (Mulvany et al., 1990). The tunica adventitia is the outer layer 
of the arterial wall consisting of collagen and elastic fibres, mast cells, macrophages, 
fibroblasts and small arterioles that feed the vessel wall. It is also laced with axons of 
sympathetic and sensory neurons, and adventitial neuronal cell bodies containing 
calcitonin gene-related peptide located in close proximity to the sensory nerve fibres 
(Somasundaram et al., 2006). Tunica media consists of several layers of thin, long 
smooth muscle cells that go around the arterial lumen, and cells with irregular shape and 
long filaments called “interstitial Cajal-like cells” (Formey et al., 2011). Lining the 
internal side of the vessel, the tunica intima consists of a single layer of longitudinal 
endothelial cells. Between the tunica intima and tunica media there is an internal elastic 
lamina, a thin layer of elastic fibres with holes in it. Endothelial cells may form 
projections which reach smooth muscle cells through these holes to create myo-
endothelial gap junctions, allowing direct cell-to-cell communication (Rhodin, 1967; 
Sandow et al., 2000).  
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1.2 Contraction and relaxation of vascular smooth muscle 
The ability of vascular smooth muscle cells to contract and relax in response to 
certain stimuli underlies the main mechanism of arterial lumen diameter regulation.  
The ignition which initializes the force generation in smooth muscle cell is a rise in 
intracellular free Ca2+ concentration ([Ca2+]i). Regardless of the source, Ca2+ binds to 
calmodulin and leads to the calmodulin-dependent activation of myosin light chain 
(MLC) kinase. The phosphorylation of MLC stimulates myosin ATPase, promoting 
hydrolysis of adenosine-5’-triphosphate (ATP) and formation of cross-bridges between 
myosin and actin filaments (Dillon et al., 1981; Hai et al., 1989). MLC phosphatase 
dephosphorylates MLC leading to smooth muscle relaxation. Therefore, control of 
vascular tone mainly occurs by means of modulation of the smooth muscle cell [Ca2+]i 
or by altering the sensitivity of contractile filaments to Ca2+ via regulation of MLC 
kinase and phosphatase activity (Ratz et al., 2005).  
1.2.1 Voltage-gated Ca2+ channels 
One of the main sources of Ca2+ during initiation of smooth muscle contraction is 
extracellular Ca2+ ([Ca2+]o), which enters the smooth muscle cell via voltage-gated Ca2+ 
channels upon depolarization of the cell membrane in response, for example, to raised 
extracellular potassium concentration [K+]o or Gq/11-protein coupled receptor signalling 
(Nelson et al., 1988). In contrast, hyperpolarization of the cell membrane will result in 
the closure of voltage-gated Ca2+ channels, reduction of [Ca2+]i and, subsequently, 
dilatation (Jaggar et al., 1998). The channel family includes ten members, with two of 
them found in the vasculature. The L-type voltage-gated Ca2+ channel (LCa channel) 
produces current that requires high depolarization in order to be activated (between -
10mV and -30mV depending on LCa channel subtype), whilst current through the T-type 
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voltage-dependent Ca2+ channel (TCa channel) is activated in lower membrane potential 
(around -45 mV). Current through these channels slowly decayes upon depolarization 
beyond -40 mV and reverses between +40 and +50 mV (Catterall et al., 2005; Smirnov 
et al., 1992). The major role of LCa channels in blood pressure maintenance was shown 
using mice globally lacking LCa channels. In this mouse model, the mean blood pressure 
was decreased by a quarter and the pressor response to Gq/11-protein coupled receptor 
stimulation was severely reduced (Moosmang et al., 2003). Comparable effects in rats 
were evoked by pharmacological blockage of LCa channels (Pinterova et al., 2010). It is 
generally assumed also that LCa channels are responsible for the vasoconstriction in 
response to depolarization in rat mesenteric arteries (Ball et al., 2009; Leung et al., 
2010; Rahman et al., 2007); the role of TCa channels was shown to increase with 
decrease of arterial size (Ball et al., 2009; Jensen et al., 2004). 
1.2.2 Gq/11 protein-coupled receptor signalling 
The majority of vasoconstrictors, such as adrenaline, thromboxane A2, and 
endothelin-1, mediate their action via stimulation of their respective seven-
transmembrane domain receptor coupled to heteromeric Gq/11 protein. Upon activation, 
the receptor acts as a guanine nucleotide exchange factor, promoting exchange of 
guanosine diphosphate (GDP) to guanosine triphosphate (GTP) in the α subunit of the  
G protein, which leads to dissociation of the α subunit from the βγ subunit (Clapham et 
al., 1997). When dissociated, the α subunit activates phospholipase C (PLC) β1 that 
catalyzes phosphatidylinositol-4,5-biphosphate (PIP2) breakdown, leading to production 
of inositol-1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) (Berridge et al., 
1989). IP3 activates IP3 receptors located on the sarcoplasmic reticulum and causes Ca2+ 
efflux from the intracellular stores (Grayson et al., 2004). This initial rise in [Ca2+]i can 
evoke further release of Ca2+ from the intracellular store via stimulation of ryanodine 
 6
receptors (so-called ‘Ca2+-induced Ca2+ release’), which contributes to the global [Ca2+]i 
and facilitates the pace of Ca2+ wave propagation within the cell (Boittin et al., 1999).  
 An additional pathway for a [Ca2+]i-dependent rise of [Ca2+]i may occur via opening 
of voltage-gated Ca2+ channels triggered by depolarization. Firstly, the release of Ca2+ 
from intracellular stores could stimulate Ca2+-sensitive chloride channels (Akata et al., 
2003; Piper et al., 2004), which evokes efflux of negative charged ions that depolarize 
the smooth muscle cell membrane (Leblanc et al., 2005). Secondly, intracellular Ca2+ 
may also activate the forward mode of the Na+/Ca2+ exchanger (NCX) to extrude one 
Ca2+ ion in return for three Na+ ions (Berra-Romani et al., 2010; Horiguchi et al., 2001; 
Weiss et al., 1993), which also results in cation influx and membrane depolarization.  
Another product of PLC activity, DAG, can also contribute to depolarization and 
increase of [Ca2+]i by activation of non-selective cation current through canonical 
transient receptor potential (TRPC) channels (Gudermann et al., 2004; Hardie, 2007). 
Rat mesenteric arterial myocytes appear to express three types of TRPC channels: 
TRPC1, TRPC4 and TRPC6 (Brueggemann et al., 2006; Hill et al., 2006), and since 
only TRPC2, TRPC3, TRPC6, and TRPC7 display sensitivity to DAG (Gudermann et 
al., 2004; Hardie, 2007; Large et al., 2009), it seems the TRPC6 channel subtype is 
responsible for the effects of DAG in rat mesenteric arteries. In accordance to this it was 
recently demonstrated that a DAG analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) 
evoked whole-cell cation currents mainly via TRPC6 channel in rabbit mesenteric 
arterial myocytes (Albert et al., 2008). 
Lastly, the βγ subunit of G-protein is also known to be an important intracellular 
effector that modulates function of Ca2+ and potassium (K+) channels as well as 
phospholipases A and C (Clapham et al., 1997), although its role in the modulation of 
smooth muscle tone during Gq/11 protein-coupled receptor signaling is to be determined.  
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1.2.3 Store-operated Ca2+ entry 
Contraction of smooth muscle in precapillary arterioles in response to Gq/11-
coupled receptor stimulation does not always depend on extracellular Ca2+, but rather on  
Ca2+ release from the from sarcoplasmic reticulum and intence Ca2+ re-uptacke by the 
SERCA (Borisova et al., 2009). In small arteries, however, Ca2+ released from 
intracellular stores is responsible for the initial contraction, and, if extracellular Ca2+ is 
unavailable, the responses to contractile stimuli appear to be transient (Lagaud et al., 
1999; Lamont et al., 2004). This occurs partly due to absence of Ca2+ efflux via LCa 
channels and due to extrusion of Ca2+ from the cell by NCX (Berra-Romani et al., 2010; 
Horiguchi et al., 2001; Weiss et al., 1993) or by plasma membrane Ca2+-ATPase (Gros 
et al., 2003); however, the main reason seems to be the limited capacitance of the 
intracellular stores, which may be easily depleted and can not serve as a sustained Ca2+ 
source to maintain prolonged contraction (Berridge, 1995; Lagaud et al., 1999). 
Store-operated Ca2+ entry (SOCE), or capacitative Ca2+ entry, is a response of the 
cell to depletion of the intracellular stores, which appears as activation of a non-
selective cation channel permeable to Ca2+ (Berridge, 1995). For a long time the 
channel responsible for the capacitative Ca2+ entry was not determined (Berridge, 
1995), however now TRPC channel is recognized as the main candidate for the store-
operated channel (Nilius, 2004). Among proposed channel subtypes responsible for 
SOCE in vascular smooth muscle cells TRPC1, TRPC4, and TRPC5 are present (Beech 
et al., 2004; Xu et al., 2001; Xu et al., 2006), with the TRPC1 subtype seemingly 
playing the main role in rat mesenteric artery smooth muscle cells (Brueggemann et al., 
2006).  
In arterial myocytes, SOCE channels were found to be regulated by two 
transmembrane proteins, STIM1 (stromal interacting molecule 1) and Orai1 (the Ca2+ 
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release-activated Ca2+ channel modulator) (Baryshnikov et al., 2009). It was 
demonstrated that upon depletion of the intracellular stores STIM1 translocates from the 
endoplasmic reticulum to the plasma membrane, functioning as a Ca2+ sensor and a link 
between store depletion and SOCE (Zhang et al., 2005). Orai1 may form the Ca2+ 
selectivity filter of the SOCE channel. This was demonstrated by a point mutation that 
resulted in change of selectivity properties of SOCE channel from being Ca2+-selective 
with inward rectification to being selective for monovalent cations and outwardly 
rectifying (Yeromin et al., 2006). The role of STIM1 and Orai1 in modulation of tone of 
rat small mesenteric arteries has not been studied yet; however, these molecules were 
shown to participate in Ca2+ handling during growth and remodelling of this tissue 
(Berra-Romani et al., 2008). 
Depletion of intracellular stores may also stimulate further Ca2+ influx by means 
of activation of NCX in reverse mode that extrudes three Na+ in exchange for one Ca2+ 
(Baryshnikov et al., 2009; Davis et al., 2009). NCX is spatially co-expressed with Orai1 
in the plasma membrane of proliferating human arterial myocytes and displays a 
functional association with SOCE (Baryshnikov et al., 2009). Functional and spatial 
association between NCX and SERCA was also shown for pig coronary artery smooth 
muscle cells (Davis et al., 2009). In rat mesenteric arteries, NCX was also demonstrated 
to participate in the Ca2+ entry after the store depletion (Lagaud et al., 1999), but the 
exact mechanisms are yet to be determined.  
1.2.4 Ca2+ sensitization mechanism 
Although signalling by vasoconstrictors acting through receptors coupled to Gq/11 
proteins evoke membrane depolarization, rises in [Ca2+]i and contraction via 
mechanisms described earlier (see Section 1.2.1), the rise in [Ca2+]i associated with Gq/11 
protein signalling leads to a greater force development than Ca2+ influx achieved in 
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response to depolarization alone (Bradley et al., 1987; Mulvany et al., 1982). This 
occurs due to so-called ‘Ca2+-sensitization’ that mainly involves activation of MLC 
kinase and/or inhibition of MLC phosphatase activity resulting in greater efficacy of 
Ca2+ (Ratz et al., 2005; Somlyo et al., 2003).  
Two major pathways have been identified in rat mesenteric arteries. The first 
pathway involves activation of protein kinase C (PKC) by signalling of receptors 
coupled to Gq/11 protein (Budzyn et al., 2006). The pathway may involve DAG, as DAG 
was shown to be involved in activation of PKC and consequent Ca2+ sensitization in rat 
cerebral arteries (Gokina et al., 1999). One of the main mechanisms implicated in PKC-
induced Ca2+ sensitization involves activation of PKC-potentiated inhibitor protein of 
17 kDa (CPI-17) that suppress MLC phosphatase (Eto et al., 1997). Another mechanism 
involves phosphorylation of calponin, a thin filament-associated protein that in basal 
conditions suppresses the binding between actin and myosin; when calponin is 
phosphorylated by PKC, it changes its conformation and promotes the contraction (Pohl 
et al., 1997). 
The second pathway involves another serine-threonine kinase, Rho-kinase, which 
is activated by α subunits of Gq/11 and G12/13 proteins via small GTPase RhoA. Rho-
kinase downregulates the activity of MLC phosphatase, resulting in enhanced force 
production for given [Ca2+]i (Ratz et al., 2005; Somlyo et al., 2003). The signalling 
pathway in rat arteries may also involve CPI-17 (Freitas et al., 2009). Rho-kinase is 
implicated in the generation of tone in rat mesenteric arteries and veins in response to a 
rises in intramural pressure (Enouri et al., 2010; VanBavel et al., 2001). It also 
participates in contraction of larger arteries, such as aorta or superior mesenteric artery, 
in response to α-adrenergic or TP receptor stimulation, or application of high K+ 
(Budzyn et al., 2006). Involvement of Rho-kinase in Ca2+ sensitization in response to 
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contractile agonists in small mesenteric arteries is subject to debate. Some studies have 
shown that small mesenteric arteries lack the Rho-kinase-dependent component of the 
contraction to the above stimulus (Budzyn et al., 2006), whilst others demonstrate a role 
for Rho-kinase in the contraction to α-adrenergic agonist (VanBavel et al., 2001). 
1.2.5 Gs and Gi/o protein-coupled receptors 
Receptors coupled to Gs or Gi/o proteins, respectively stimulate or inhibit 
adenylyl cyclase, the enzyme that produces cyclic adenosine monophosphate (cAMP) 
from adenosine triphosphate (ATP). In vascular tissues, cAMP can directly activate 
cyclic nucleotide-gated ion channels (Leung et al., 2010; Shen et al., 2008) as well as 
act on two distinct effector proteins: protein kinase A (PKA) (Simonds, 1999) and 
exchange proteins directly activated by cAMP (Epac) (Purves et al., 2009).  
Cyclic nucleotide-gated channels are nonselective cation channels that belong to 
the voltage-gated ion channel family and are opened by the direct binding of cyclic 
nucleotides, cAMP and cGMP (Kaupp et al., 2002). Cyclic nucleotide-gated channels 
were shown to be involved in adrenaline-mediated rises in [Ca2+]i in cultured 
endothelial cells from bovine aorta (Shen et al., 2008). These channels were shown to 
be expressed in rat mesenteric artery smooth muscle (Kruse et al., 2006), where they 
may contribute to contraction mediated by the TP receptor agonist U46619 (Leung et 
al., 2010). 
PKA has diverse signalling cascades. On the one hand, PKA phosphorylates and 
inactivates MLC kinase (Conti et al., 1981), on the other hand, it reduces Ca2+ entry via 
LCa channels by opening ATP-sensitive K+ (KATP) channels (Quinn et al., 2004; Shi et 
al., 2007), voltage-gated K+ (Kv) channels (Aiello et al., 1998; Waldron et al., 1999), 
and big conductance Ca2+-sensitive K+ (BKCa) channels (Tian et al., 2004). In addition, 
PKA causes direct inhibition of store-operated (Liu et al., 2005) and LCa channels (Liu 
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et al., 1997; Orlov et al., 1996; Xiong et al., 1994). All these effects result in 
hyperpolarization, decrease in smooth muscle cell [Ca2+]i and relaxation. On the other 
hand, PKA has been also shown to activate PKC (Wooten et al., 1996), potentially 
leading to Ca2+ sensitization in smooth muscle cells, although this evidence has not 
received wide acclaim. 
Finally, cAMP signalling involves stimulation of Epac, a guanine nucleotide 
exchange factor for the small G protein Rap (Bos, 2006; Bos, 2003; Gloerich et al., 
2010), which was shown to reduce KATP channel activity in rat aortic smooth muscle 
cells (Purves et al., 2009). Markedly, it was reported that Epac is able to stimulate PLC 
in cultured human embryonic kidney cells (Schmidt et al., 2001), although whether it 
exhibits similar actions in small resistance arteries has yet to be confirmed. 
1.2.5 K+ channels in vascular smooth muscle cells 
K+ channels largely contribute to control of smooth muscle cell membrane 
potential. Outward K+ current through the majority of K+ channels results in cell 
membrane hyperpolarization, which leads to closure of voltage-gated Ca2+ channels and 
vasodilatation. Some K+ channels may cause influx of K+ into the cell; therefore fine 
control of vascular tone is also enabled by modulation of K+ channel conductivity (Ko 
et al., 2008). 
One of the main K+ channels responsible for maintenance of the smooth muscle 
cell membrane potential is the delayed rectifier Kv channel (Ko et al., 2008; Nelson et 
al., 1995). The channel consists of a pore-forming α-subunit and regulatory β-subunit, 
and activates when depolarization reaches to approx. -40 mV with a single channel 
conductivity of ~10 pS (Ko et al., 2008; Nelson et al., 1995; Shibasaki, 1987). The Kv 
channel is regulated by PKA, PKC and PKG (Ko et al., 2010), and is sensitive to 
intracellular magnesium concentration (Tammaro et al., 2005). In mesenteric arteries, 
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Kv channels are expressed in smooth muscle cells (Xu et al., 1999), where they 
participate in hyperpolarization in response to nitroxyl anion (Irvine et al., 2003a; Yuill 
et al., 2010). 
Although a rise in [Ca2+]i is generally associated with contraction, it can also 
activate an outward K+ current via BKCa channels (Xia et al., 2002). The channel is also 
sensitive to membrane potential, and, as in other Kv channels, the voltage sensor is 
located in a pore-forming α-subunit, whilst the β-subunit provides the Ca2+-sensitivity 
of the BKCa channel (Ko et al., 2008). In the presence of high [Ca2+]i (starting from 500 
nM), the channel open probability is increased, enabling outward K+ current of 200-250 
pS (Nelson et al., 1995; Xia et al., 2002). BKCa channel is coupled to ryanodine 
receptors and is implicated in Ca2+ spark-induced membrane hyperpolarization in 
arteries (Jaggar et al., 1998) or urinary bladder (Petkov et al., 2005). Moreover, BKCa 
channels were found to form a complex with vanilloid TRP (TRPV) channels, enabling 
relaxation of cerebral arteries to endothelium-derived epoxyeicosatrienoic acids (EETs) 
(Earley et al., 2005).  
Less abundant is an inward-rectifying K+ (Kir) channel, which is characterized by 
conduction of inward current at membrane potentials negative to the equilibrium 
potential and smaller outward currents at membrane potentials positive to equilibrium 
potential (Nelson et al., 1995). Therefore, the activity of Kir channels provide a pathway 
by which changes in extracellular K+ can alter smooth muscle membrane potential 
(Quayle et al., 1997). This mechanism plays a crucial role in endothelium-derived 
hyperpolarization (Dora et al., 2008; Edwards et al., 1998). 
Sarcoplasmic KATP channel is a hetero-octamer, which consists of four Kir 
channels and four sulphonylurea receptors (SURs). Decreasing levels of intracellular 
ATP allow the KATP channel to open with a conductivity of 50-250 pS in rat vascular 
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smooth muscle cells (Ko et al., 2008). The KATP channel is responsible for 
hyperpolarization in response to β-adrenoceptor stimulation (Garland et al., 2011; 
White et al., 2001), consistent with channel phosphorylation by PKA (Quinn et al., 
2004; Shi et al., 2007). PKC was also shown to modulate channel activity, for example 
by inhibition of K+ current in response to angiotensin II (Kubo et al., 1997; Sampson et 
al., 2007). 
1.3 Vascular endothelium: contrating and relaxing factors 
The discovery of endothelium-derived relaxing factor (EDRF) around thirty years 
ago helped to establish a central role for the endothelium in the physiology and 
pathophysiology of the cardiovascular system (Furchgott et al., 1980). Now it is well 
recognised that the endothelium is not just a passive barrier between circulating blood 
and the vessel wall, but plays a crucial role in inflammation, thrombosis and regulation 
of local blood flow and systemic blood pressure (Dora, 2010; Feletou et al., 2010b; 
Garland et al., 2010a).  
The vascular endothelium lining the intima of the blood vessels is long known to 
be a semi-permeable barrier that regulates the conduction of liquid and solutes, 
including plasma proteins, between the blood and surrounding tissue. Transport across 
the endothelium occurs via two different pathways: through the endothelial cell 
(transcellular) or between adjacent cells, through interendothelial junctions 
(paracellular) (Mehta et al., 2006). Thus, the endothelium creates an interactive 
diffusion barrier which separates vasoactive substances dissolved in blood plasma from 
the vascular smooth muscle cells (Lew et al., 1989). 
More importantly, the endothelium is also able to regulate tone of adjacent smooth 
muscle cells directly, by propagation of the electrical signal via gap junctions (de Wit et 
al., 2010; Dora, 2010; Figueroa et al., 2009a) and by release of vasodilators as well as 
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vasoconstrictors (Iwatani et al., 2008) in response to different physical and chemical 
factors, such as shear stress (Katada et al., 2002), hypoxia (Aley et al., 2005), and 
numerous vasoactive substances. The most important endothelium-derived vasoactive 
factors are endothelium-derived relaxing, contracting, and hyperpolarizing factors 
(EDRF, EDCF, and EDHF, respectively).  
1.3.1 Endothelial cell Ca2+ 
Activation of the vascular endothelium is usually associated with a rise in 
endothelial cell [Ca2+]i, which is released from intracellular Ca2+ stores and/or enters 
from the extracellular space.  
It is well known that stimulation of Gq/11 protein-coupled receptors in rat 
mesenteric arteries elevates endothelial cell [Ca2+]i (McSherry et al., 2005; Mumtaz et 
al., 2011; Oishi et al., 2001; Rodriguez-Rodriguez et al., 2009). The signalling cascade 
involves phospholipase C-mediated production of IP3, which evokes efflux of Ca2+ from 
intracellular stores in a similar way as it does in smooth muscle cells (see Section 1.2.2 
for details) (Fukao et al., 1997; Mumtaz et al., 2011). Although ryanodine receptors 
were shown to participate in the [Ca2+]i rise in human umbilical vein endothelial cells 
(HUVEC) (Paltauf-Doburzynska et al., 2000), spontaneous [Ca2+]i events (Kansui et al., 
2008) as well as a [Ca2+]i rise in response to muscarinic receptor stimulation (Mumtaz et 
al., 2011) were insensitive to ryanodine in endothelial cells from rat mesenteric arteries.  
The importance of Ca2+ influx from the extracellular space in mesenteric arteries 
is demonstrated by a decrease in the magnitude of endothelium-dependent 
hyperpolarization (Dora et al., 2008; Fukao et al., 1997) as well as suppression of 
[Ca2+]i responses in low [Ca2+]o(McSherry et al., 2005; Mumtaz et al., 2011).  
Additionally, attenuation of mesenteric artery hyperpolarization was observed after 
inhibition of the sarcoplasmic reticulum Ca2+-ATPase (SERCA) (Fukao et al., 1997). 
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Therefore it was hypothesized that store depletion in endothelial cells activates 
capacitative Ca2+ entry, possibly, via a channel from the TRP family (Mumtaz et al., 
2011). 
 TRP channels are non-selective cation channels that serve as a potent source of 
Ca2+ in many cell types. Endothelial cells were reported to express all, canonical, 
vanilloid, and melastatin (TRPM) subfamilies of TRP channels (Hill et al., 2006; Yao et 
al., 2005; Zholos et al., 2011), with TRPC being the main candidate for SOCE 
(Tiruppathi et al., 2006; Yao et al., 2005). In accordance to this, it was shown that the 
TRPC channel may form a complex with IP3 receptors in order to optimize Ca2+ 
signalling (Rath et al., 2009), although discrepancies between SOCE and TRPC 
signalling profiles may argue against TRPC being solely responsible for the capacitative 
Ca2+ entry (Nilius, 2004). 
Another important pathway of Ca2+ entry may be via myo-endothelial gap 
junctions. It was shown for rat mesenteric arteries that stimulation of smooth muscle 
cells with a Ca2+ raising agent may result in increased [Ca2+]i in adjacent endothelial cell 
(Dora et al., 2000; Oishi et al., 2001). This may serve as a negative feedback aimed to 
reduce vascular tone in response to excessive elevation of smooth muscle cell [Ca2+]i 
through the release of dilator factors or hyperpolarization. 
Lastly, endothelial cell cyclic nucleotide gated channels may play a role in 
endothelium-dependent vascular dilation to a number of cAMP-elevating agents 
including adenosine, adrenaline (Shen et al., 2008) and ATP (Kwan et al., 2010).  
Regardless of the source, increases in [Ca2+]i will potentially stimulate endothelial 
nitric oxide synthase (eNOS) and cyclooxygenase (COX) enzymes, leading to the 
release of nitric oxide (NO) and prostanoids, respectively. It can also stimulate the 
intermediate and small conductance Ca2+-sensitive K+ channels (IKCa and SKCa, 
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respectively); activation of these channels will cause efflux of K+ and hyperpolarization 
of the endothelium (Chen et al., 1997; Edwards et al., 1998; Zygmunt et al., 1996). 
Therefore, endothelium-dependent modulation of vascular tone can occur via Ca2+-
dependent formation of NO, prostanoids, and hyperpolarization. 
1.3.2 Nitric oxide signalling pathway 
Shortly after the discovery of the obligatory role for the endothelium in dilatation 
response to acetylcholine (ACh) (Furchgott et al., 1980), the close similarities between 
EDRF and nitric oxide (NO) were noticed (Ignarro et al., 1987; Palmer et al., 1987), 
establishing a whole new era in vascular research (Fleming, 2010). 
It was found that in the vascular endothelium NO is generated by endothelial nitric 
oxide synthase (eNOS), an enzyme which converts L-arginine to L-citrulline and NO 
(Bredt et al., 1990; Palmer et al., 1988). The functional enzyme is a dimer, with each 
monomer consisting of an oxygenase domain that includes a binding site for heme, 
tetrahydrobiopterin (BH4) and L-arginine, and a reductase domain that contains binding 
sites for nicotinamide adenine dinucleotide phosphate (NADPH), flavines and 
calmodulin. Upon activation, electrons migrate from NADPH through flavines, BH4 and 
calmodulin to the heme, which binds O2 and catalyses NO production from L-arginine 
(Fleming, 2010). In order to be activated, eNOS, with help of dynamin, has to be 
translocated from the plasma membrane to the Golgi apparatus, where it can dissociate 
from caveolin-1 and bind calmodulin (Cao et al., 2001; Figueroa et al., 2002; Fleming, 
2010; Maniatis et al., 2006). Although this is believed to be the predominant 
mechanism of endogenic NO synthesis, several other pathways of possible NO 
production have been suggested, such as non-enzymatic NO release via reaction of 
hydrogen peroxide (H2O2) and arginine (Nagase et al., 1997), or during acidic 
conditions via reduction of inorganic nitrite (Modin et al., 2001). 
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There are diverse stimuli that can lead to eNOS activation in rat mesenteric 
arteries. This can be signalling of endothelial G protein-coupled receptor (Simonsen et 
al., 1999; Wu et al., 1997), shear stress (Koller et al., 1994; Liu et al., 2006), or even 
Ca2+ incoming from smooth muscle cells via myo-endothelial gap junctions (Dora et al., 
1997; Dora et al., 2000). Also, NO is basally produced by rat arterial endothelium in 
resting conditions (Figueroa et al., 2009b; Fukuda et al., 1992).  
Initially, eNOS was classified as a Ca2+-calmodulin-dependent enzyme and its 
activation upon muscarinic receptor stimulation was attributed predominantly to 
elevation of [Ca2+]i (Bredt et al., 1990). However, recent investigations have revealed 
that phosphorylation of the enzyme may enhance or reduce the sensitivity to [Ca2+]i, 
thus enabling NO production at resting levels of Ca2+ or suppressing its signalling even 
if [Ca2+]i is elevated (Fleming, 2010). eNOS activity was shown to be altered by 
phosphorylation or dephosphorylation of stimulatory (Ser 635 and Ser 1177) or 
inhibitory (Ser116 and Thr 495) sites by a wide range of kinases and phosphatases, such 
as serine/threonine (Akt) kinase, Rho kinase, protein phosphatase 2A and PKC 
(Dudzinski et al., 2006; Hirata et al., 1995; Matsuda et al., 2006; Seya et al., 2006). 
eNOS is also highly dependent on calmodulin, which by itself is under the control of 
protein casein kinase 2 (CK2) (Greif et al., 2004). In cultured cells, PKA was shown to 
have no effect (Hirata et al., 1995) or a stimulatory effect on eNOS activity (Hashimoto 
et al., 2006). In addition, PKA upregulates PKC and CK2 (Blanquet, 1998; Wooten et 
al., 1996), which each have an inhibitory influence on eNOS (Greif et al., 2004; Hirata 
et al., 1995). Interestingly, NO production in the endothelium from resistance arteries 
can also be triggered by the β-subunit of Gq or Gi/o proteins (Vequaud et al., 2001). 
Although the uncharged free radical state of the NO molecule (NO•) was thought 
to be the main EDRF (Dierks et al., 1996b; Feelisch et al., 1994; Ignarro et al., 1987), 
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nitric oxide can also exist as nitrosonium cation (NO+) and nitroxyl anion (NO-) 
(Hughes, 1999). It was demonstrated that NO- can also potently dilate rat aorta (Pino et 
al., 1994b) or mesenteric  arteries (Irvine et al., 2003a; Wanstall et al., 2001); moreover, 
scavenging NO- with L-cysteine has uncovered the endogenous production of this 
molecule by vascular tissues (Andrews et al., 2009; Ellis et al., 2000; Rajanayagam et 
al., 1993; Wanstall et al., 2001; Yuill et al., 2010).  
Arteries dilate to NO by means of at least three different mechanisms. The first 
mechanism includes smooth muscle cell hyperpolarization, which has been shown to be 
a result of opening of KATP (Garland et al., 1992a) or KCa channels (Archer et al., 1994; 
Mistry et al., 1998; Sampson et al., 2001; White et al., 1993; Yuill et al., 2010). 
Recently, NO- was also shown to hyperpolarize smooth muscle cells via activation of 
Kv channels (Andrews et al., 2009; Yuill et al., 2010). Although there is evidence of a 
direct action of NO on K+ channels (Bolotina et al., 1994; Mistry et al., 1998), the main 
pathway involves activation of guanylyl cyclase via binding of NO with the prosthetic 
heme of the enzyme. This leads to formation of cyclic guanosine monophosphate 
(cGMP) from guanosine triphosphate (GTP), which promotes translocation of soluble 
protein kinase G (PKG) to the plasma membrane (Carvajal et al., 2000). 
PKG is also responsible for a second and third pathway of NO-mediated 
dilatation, which includes reduction of smooth muscle Ca2+ and desensitization of the 
contractile apparatus to Ca2+. PKG reduces smooth muscle cell [Ca2+]i  by means of 
direct suppression of the LCa channel (Liu et al., 1997; Sumii et al., 1995), inactivation 
of IP3 receptors  (Komalavilas et al., 1996), and stimulation of plasma membrane Ca2+-
ATPase (Furukawa et al., 1988) and SERCA (Andriantsitohaina et al., 1995).  And, 
lastly, PKG increases MLC phosphatase activity (Etter et al., 2001; Iwatani et al., 2007; 
Somlyo et al., 2003), contributing to a reduction in vascular tone. 
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Figure 1.1 Diagram illustrating the signalling of eNOS in resistance arteries 
A rise in endothelial cell (EC) [Ca2+]i in response to stimulation of Gq/11–coupled 
receptors or due to a Ca2+ signal from an adjacent smooth muscle cell simulates 
eNOS leading to the production of NO• and NO-, which diffuse to underlying 
smooth muscle cells (SMC) where they trigger production of cGMP by guanylyl 
cyclase. NO• can act directly (not shown) or via PKG, suppressing Ca2+ release 
from intracellular stores, stimulating Ca2+ extrusion by the Ca2+-ATPase, 
Na+/K+-ATPase and Na+/Ca2+ exchanger, and Ca2+ uptake via SERCA. NO• 
signalling can also stimulate BKCa and KATP channels, and suppresses LCa 
channels. NO- acts mainly via PKG, promoting opening of Kv and BKCa 
channels. 
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1.3.3 Endothelium-derived hyperpolarizing factor 
The ability of the endothelium from resistance arteries to evoke smooth muscle 
hyperpolarization emerged soon after the discovery of EDRF (Bolton et al., 1984). It 
was found later that this hyperpolarization was not mediated by NO or prostacyclin 
(Chen et al., 1988; Garland et al., 1992a; Plane et al., 1996), but was thought to be 
evoked by an unidentified factor, EDHF (Taylor et al., 1988; Waldron et al., 1994). 
Nowadays it is clear that the hyperpolarization relies not on single pathway, but several 
complex pathways, therefore it can be more accurately described as endothelium-
derived hyperpolarization (EDH) (Dora, 2010; Garland et al., 2010a). At least three 
pathways of EDH have been identified in resistance arteries: K+ released by the 
endothelium, hyperpolarization transferred via myo-endothelial gap junctions, and 
diffusible hyperpolarizing factors. 
K+ as EDH 
The major role for EDH in small arteries is based, at least in part, on the enhanced 
dependency of contraction of these vessels on voltage-gated Ca2+ channels, and, 
therefore, the bigger reliance of vascular tone on smooth muscle membrane potential 
(for review please see Garland et al., 2010a; Taylor et al., 1988). The membrane 
potential is largely controlled by K+ channels, and the idea that K+ channels 
predominantly contribute to the EDH was supported by the evidence that ACh evokes 
86Rb efflux form the 86Rb-treated arteries (Chen et al., 1988). Apparently, neither KATP 
channels (Garland et al., 1992b) nor Kv channels (Adeagbo et al., 1993) were 
responsible for the hyperpolarization, but inhibition of SKCa and IKCa channels 
(Adeagbo et al., 1993; Doughty et al., 1999; Zygmunt et al., 1996) as well as Kir 
channels and Na+/K+-ATPase (Edwards et al., 1998) suppressed EDH. Therefore it was 
hypothesized that efflux of K+ from endothelial SKCa and IKCa channels may activate 
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smooth muscle Kir and Na+/K+-ATPase and thus cause smooth muscle cell 
hyperpolarization. This hypothesis was proven to be true by means of a K+-selective 
electrode that measured a 10 mM increase in K+ close to myo-endothelial space after 
stimulation of the artery with ACh, and by rise of extracellular K+ mimicking the 
endogenous EDH (Edwards et al., 1998). This pathway, however, can be masked with a 
high level of tone via saturation of Na+/K+-ATPase with K+ incoming from BKCa 
channels (Dora et al., 2002), or when levels of Ca2+ in the myo-endothelial space 
increase, for example, when smooth muscle LCa are inactive (Dora et al., 2008). Under 
these circumstances EDH may rely solely on a second pathway, namely direct transfer 
of hyperpolarization via myo-endothelial gap junctions. 
Direct transfer of hyperpolarization via myo-endothelial gap junctions 
It was clearly demonstrated that whilst IKCa channels are co-expressed together 
with Na+/K+-ATPase within the myo-endothelial projections, SKCa channels are also 
localized at endothelial cell borders (Dora et al., 2008) in caveolin-rich domains, 
together with TRP channels and eNOS (Rath et al., 2009). This difference in 
localization may underlie the difference in EDH pathway that includes these channels 
signalling. 
It was established that hyperpolarization to ACh in endothelial cells is similar to 
that in adjacent smooth muscle cells (Yamamoto et al., 1999). Therefore, it was 
proposed that myo-endothelial gap junctions may provide a pathway for EDH being 
transferred from the endothelium to the smooth muscle (Griffith et al., 2002). 
Immunological studies revealed the presence of these structures in the area of myo-
endothelial projections, and that their incidence increased with decrease in arterial size 
(Sandow et al., 2000). Indeed, suppression of gap junctional communication affected 
the degree of hyperpolarization and EDH-dependent dilatation in resistance arteries 
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(Dora et al., 1999; Dora et al., 2003a). Inhibition of connexin-40 with the specific anti-
conexin antibody also suppressed the EDH pathway; the inhibition was especially 
evident when a high level of tone was used in order to affect signalling via the Na+/K+-
ATPase-dependent mechanism described above (Mather et al., 2005). When gap 
junctions were blocked, inhibition of the IKCa channel or Na+/K+-ATPase alone was 
sufficient to inhibit the EDH in rat mesenteric arteries, indicating that SKCa channels are 
responsible for the hyperpolarization that transfers from the endothelium via gap 
junctions, whilst IKCa channels most probably provide K+ for Na+/K+-ATPase-mediated 
repolarization of the smooth muscle cell (Dora et al., 2008). Co-expression of SKCa 
channels with Kir channels at endothelial cell borders (Dora et al., 2008) may provide an 
amplification mechanism, impairment of which underlies the reduced EDH response in 
the hypertensive rat model (Weston et al., 2010). 
Diffusible hyperpolarizing factors  
Although in rat mesenteric arteries the above pathways are predominant routes for 
EDH, we cannot rule out the possibility that other diffusible hyperpolarizing factors 
may also play a role. It is known, for example, that increases in endothelial cell [Ca2+]i 
also activates phospholipase A leading to production of arachidonic acid, a substrate for 
epoxyeicosatrienoic acids (EETs) formation by cytochrome P-450. EETs were shown to 
evoke hyperpolarization via KCa channels (Campbell et al., 1996), possibly via 
stimulation of TRP channels (Campbell et al., 2010) or ryanodine receptors closely 
located to the channel (Earley et al., 2005). Athough EETs were also shown to be 
selective TP receptors antagonists (Fetalvero et al., 2007), which can explain relaxation 
produced by EETs apart from participation in EDHF signalling. 
Following administration of carbachol, the endothelium was shown to produce 
another product of cytochrome P-450, cannabinoid anandamide (Mechoulam et al., 
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1998), which hyperpolarized mesenteric arteries in a similar manner as EDH (Randall et 
al., 1997). However, application of anandamide inhibited the endogenous EDH 
response in porcine coronary arteries (Fleming et al., 1999b). 
C-natriuretic peptide was also proposed as candidate for EDHF. In support of this, 
it was demonstrated that C-natriuretic peptide can be released by the endothelium 
(Chauhan et al., 2003; Hobbs et al., 2004); moreover, the profile of hyperpolarization 
evoked by C-natriuretic peptide, e.g., sensitivity to ouabain and Ba2+, were similar to 
those evoked by endogenous EDH in rat mesenteric arteries (Chauhan et al., 2003). On 
the other hand, differences in EDH and responses to C-natriuretic peptide in guinea-pig 
coronary artery (Leuranguer et al., 2008) discounted a possible role for C-natriuretic 
peptide as EDHF (Garland et al., 2008). 
Another putative EDHF may be H2O2 (Matoba et al., 2003; Shimokawa et al., 
2004), which can be produced by endothelial eNOS (Fleming, 2010), COX (Sobey et 
al., 1998), and NADPH oxidase (Zhou et al., 2008) in sufficient amounts to cause 
hyperpolarization (Beny et al., 1991). But H2O2 can also cause contraction (Gao et al., 
2001; Lucchesi et al., 2005) as well as be responsible for endothelial dysfunction in 
hypertensive rat models (Gao et al., 2001; Zhou et al., 2008), which makes it unlikely to 
be the EDHF.  
Regardless the mechanism, all three pathways of hyperpolarization will lead to 
closure of LCa channels, thus reduce smooth muscle cell [Ca2+]i and, therefore, cause 
vasodilatation. 
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1.3.4 Endothelium-derived contracting factor 
The first endothelium-derived factor discovered was prostacyclin (PGI2) 
(Moncada et al., 1976), a product of COX metabolism of arachidonic acid that potently 
dilates conduit arteries via activation of the cAMP pathway in smooth muscle cells 
(Kukovetz et al., 1979; Miller et al., 1979); however, it was soon noticed that PGI2 can 
evoke not only vasodilatation, but also vasoconstriction (Dusting et al., 1977). Other 
COX metabolites, such as prostaglandin (PG)H2, PGE2, PGD2, PGF2α, and thromboxane 
(Tx)A2, exhibit even higher vasoconstrictor properties, in part due to their ability to bind 
to thromboxane prostanoid (TP) receptor (Feletou et al., 2010a). In physiological 
conditions, COX activity is mainly controlled by [Ca2+]i directly (Tang et al., 2007) or 
via enhanced production of arachidonic acid (Wong et al., 2010a); kinases, such as 
PKA, were also shown to modulate its function (Samokovlisky et al., 1999).  
Although prostanoids are the main contributors of EDCF (Feletou et al., 2010b), 
one of the most potent vasoconstrictors known is an endothelium-derived 21-amino acid 
peptide, endothelin-1 (Yanagisawa et al., 1988). In the vasculature, endothelins mediate 
their action via two G-protein-coupled receptor subtypes, ETA and ETB, with ETA being 
expressed predominantly by the vascular smooth muscle cells and being mainly 
responsible for the vasoconstriction to endothelin-1 (Gilbert et al., 2001; Maguire et al., 
1994; Montagnani et al., 2000).  
The vascular endothelium, especially in pathophysiological conditions, produces 
large amounts of reactive oxygen species (ROS) (Tang et al., 2007; Zhou et al., 2008). 
ROS can evoke vasoconstriction by Rho-kinase-mediated phosphorylation of MLC 
phosphatase (Knock et al., 2009) or via enhancement of TP receptor signalling (Gao et 
al., 2004). ROS can also facilitate eNOS uncoupling, which causes further ROS 
formation (Dikalova et al., 2010; Gayen et al., 2010).  
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1.4  Propagated vasomotor responses 
One of the important characteristics of resistance arteries is the ability to 
synchronise activity within a certain length of the vessel segment. It was noticed that 
hyperpolarization originating in endothelial cells can spread radially into the adjacent 
smooth muscle cells (Emerson et al., 2001; Emerson et al., 2000; Takano et al., 2004; 
Yamamoto et al., 1999; Yamamoto et al., 2001), whilst changes in the membrane 
potential of smooth muscle can cause similar membrane potential changes in the 
endothelium of some blood vessels (Marchenko et al., 1994; Muraki et al., 2000). 
Intercellular connections in resistance arteries were also demonstrated by microinjection 
of a fluorescent dye that could readily spread from the injected endothelial cell to a 
neighbouring endothelial cell via gap junctions and, less effectively, to adjacent smooth 
muscle cells (Dora et al., 2003a; Takano et al., 2004). Dye spread between smooth 
muscle cells was shown to be limited (Takano et al., 2004), especially in hypertensive 
animals (Sandow et al., 2003). These experiments suggest a presence of both 
homocellular and heterocellular gap junctions; this assumption is supported by electron 
microscopy studies showing prevalant interendothelial gap junctions and smaller 
clusters of myo-endothelial gap junctions in rat resistance arteries (Sandow et al., 2000). 
Generally, gap junctions are formed by the docking of two connexons 
(hemichannels) from opposing cells. Each connexon contains six protein subunits, 
called connexins, that can change the conformation of their extracellular loops in order 
to form an aqueous pore that allows diffusion of charged molecules up to 1 kDa 
between the connected cells (de Wit et al., 2010; Figueroa et al., 2009a). Four connexin 
subtypes were found in the vasculature: Cx37, Cx40, Cx43 and Cx45, with the first 
three subtypes playing the predominant role in rat mesenteric arteries (Kansui et al., 
2004; Sandow et al., 2006). Markedly, whilst IKCa, Cx40 and Cx37 were co-expressed 
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in the myo-endothelial gap junction-associated endothelial cell projection, SKCa, Cx37, 
Cx40 and Cx43 were localized to adjacent endothelial cell gap junctions, indicating 
differential signalling pathways of this microdomains (Sandow et al., 2009; Sandow et 
al., 2006). Despite the expression of all three connexins, inhibition of Cx40 alone could 
block the EDH response in rat mesenteric arteries (Mather et al., 2005). A role of gap 
junctions in the coordination of smooth muscle and endothelial membrane potential is 
also confirmed by the evidence that in the vessels lacking myo-endothelial gap 
junctions, such as femoral or saphenous arteries of adult animals, conductance of 
hyperpolarizing currents is greatly reduced (Sandow et al., 2004; Sandow et al., 2002). 
Gap junctional permeability can be regulated by a range of mechanisms, such as 
phosphorylation of connexins by PKC (Heyman et al., 2009) or PKA (Griffith et al., 
2002; Popp et al., 2002; van Rijen et al., 2000), Epac-mediated Cx43 phosphorylation 
(Duquesnes et al., 2010) and changes in [Ca2+]i (Matchkov, 2010), enabling a fine 
control of the propagated vasomotor response both radially and longitudinally. 
1.4.1 Conducted vasodilatation 
In order to achieve a significant increase in tissue blood flow, it is important that 
the focal dilatation to a vasodilator agent could evoke response that spreads axially 
along the vessel wall and, therefore, enables a wide drop in vascular resistance. 
Homocellular and heterocellular gap junctions provide a pathway for such spreading, or 
‘conducted’, dilatation (de Wit et al., 2010; Dora, 2010; Garland et al., 2010a). 
Initially, the conducted response was thought to be a consequence of a simple 
current transfer to adjacent cells (Segal et al., 1989). Indeed, vasodilators that do not 
lead to potent changes in membrane potential, such as NO• donors, were shown to 
evoke poor or no conducted dilatation (Delashaw et al., 1991; Dora, 2010; Winter et al., 
2007), whilst agonists which can cause potent hyperpolarization evoked dilatation that 
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was able to spread over 2 mm from the site of application (Dora et al., 2003b; Garland 
et al., 2011; Segal et al., 1999; Takano et al., 2004; Winter et al., 2007; Yuill et al., 
2010). However, the fact that hyperpolarization evoked by ACh decayed less than the 
injected current demonstrates the presence of an as yet unidentified amplification 
mechanism (Emerson et al., 2002). A role for Kir channels has been suggested (Goto et 
al., 2004; Jantzi et al., 2006), but experiments performed in rat mesenteric arteries have 
shown no effect of Kir channels inhibition on the magnitude of the conducted dilatation 
(Takano et al., 2004). Among other candidates, Na+/K+-ATPase and/or NCX are present 
(Dora, 2010; Garland et al., 2010a; Matchkov, 2010). Voltage-dependent Na+ channels 
via activation of Ca2+ influx through endothelial LCa channel were also shown to 
contribute to conducted dilatation in mouse cremaster arteries (Figueroa et al., 2007). 
Although a rise in [Ca2+]i seems unlikely to be the amplification mechanism because, on 
the one hand, hyperpolarization was shown not to alter endothelial cell [Ca2+]i 
(McSherry et al., 2005), and, on the other hand, no changes in [Ca2+]i were observed 
during conducted responses in rat mesenteric arteries (Takano et al., 2004). However, 
this possibility cannot be completely excluded since a slow [Ca2+]i wave was detected in 
endothelium of skeletal muscle arterioles (Tallini et al., 2007; Uhrenholt et al., 2007). 
Since endothelium-independent agonists, such as levcromakalim, isoprenaline or 
NO- could evoke conducted dilatation (Garland et al., 2011; Takano et al., 2004; Yuill 
et al., 2010), it may seem that the endothelium does not play a significant role in this 
process; however, endothelium removal prevented spread of the dilatation in response 
to all tested agonists (Garland et al., 2011; Takano et al., 2004; Yuill et al., 2010). This 
may be explained in two ways. First, endothelial cells possess a much higher dencity of 
gap junctions than smooth muscle cells (Sandow et al., 2003; Sandow et al., 2000), 
thus, providing a better intercellular communication pathway, and second, endothelial 
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cells align along the principal axis of the artery, therefore less intercellular connections 
are needed in order to conduct the signal for longer distances (Garland et al., 2010a). 
1.4.1 Synchronization of vasomotion 
Vasomotion is seen as oscillations in tension or diameter associated with 
corresponding oscillations in membrane potential and [Ca2+]i that are spatially uniform 
within individual smooth muscle cells and synchronous between adjacent smooth 
muscle cells (Gustafsson, 1993; Peng et al., 2001).  
The endothelium clearly plays a leading role in the coordination of vasomotion in 
rat mesenteric arteries since endothelial denudation resulted in loss of coordinated 
oscillations of vascular tone in this tissue (Gustafsson, 1993; Mauban et al., 2004; Peng 
et al., 2001; Rahman et al., 2007). Participation of the eNOS/cGMP system in the 
generation and maintenance of these rhythmical tone oscillations was initially 
hypothesised and the synchronising effect of a membrane-permeable analogue of cGMP 
on vasomotion was clearly shown in rat resistance arteries (Gustafsson, 1993; Peng et 
al., 2001; Rahman et al., 2005); however, further studies revealed the desynchronising 
effect of endothelium-derived NO (Sell et al., 2002; Yuill et al., 2009) and even 
supported a leading role of EDHF in initiating and maintaining vasomotion (Mauban et 
al., 2004; Rahman et al., 2007). Vasomotion was abolished when the activity of 
chloride channels, LCa channels and/or the Na+/K+-ATPase was blocked (Boedtkjer et 
al., 2008; Gustafsson, 1993). The current model suggests that initial asynchronous 
oscillations in Ca2+ in individual cells activates a depolarizing current, which can spread 
via homocellular and myoendothelial gap junctions and after achieving a certain 
threshold, evoke simultaneous depolarization of all smooth muscle cells, which will 
cause activation of LCa channels, simultaneous [Ca2+]i elevation and vasoconstriction, 
thus initiate synchronous vasomotion (Peng et al., 2001; Rahman et al., 2007). 
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1.5 Receptors regulating vascular tone 
Since blood carried by arteries plays such a crucial role in tissue homeostasis, 
there are multiple pathways for controlling the level of blood flow to tissues and organs. 
In the majority of cases, this control is enabled by means of numerous receptors 
expressed in both smooth muscle and endothelial cells. Interaction of these receptors 
with a variety of vasoactive molecules released by perivascular nerve endings 
(Kawamura et al., 1989; Lamont et al., 2003) or present in circulating blood through a 
complex network of signal transduction pathways act to modulate the level of vascular 
tone and, subsequently, the blood flow. Adrenergic, muscarinic, and TP receptors are 
the most widely expressed receptors in vascular tissue, and therefore, their downstream 
signaling significantly contributes to the regulation of the circulation. 
1.5.1 Vascular adrenoceptors 
Adrenergic receptors (adrenoceptors) are activated by binding of endogenous 
catecholamines adrenaline and noradrenaline (NA). NA is synthesized in noradrenergic 
neurons and the adrenal medulla from the amino acid L-tyrosine. Methylation of NA by 
phenylethanolamine N-methyltransferase to produce adrenaline occurs only in 
chromaffin cells of adrenal medulla. Vesicles containing adrenaline or NA are 
discharged upon depolarization (Marcantoni et al., 2007). Concentrations of adrenaline 
and NA in rat plasma reach 3 ng/ml and 1.6 ng/ml respectively, and this amount 
increases several fold during exercise and disease (Barbieri et al., 1996; Benthem et al., 
1995; De Boer et al., 1987). The action of NA/adrenaline is terminated mainly by their 
reuptake into the nerve endings or chromaffin cells, a process controlled by presynaptic 
adrenoceptors, where they can be recycled or degraded (Dunn et al., 1999; Floras, 
1992). 
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Adrenoceptors are seven-transmembrane domain G protein-coupled receptors, 
with nine different subtypes currently being cloned and characterized (for review see 
Guimaraes et al., 2001). 
α1-adrenoceptors are coupled to Gq proteins, which stimulate phospholipase C and 
through elevation of [Ca2+]i cause vasoconstriction (see Section 1.2.2 for details).  α1-
adrenoceptors can be further subdivided into α1A, α1B, and α1D subtypes; a postulated 
fourth α1-adrenoceptor subtype, the α1L-adrenoceptor, seems to represent a functional 
phenotype of the α1A-adrenoceptor in a particular, energetically favourable, 
conformational state (Docherty, 2010; Guimaraes et al., 2001). Contractile responses of 
the smooth muscle of rat mesenteric arteries to NA/adrenaline were shown to be 
predominantly mediated via α1D-adrenoceptors, with α1B-adrenoceptors found to be only 
partly involved (Hussain et al., 2000; Piascik et al., 1997); however, 
immunohistochemical and mRNA analysis demonstrated expression of all three cloned 
α1-adrenoceptor subtypes in this tissue (Hrometz et al., 1999; Xu et al., 1997). A 
functional response of endothelial cells to stimulation of α1D-adrenoceptors was also 
shown in the mesenteric vascular bed (Filippi et al., 2001), although this effect may be 
mediated by an indirect influence of smooth muscle α1-adrenoceptor signaling (Dora et 
al., 1997; Dora et al., 2000).  
α2-adrenoceptors are linked to Gi proteins which inhibit adenylyl cyclase and in 
vascular tissue have three subtypes: α2A/D, α2B, and α2C (Guimaraes et al., 2001). 
Receptor activation can also cause vascular smooth muscle contraction, particularly in 
veins (Paiva et al., 1999). In rat mesenteric arteries, a selective α2-adrenoceptor agonist, 
clonidine, was shown to evoke both depolarization/contraction and 
hyperpolarization/relaxation, where depolarization was an effect of partial activation of 
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α1-adrenoceptors, and hyperpolarization was a result of via α2-adrenoceptor-mediated 
opening of K+ channels (Silva et al., 1996). 
Whilst evidence of α2-adrenoceptor functional relevance in mesenteric artery 
smooth muscle cell is poor, clonidine caused concentration-dependent dilatation of the 
artery via NO production by the endothelium (Bockman et al., 1996; Borhani et al., 
2005; Figueroa et al., 2001). The main subtype participating in the dilatation was shown 
to be α2A/D, which, surprisingly, did not mediate its effect via cAMP (Bockman et al., 
1996; Figueroa et al., 2001). Possibly, the β subunit of Gi protein is responsible for the 
eNOS activation in this case (Vequaud et al., 2001). 
There are three main subtypes of β-adrenoreceptor: β1, β2 and β3, all linked to 
adenylyl cyclase through Gs protein, which leads to vessel dilatation through 
mechanisms described in Section 1.2.3; although a link between the β3 subtype and Gi 
protein has also been reported (Guimaraes et al., 2001).  
Distribution of β-adrenoceptor subtypes depends on the vascular bed and species. 
β1-adrenoceptor-mediated relaxation of smooth muscles was thought to predominate in 
coronary and cerebral arteries (Begonha et al., 1995; Edvinsson et al., 1974), whilst the 
β2 subtype is widely distributed among the majority of blood vessels. The atypical β3 
subtype, which initially was considered to participate mainly in lipolysis in rat 
adipocytes (Harms et al., 1974), later was suggested to play a significant role in control 
of vascular tone (Dessy et al., 2004; MacDonald et al., 1999; Shen et al., 1994; Sooch 
et al., 1995), particularly, when resistance of β3 adrenoceptor to desensitization was 
taken into account (Liggett et al., 1993). However, more extensive pharmacological 
studies revealed that the atypical β-adrenoceptor in the vasculature was distinct from the 
β3-adrenoceptor and was suggested to be a “putative β4-adrenoceptor” (Brawley et al., 
2000; Kozlowska et al., 2003; Torrens et al., 2002), although parallel studies revealed 
 32
that this atypical β-adrenoceptor differed from the putative β4-adrenoceptor too, and was 
just a low-affinity state of the β1-adrenoceptor (Kaumann et al., 2001). A recent study 
by our group confirmed an earlier observation that in the dilatation of rat mesenteric 
arteries to β-adrenergic agonists β1-adrenoceptors are predominantly involved, and β2-
adrenoceptors play only a secondary role (Briones et al., 2005; Garland et al., 2011; 
Zwaveling et al., 1996). 
Another controversy exists regarding the contribution of endothelial β-
adrenoceptors in the regulation of vascular tone (see Section 4.1 for details). The main 
role seems to belong to β3 adrenoceptor-mediated NO production (Dessy et al., 2004; 
Dessy et al., 2005; Figueroa et al., 2009b; Kou et al., 2007; Napp et al., 2009); 
however, this receptor was shown not to participate in the responses to β-adrenergic 
agonists in rat mesenteric arteries (Garland et al., 2011). 
1.5.2 Vascular muscarinic cholinergic receptors  
Muscarinic cholinoceptors are seven-transmembrane domain receptors coupled to 
Gq/11 protein. They are activated by a cholinergic neurotransmitter ACh, synthesized by 
choline acetyltransferase from choline and acetyl-CoA, with the concentration reaching 
~1.2 nM in rat blood plasma (Fujii et al., 1995). Signalling of all five subtypes of the 
receptor causes rise in [Ca2+]i via phospholipase C-mediated PIP2 breakdown (Eglen, 
2006) (see Section 1.2.2 for details).  
ACh mainly activates endothelial muscarinic M3 receptors in rat mesenteric 
arteries (Fujimoto et al., 1991; Wu et al., 1997), which was shown to be localized at 
endothelial cell borders near gap junctions as well as endothelial cell projections 
(Rodriguez-Rodriguez et al., 2009). Activation of the receptor is associated with a rise 
in endothelial [Ca2+]i (McSherry et al., 2005; Oishi et al., 2001; Rodriguez-Rodriguez et 
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al., 2009), which leads to formation of EDRF, EDCF and EDH via mechanisms 
described earlier.  
1.5.2 Thromboxane receptor 
The thromboxane (TP) receptor is a seven-transmembrane domain receptor that is 
coupled to Gq and G12/13 proteins leading to activation of phospholipase C and a small 
GTPase RhoA (Hirata et al., 1996; McKenzie et al., 2009; Zhang et al., 2006a). It is 
activated by thromboxane A2, a product of enzymatic cleavage of PGH2 by 
thromboxane synthase located mainly in platelets or the endothelium. Blood plasma 
thromboxane metabolite (thromboxane B2) concentration in healthy rats is ~7.5 nM, 
whilst in the hypertensive rat model it reaches ~10.4 nM (Sugimoto et al., 2000). 
Although thromboxane A2 is the most potent agonist, other eicosanoids, such as 
prostacyclin and prostaglandins, are also able to activate the TP receptor. This may lead 
to potent vasoconstriction and inflammation of the endothelium, contributing to 
pathophysiological processes in the vasculature (Feletou et al., 2009; Wong et al., 
2010b). 
So far, two subtypes of the TP receptor have been identified, the first one being 
characterized for placenta (TP-P(α)) and the second one being expressed in the vascular 
endothelium (TP-E(β)) (Hirata et al., 1996; Raychowdhury et al., 1994). Both subtypes 
are coupled to phospholipase C, however, TP-P(α) activates, whilst TP-E(β) inhibits 
adenylyl cyclase (Hirata et al., 1996). TP receptor activation was also shown to impair 
cAMP-signalling via Rho kinase-dependent stimulation of phosphodiesterases (Liu et 
al., 2010).  
Immunohistochemical analysis demonstrated that rat mesenteric artery smooth 
muscle cells express TP receptors (Zhang et al., 2009a), activation of which evokes 
asynchronous [Ca2+]i oscillations and potent constriction that is associated with a greater 
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Ca2+-sensitization than mediated by α-adrenoceptors (Shaw et al., 2004). The 
endothelium of human arteries (Raychowdhury et al., 1994; Shirasaki et al., 2007) as 
well as of rabbit aorta (Pfister, 2008) was shown to express TP receptors; although, to 
our knowledge, TP receptor expression in the endothelium of rat mesenteric arteries has 
not been yet shown. Endothelial TP receptor activation leads to Rho kinase-dependent 
inhibition of NO production (Liu et al., 2009), and/or to PKC-mediated uncoupling of 
eNOS and release of ROS (Zhang et al., 2010). Moreover, TP receptor signalling was 
shown to prevent insulin-dependent phosphorylation of eNOS at the stimulatory Ser 
1177, and this pathway was implicated in vascular dysfunction during high fat diet-
induced diabetes in mice (Song et al., 2009).  
ROS that can be released by uncoupled eNOS (Zhang et al., 2010) may evoke 
contraction via TP receptor signalling (Gao et al., 2001), seemingly, acting on COX and 
promoting thromboxane A2 production (Garcia-Redondo et al., 2009). Released 
thromboxane A2 can bind to endothelial TP receptors, leading to further prostacyclin 
production (Hunt et al., 1992); prostacyclin in turn can also activate TP receptors,  
contributing to altered signalling, that may lead to endothelial dysfunction, hypertension 
and atherosclerosis (Belhassen et al., 2003; Feletou et al., 2009).  
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1.5 Endothelial dysfunction in age and disease.  
Directly or indirectly blood vessels are the source of many serious diseases. 
Systemic hypertension is a well-known disorder that leads to increased risks of 
cardiovascular and renal complications and reduced life expectancy. There are several 
identified reasons for development of high blood pressure, such as tumours of the 
adrenal medulla and adrenal cortex, which can be treated and therefore lead to 
restoration of normal blood pressure; however, the causes of essential hypertension, a 
persistent rise in blood pressure without an identified reason, are not yet clarified 
(Dharmashankar et al., 2010; Feletou et al., 2010b; Guimaraes et al., 2001).  
Studies on hypertensive or old animals demonstrate that their endothelial function 
is greatly altered (see elsewhere, Dharmashankar et al., 2010; Feletou et al., 2010b). 
Impairment of the EDH pathway (Brahler et al., 2009; Weston et al., 2010; Wu et al., 
1997) as well as the NO pathway (Kedziora-Kornatowska et al., 2006; Kleinbongard et 
al., 2006; Monti et al., 2010; Schulz et al., 2000) is known to exist alongside augmented 
EDCFs production during hypertension (Feletou et al., 2009). On the other hand, raised 
levels of adrenaline are associated with hypertension in humans (Brown et al., 1981; 
Goldstein, 1983), and in a hypertensive rat model high blood pressure was shown to be 
attributed to excessive activity of the sympathetic nervous system (Pinterova et al., 
2010). Even early studies have demonstrated that hypertension remains long after the 
injected adrenaline has disappeared from the blood plasma (Majewski et al., 1981), 
whilst adrenergic agonists trigger release of EDRFs ex vivo (Figueroa et al., 2009b; 
Figueroa et al., 2001; Filippi et al., 2001; Guimaraes et al., 2001; Seya et al., 2006). 
Despite extensive studies, the role that adrenoceptors may play in modulating 
endothelium-derived control of vascular tone remains to be understood. 
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1.6 Research aims 
The experiments presented within this thesis were designed to evaluate the role of 
the endothelium in local and distant changes of vascular tone following activation of 
endothelium-dependent and -independent signalling pathways. 
 
1. Signalling of β-adrenergic receptors causes relaxation and 
hyperpolarization of resistance arteries (Briones et al., 2005; Garland et 
al., 2011; Kozlowska et al., 2003; White et al., 2001), although the role of 
KATP channels in the functional responses that follow the receptor 
stimulation is not clear. Therefore, we aimed to clarify if signalling 
through the KATP channel contributes to local and conducted 
vasodilatation. 
2. Vascular endothelium has been shown to express β-adrenoceptors 
(Briones et al., 2005), although whether the endothelium participates in 
the dilatation to β-adrenergic agonist application by release of relaxing 
factors is a subject to debate. Therefore, we attempted to reveal a role that 
the endothelium may play in the β-adrenergic-mediated dilatation. 
3. The levels of endogenous adrenergic agonists adrenaline and NA were 
shown to be increased during disease (Borkowski et al., 1992; Brown et 
al., 1981; Floras, 1992; Gayen et al., 2010; Goldstein, 1983; Grassi et al., 
2010; Higashi et al., 2002; Majewski et al., 1981; Tung et al., 1981), 
although whether adrenaline and NA can affect endothelial cell function is 
not known. Therefore, we decided to elucidate the effects of adrenergic 
agonists on the local and conducted dilatation to endothelium activation 
using the endothelium-dependent agonist ACh. 
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4. Together with EDH, NO is one of the most important endothelium-
derived factors (Fleming et al., 1999a). Recently, an important role for 
NO- in rat vasculature was suggested (Irvine et al., 2003a). We were 
interested in the signalling pathways of NO--mediated dilatation and 
tested the hypothesis that endogenously produced NO- may evoke a 
propagated response. 
5. Endothelial function is known to be impaired in age and hypertension, 
leading to an imbalanced production of endothelium-derived relaxing and 
contracting factors (Feletou et al., 2010b), whilst signalling of β-
adrenoceptors is reduced (Borkowski et al., 1992). The participation of 
EDCFs in responses to ACh and isoprenaline therefore were studied in 
small mesenteric arteries of young, old and old hypertensive rats. 
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Chapter 2. Methods 
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2.1 Rat mesenteric artery isolation and preparation 
All experiments described in this thesis were performed using rat small mesenteric 
arteries. To obtain the arteries, young (12-14 weeks, 225-255g) or old (6 months, 550-
650g) male Wistar rats were killed by cervical dislocation and exsanguination according 
to Schedule 1 of the Animals (Scientific Procedures) Act 1986 and monitored by the 
Home Office, UK. The mesenteric arcade was removed and placed in ice-cold MOPS 
buffered physiological solution (MOPS buffer, for salt composition see section 2.6) 
with pH adjusted to 7.40 ± 0.02 (at 37oC). Part of the intestine together with its feeding 
vasculature was placed into a Sylgard-coated Petri dish filled with fresh ice-cold MOPS 
buffer (Figure 1B). Each mesenteric arcade was gently fixed with several small pins. 
Third-order branches of mesenteric artery were dissected free of adherent tissue under a 
dissecting microscope. Segments of the arteries, which contained no visible side 
branches, were cut to give a final length of ≥ 2 mm.  
An external diameter of the arteries used in this work at 70 mmHg was between 
220-340 μm for young rats and 351±18 (n=4) μm for mature animals.  
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2.2 Wire myography 
Wire myography is a useful and convenient technique to perform in vitro studies 
of functional responses and vascular reactivity of vessels as small as 100 µm in 
diameter (Mulvany et al., 1977). First developed in 1972 by Bevan and Osher (Bevan et 
al., 1972), it was improved by Professors Mulvany and Halpern in 1976 (Mulvany et al., 
1977). They secured both ends of each mounting wire with screws to fixed supports 
(‘jaw’) to keep the artery under tension, allowing the circumference of the vessels to be 
kept constant; therefore, the vessels were examined under near isometric conditions. 
Compounds were added directly to the chamber and vessel tension was monitored for 
contractile or relaxant responses. 
Segments (2 mm long) of third-order mesenteric arteries of rat were mounted in a 
Mulvany-Halpern multi-channel myograph (Model 610M, DMT Denmark, Figure 1) 
using gold-plated tungsten wires (25 μm diameter) in Krebs solution (for salt 
composition see section 2.6). The arteries then were warmed up to 37 ºC and left to 
equilibrate for 20 minutes. Following the equilibration period, the arteries were 
normalised in order to obtain an optimal and standardized stretch according to Laplace’s 
Law. For this, the internal diameter of the vessel was set to a resting tension equivalent 
to that generated at 0.9 times the diameter of the vessel at 70 mmHg.  
After an additional 30 minutes of equilibration at the set resting tension, viability 
of the arteries were assessed by precontraction with phenylephrine (PE, 1-5 µM) and the 
following endothelium-dependent relaxation to ACh (0.1- 1 µM). Only arteries, which 
relaxed > 95% to 1μM ACh, displaying the functional endothelium, were used in 
subsequent experiments. To avoid effects of evaporation, bath solutions were changed 
each 20 minutes. 
 41
 
 
 
 
 
Figure 2.1 Experimental setup for wire myography and vessel mounting 
A. Photograph of a front panel of the 4-channel wire myograph (DMT, Denmark), 
similar to the one used in this work*; 
B. Schematic diagram of vascular bed with veins dissected away revealing arteries 
beneath. The vessel labelled Main is a main mesenteric artery, 1st, 2d, 3d, and 4th – 
are, subsequently, first, second, third and fourth order of mesenteric arteries. In wire 
myography experiments 3d order arteries were used. 
C. Photograph of a third order rat mesenteric artery mounted in wire myograph jaw*. 
 
 
 
 
 
 
* Photos are taken from DMT website: http://www.dmt.dk 
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2.2 Pressure myography 
The internal elastic lamina together with the endothelial cell layer creates a barrier, 
which can hinder or even prevent the passive diffusion of molecules from blood plasma 
in and from surrounding tissue. To allow the possibility to change solution inside the 
vessel (luminal) independently of the external solution in the bath (abluminal) a 
pressure myography technique was used. Moreover, pressure myography allows 
studying responses of the arteries under isobaric conditions that may be more 
physiological than the wire myograph. 
This technique was first developed in 1967 to study arterioles, up to 50 µm in 
diameter, perfused and pressurized through a single cannula (Uchida et al., 1967), later 
the method was optimised to study microvessels as small as 12 µm (Duling et al., 
1981). Further improvements included continuous vessel imaging and introduced 
second cannula to allow changing luminal solution independently of abluminal 
(VanBavel et al., 1990), importance of longitudinal stretching was emphasized (Coats et 
al., 1999). 
For pressure myography, all branches of the artery (two for local and three for 
spreading dilatation studies) were cannulated with glass pipettes, connected with 
gravity-fed pressure system. The preparation then was warmed up to 37°C and 
superfused with MOPS buffer for at least 20 min, then pressure, driven by gravity-fed 
inflow and outflow system, was gradually risen to 80 mm Hg. After the vessel was 
straightened and stretched, the pressure was subsequently decreased to 70 mm Hg and 
was maintained at this level during the whole experiment. Following 20 minutes of 
equilibration time, reactivity of the artery was assessed by precontraction of the artery 
with phenylephrine (PE) (0.5-3 μM) followed by endothelium-dependent relaxation to 
ACh (0.1 and 1 µM). Only vessels relaxing to 1 μM ACh by more than 95%, reflecting 
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viable endothelium, were subsequently used for further experiments. This method was 
used to study both local and distant (conducted) responses. 
2.2.1 Luminal and abluminal application of agonists 
During experiment, substances were either added directly into the bath 
(abluminally), or infused via the lumen (lumenally) by means of syringe pumps 
(BeeHive syringe pump system, Bioanalytical systems, USA). For luminal perfusion, 
one of the pipettes was disconnected from the gravity-fed pressurizing syringe 
reservoirs and attached to the syringe pump system. To obtain concentration-dependent 
responses, studied substances were added cumulatively, or non-cumulatively, when 
indicated. For the luminal application only five concentrations of agonist were used 
during one sequence of cumulative concentration response on each vessel. The speed of 
luminal flow did not exceed 50 μL/min for the initial phase of perfusion and 10 µL/min 
after the dead volume of the pipette was overcame. To check endothelial cell viability 1 
µM ACh was applied at the end of each trace if relaxation was not absolute. 10 µM of 
levcromakalim was added at the end of experiments, when endothelial dependent 
dilatation of the artery was impaired.  
 
2.2.2 Measurement of local responses 
To study local responses, double cannulated vessels were used (Figure 2). For this, 
segments of arteries free from side branches were cut to give a final length of 3-4 mm, 
then cannulated with two glass pipettes (external diameter 150-200 μm) and positioned 
near the basement of a temperature-regulated chamber (10 mL, 120CP, Danish Myo 
Technology, Denmark) seated in a stage insert of an inverted microscope (IX71, 
Olympus). After equilibration, arteries where pressurized and stretched, and viability of 
the vessels was tested with PE and ACh, as described above (section 2.2). 
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B 
Figure 2.2 Experimental setup for studies of local responses 
Isobaric diameter recordings by means of pressure myograph 120CP (DMT, 
Denmark) and system for luminal perfusion of agonists (BeeHive syringe pump 
system, Bioanalytical systems, USA).  
A. A photograph illustrating the 120CP pressure myograph for double cannulated 
arteries*.  
B. The diagram illustrates a cross-section of the setup. Artery is mounted on two 
pipettes in a 10 mL organ bath. One of the pipettes may be connected to syringe 
pump system, allowing luminal perfusion of studied compounds, whilst the other 
pipette is connected to a 5 ml syringe reservoir, raised to a calibrated height to exert 
intramural pressure of 70 mmHg.  
 
 
* Photo is taken from DMT website: http://www.dmt.dk 
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 45
The arteries were visualized using with 4 x/0.13 NA objective and cool snap CCD 
camera (KP-M1E/K-S10, Hitachi Kokusai Electric Inc., Japan) attached to the 
microscope. Vessel diameter changes were tracked by Vedi View software (v.1.2, 
Photonics Engineering). 
 
 2.2.3 Measurement of spreading responses 
In experiments where conducted (or spreading) responses were studied, a recently 
developed method of triple cannulated vessels was used (Figure 3) (Winter et al., 2007; 
Yuill et al., 2009). For this, third order branch with a bifurcation (two forth order 
branches, subsequently) was isolated and all three ends were cannulated with glass 
pipettes (external diameter 100-200 μm), then the artery was positioned near the base of 
a 2 mL temperature-regulated chamber in a stage insert (RC-27 chamber, PH-6 
platform, Warner Instruments, CT, USA), as previously described (Winter et al., 2007). 
The arteries were subsequently pressurized, stretched and tested, as indicated above. 
The studied agonist was perfused into Branch 1 together with 10-7 M 
carboxyfluorescein; a constant flow of 1 µl/min was applied into Feed branch in order 
to restrict the studied agonist to Branches 1 and 2.  Branch 2 served as an outflow for 
solutions derived from Branch 1 and Feed branch. Speed of the luminal flow did not 
exceed 5 µl/min during experiment. Additionally introduced superfusion flow (2 
ml/minute) was constantly applied in the direction of flow inside the Feed branch.  
In these experiments, brightfield images were captured together with fluorescence 
images (excitation 488 nm, emission 505 nm) to enable monitoring of agonist delivery. 
Using scanning confocal microscope (FV300-SU, Olympus, Japan) images were 
recorded with Fluoview Software (v.5.0, Olympus, Japan) at 1 Hz and processed with 
Metamorph software (Version 6.1, Universal Imaging, USA; Figure 4). 
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Figure 2.3 Experimental setup for studies of spreading responses 
A. The figure shows a photograph illustrating the experimental setup for triple 
cannulated arteries. Arteries are mounted on three pipettes; two of the pipettes are 
connected to syringe pump system, allowing luminal perfusion of studied 
compounds, whilst the outflow pipette is connected to a 5 ml reservoir, raised to exert 
intramural pressure of 70 mmHg.  
B. The diagram illustrates a triple cannulated artery. The studied agonist (here ACh) 
is perfused into Branch 1 together with carboxyfluorescein; a small constant flow is 
applied into Feed branch in order to restrict the studied agonist to Branches 1 and 2;  
Branch 2 serves as an outflow for solutions derived from Branch 1 and Feed branch. 
Additionally introduced superfusion flow is constantly applied in the direction of 
flow inside the Feed branch. 
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Figure 2.4 Analysis of spreading responses 
A. The figure shows regions used for tracing artery motion (outer diameter) by the 
software program Metamorph (Universal Imaging, USA). Diameter measurements 
were performed at multiple sites along the Feed branch (distance between search 
regions is 0.5 mm) and at Branch1 (analyzed separately), using recorded time series 
from the brightfield channel. The 0 mm point represents nearest position to the edge 
of the stimulated area. 
B. The figure represents an averaged image of the time series recorded at 505 nm, an 
emission wavelength of carboxyfluorescein added to the perfused solution together 
with agonist (stimulated area). 
C. A representative trace illustrating the spread of dilatation in response to perfusion 
of ACh into Branch 1. The values for % maximum diameter at 70 s are shown in the 
box to the right, and correspond to each position along the artery. 
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2.4 Measurement of endothelial cell [Ca2+]i in pressurized arteries 
In separate experiments, small mesenteric arteries were dissected, double-cannulated 
and tested as described in section 2.1. Then the endothelial cells were loaded with Ca2+ 
dye, as shown previously (Kansui et al., 2008; Rodriguez-Rodriguez et al., 2009). 
Briefly, the pressure was lowered to 4 mm Hg and the artery was perfused with a 
filtered (0.22 µm pores) buffer containing 0.02% Pluronic F-127 and a cell-permeable 
Ca2+ dye Oregon Green 488 BAPTA-1 AM (10 µM) for 30 minutes to selectively load 
endothelial cells (Kansui et al., 2008). After the dye was washed out with MOPS buffer, 
the pressure was re-introduced and artery was left for another 30 minutes for de-
esterification. Using Olympus IV70 with Andor IQ 1.8.1 spinning disc microscope the 
sample was exited at 488 nm and emitted light was collected at 515 nm with 40x water 
immersion objective (UApo N340, Olympus, Japan). Endothelial cells were visualised 
in a clip box of 511x272 pixels to allow 10 Hz scan frequency. Cells in a good focus (6-
10 cells) were selected and fluorescence intensity was determined off-line using Andor 
IQ 1.5 software. The data were then analysed and presented as (F/F0), where F0 is 
averaged basal intensity. 
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2.5 Data analyis  
Data were analyzed using Microsoft Excel 2003 (Microsoft Corporation) and Graph 
Pad Prism (v4.03, GraphPad Software, USA) software. Relaxation is expressed as 
percentage of the maximal diameter of the artery (ΔD/ΔDmax) and contraction is 
expressed as percentage of the maximal contraction of the artery (ΔD/ΔDmin). Results 
are summarized as mean ± S.E.M. of n replicates, where n is number of arteries, each 
obtained from an individual animal. Concentration-response curves (CRCs) were fitted 
where possible using nonlinear regression, sigmoidal dose response function (variable 
slope): 
                                           SlopeHillXEC
BottomTopBottomY .)(log 50101
)(
−+
−+= ,                       (Equation 3) 
where X is the logarithm of concentration; Y is the response; X starts at Bottom and 
goes to Top with a sigmoidal shape; EC50 is the concentration (M) of agonist that 
produces 50% of its maximum response. Agonist efficacy was expressed as the negative 
logarithm to base 10 of the EC50 value.  
Spreading dilatation data were fitted using nonlinear regression, one-phase 
exponential decay: 
                                   PlateauXKSpanY +⋅−⋅= )exp(  ,                    (Equation 4) 
where K=1/Xmid, Span=Ymax-Ymin, Plateau=Ymin; starts at Span+Plateau and decays to 
Plateau with decay constant K. 
Statistical analysis were performed using Student's t-test, one-way or two-way 
ANOVA analysis followed by Bonferroni post test. A value of p < 0.05 was considered 
to be statistically significant (*p<0.05, **p<0.01 and ***p<0.001 vs. control; #p<0.05, 
##p<0.01, ###p<0.001 vs. treated).  
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2.6 Drugs and solutions 
All drugs were obtained from Sigma (Poole, UK) with exception of apamin and 
iberiotoxin (Latoxan, France), forskolin (Biomol International), bisindolylmaleimide 
(BIS I; Calbiochem), Pluronic and Oregon green BAPTA-1 AM (Molecular Probes, 
UK) and Angeli’s salt (odium trioxodinitrate), which was ordered from Axxora. 
U46619, TRAM-34 and forskolin were dissolved in dimethyl sulfoxide, indomethacin 
was dissolved in 5% NaHCO3, adrenaline and noradrenaline bitartrate salts were 
dissolved in 10-4 M ascorbic acid, iberiotoxin was reconstituted in physiological buffer 
and Angeli’s salt was dissolved in 10-2 M NaOH to prevent decomposition prior to use 
(Favaloro et al., 2009). L-cysteine was added to a specially prepared MOPS buffered 
solution with reduced amount of NaCl in it to balance excess of Na+ incoming with 
NaOH (to reach pH=7.4). To get saturated solution of NO• with NO concentration of 1.9 
mM (Zacharia et al., 2005), de-gassed MOPS buffered solution was bubbled with NO 
gas (Favaloro et al., 2009; Friedemann et al., 1996; Rajanayagam et al., 1993; 
Simonsen et al., 1999). All other stock solutions were prepared using MilliQ water. All 
stock solutions were 10-2 M, except of L-NAME 10-1 M, and were diluted to working 
concentrations in physiological buffer before the experiment. Inhibitors were pre-
incubated with the tissue for at least 20 minutes before agonist application. 
Krebs buffer contains (in mM): NaCl, 118.0, NaCO3, 25; KCl, 3.6; MgSO47H2O, 1.2; 
KH2PO4, 1.2; glucose, 11.0; CaCl2, 2.5; and gassed with 95 % O2 and 5 % CO2 before 
and during experiment.  
MOPS buffer contains (in mM): NaCl, 145; KCl, 4.7; CaCl2, 2.0; MgSO4·7H2O, 1.17; 
MOPS, 2.0; NaH2PO4·H2O, 1.2; glucose, 5.0; pyruvate, 2.0; EDTA, 0.02; NaOH, 2.75; 
with pH adjusted to 7.40 ± 0.02 (at 37oC). 
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Chapter 3.  The role of KATP channels in β-adrenoceptor-mediated 
vasodilatation 
 52
3.1 Introduction 
More than a century ago it was reported that vasoconstriction occurs following 
injection of adrenal gland extracts (Oliver et al., 1895). Later it was found that 
adrenaline, the compound responsible for the observed phenomenon, can also evoke 
vasodilatation in the presence of the alkaloid ergotoxine (Dale, 1913). Observations 
such as these led to the discovery of two main groups of adrenoceptors: α-adrenoceptors 
and β-adrenoceptors (Ahlquist, 1948), with the subsequent development of a selective 
α-adrenoceptor antagonist phentolamine (Urech et al., 1950) and β-adrenoceptor 
antagonist propranolol (Black et al., 1965). Each adrenoceptor group was further 
subdivided into several subtypes, such that nine subtypes of the receptor are now 
recognized. α1-adrenoceptors are coupled to Gq protein, which stimulates phospholipase 
C and through elevation of [Ca2+]i causes vasoconstriction, while α2-adrenoceptors are 
linked to Gi protein and decrease [cAMP]i. All β-adrenoceptor subtypes stimulate 
adenylyl cyclase and enhance cAMP production, and in the vasculature this leads to 
vasodilatation (for review see Guimaraes et al., 2001).  
In the mesenteric vascular bed, the contractile response of smooth muscle to 
catecholamines is mediated predominantly through the α1-adrenoceptor (Hussain et al., 
2000; Piascik et al., 1997). The subtype of β-adrenoceptors that is responsible for 
dilatation in rat mesenteric arteries remains unclear. Whilst a leading role for the β2-
adrenoceptor was suggested initially (Kozlowska et al., 2003), others demonstrated less 
sensitivity to the β2-adrenoceptor agonist salbutamol and suggested a predominant 
contribution of β1-adrenoceptors to vasodilatation (Briones et al., 2005). On the other 
hand, participation of both receptor subtypes in the response to β-adrenoceptor agonists 
was previously shown for this vascular bed (Zwaveling et al., 1996). Further studies of 
 53
the propranolol-resistant component of the isoprenaline-induced arterial dilation 
revealed the involvement of a third, atypical subtype of the β-adrenoceptor family 
(Kozlowska et al., 2003; Sooch et al., 1995), possibly the β3-subtype (Dessy et al., 
2004; Figueroa et al., 2009b).  
Stimulation of β-adrenoceptors was also associated with smooth muscle cell 
hyperpolarization (Holman et al., 1968; Prehn et al., 1983; Somlyo et al., 1970), which 
was a result of the adenylyl cyclase-dependent activation of K+ channels, predominantly 
the KATP channel (Fujii et al., 1999; Nakashima et al., 1995; Somlyo et al., 1970). 
Although cAMP signalling also involves stimulation of Epac (Gloerich et al., 2010), it 
has been shown that Epac activation  inhibits KATP channel activity (Purves et al., 
2009), whilst the stimulatory pathway involves phosphorylation of the SUR2 subunit of 
the KATP channel by PKA (Shi et al., 2007). 
Recent experiments by our group have demonstrated that both classical β-
adrenoceptor subtypes could evoke hyperpolarization and dilatation in rat small 
mesenteric arteries (Garland et al., 2011). The principal route for hyperpolarization was 
via β1-adrenoceptors, with β2-adrenoceptors playing less of a role, whereas β3-
adrenoceptor stimulation failed to induce any change in membrane potential. In both 
cases, the KATP channel antagonist glibenclamide was sufficient to suppress the 
hyperpolarization. 
Although hyperpolarization of vascular tissue is generally associated with 
dilatation (Waldron et al., 1994), it is not clear to what extent the KATP channels 
contribute to the functional response of β-adrenergic stimulation, particularly in 
response to physiological agonists such as noradrenaline (NA) and adrenaline.  
One of the established essential characteristics of resistance arteries is the ability 
to synchronise responses within a certain length of the vessel, which reflects the 
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electrochemical coupling of the vascular cells through the myoendothelial gap junctions 
(Dora, 2010; Figueroa et al., 2009b; Garland et al., 2010a). It has been recently reported 
that the hyperpolarization to the KATP channel opener levcromakalim can propagate 
along the wall of the mesenteric artery and evoke distant vasodilatation (Takano et al., 
2004). Thus, we hypothesized that β-adrenoceptor-mediated activation of the KATP 
channels may initiate a similar spread of dilatation, termed ‘conducted dilatation’.  
Therefore, the goal of this part of my study was to examine the role of KATP 
channels in the local and conducted response to adrenoceptor stimulation, and evaluate 
the receptor subtypes involved and the pathways of propagation of the response in rat 
small mesenteric arteries. 
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3.2 Methods 
3.2.1 Rat mesenteric artery isolation and preparation 
See section 2.1 for detailed description of artery isolation and preparation. 
3.2.2 Wire myography 
The arterial segments were mounted in a Mulvany-Halpern 4-channel myograph 
(Model 610M, DMT Denmark) and normalized as described in section 2.2. Artery 
viability was examined by pre-contraction with the α-adrenergic agonist phenylephrine 
(PE, 1-10 µM) and > 95% relaxation to ACh (0.1-1 µM).  
3.2.3 Pressure myography for the spreading dilatation studies 
The pressure myograph system was employed to study the spreading responses. 
To enable selective stimulation of one part of the vessel, rat small mesenteric arteries 
possessing a bifurcation were cannulated and pressurized as described in section 2.2. To 
obtain denuded arteries, the pressure was decreased and an air bubble (∼2.5 mm3) was 
perfused through the artery using a syringe pump system. The lumen was then washed 
for 5 minutes and 70 mm Hg pressure was re-introduced.  
3.2.4 Measurement of the spreading responses 
The protocol for the spreading dilatation studies is described in section 2.2.3. 
Figure 3.1 demonstrates a diagram of the triple cannulated vessels and the principle of 
the spreading dilatation measurements.  
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3.2.5 Cumulative concentration-response curves 
Increasing concentrations of the studied agonists were introduced directly to the 
bath following submaximal (70-80% of maximal tone) precontraction with PE. A stable 
TP receptor agonist U46619 was used to achieve the tone when α-adrenergic inhibitors 
had been applied to reveal β-adrenoceptor-mediated responses. In the presence of the 
KATP channel inhibitor glibenclamide (5 µM) the concentration of U46619 was 
increased in order to reach similar level of tone as in the control (from 32.3 ± 1.9 nM to 
728.4 ± 133.9 nM, n = 4). This may be explained by an antagonistic effect of 
glibenclamide on the TP receptor established for rat arteries (Kemp et al., 1998). 
3.2.6 Data analysis  
The data were analyzed as described previously (see section 2.5). 
3.2.7 Drugs and solutions  
See section 2.6 for the preparation details.  
Krebs buffer, continuously gassed with 95% O2 and 5% CO2, was used for the 
wire myograph experiments, whilst MOPS buffered solution was used for the conducted 
dilatation studies. 
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Figure 3.1 Diagram illustrating triple cannulated segment of artery for 
measurements of conducted dilatation responses  
The agonist was infused via Branch 1 together with carboxyfluorescein (CF). 
Luminal flow (1-2 µl/min) inside the Feed branch (magenta arrow) restricted 
flow of the studied agonist within the bifurcation. Abluminal flow (2 ml/min) 
was introduced in the direction opposite of the direction of conducted response 
(blue arrow) to prevent agonist diffusion upstream from the point of bifurcation. 
Diameter was measured in Branch 1 and at 0.5 mm increments from the edge of 
applied agonist (evaluated by CF) along the Feed branch. 
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3.2 Results 
3.2.1. Effects of adrenaline and noradrenaline on tension 
There is evidence that stimulation of adrenoceptors may lead to release of nitric 
oxide (NO) in rat mesenteric arteries (Figueroa et al., 2009b), therefore all experiments 
in this section were performed in the presence of NOS inhibitor L-NAME (100 µM).  
Adrenaline and NA constricted rat small mesenteric arteries in a concentration-
dependent manner (Figure 3.2A). Adrenaline was a significantly more potent 
vasoconstrictor than NA (pEC50 = 6.92 ± 0.05, n = 14 and pEC50 = 6.05 ± 0.08, n = 14, 
respectively, p<0.05). The α1-adrenoceptor antagonist prazosin (1 µM) blocked the 
contraction and revealed a concentration-dependent dilatation to adrenaline and NA in 
arteries preconstricted with the thromboxane mimetic U46619 (Figure 3.3B). Though 
the relaxation to adrenaline tended to have a higher efficacy than NA, the difference 
was not statistically significant (pEC50 = 6.33 ± 0.09, n = 10 and pEC50 = 5.93 ± 0.07, n 
= 10, respectively, p>0.05). Treatment with the classical β-adrenoceptor antagonist 
propranolol (1 µM) resulted in unaltered contraction to adrenaline (from pEC50 = 7.09 ± 
0.06 to pEC50 = 7.04 ± 0.05, n = 8, p>0.05) and NA (from pEC50 = 6.32 ± 0.06 to pEC50 
= 6.48 ± 0.07, n = 8, p>0.05), but dramatically suppressed the vasodilatation to 
adrenaline (from pEC50 = 6.64 ± 0.05 to pEC50 = 4.11 ± 2.3, n = 6, p<0.05) and NA 
(from pEC50 = 6.18 ± 0.06 to pEC50 = 5.09 ± 0.08, n = 6, p<0.05), indicating that β-
adrenoceptors are the predominant receptors involved in the vasodilatation to the 
nonselective adrenergic agonists (Figure 3.3A,B).  
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Figure 3.2 Concentration-response curves to adrenaline and NA in small 
mesenteric arteries mounted in wire myograph.  
A. Summarized data showing the concentration-dependent contraction to 
adrenaline and NA (n = 14, p<0.05);  
B. Summarized data showing concentration-dependent relaxation to adrenaline 
and NA in the presence of α1-adrenoceptor inhibitor prazosin (1 µM; n = 10, 
p>0.05). Arteries were submaximally preconstricted using the TP receptor 
agonist U46619.  
 
Results shown are the mean ± s.e.mean, **p<0.01, ***p<0.001 vs. NA. 
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Figure 3.3 Effect of propranolol on the concentration-response curves to 
adrenaline and NA of small mesenteric arteries mounted in wire myograph 
A. Summarized data showing contraction and relaxation of the artery to rising 
concentrations of NA. In control β-adrenergic antagonist propranolol (1 µM) had 
no effect (n = 8, p>0.05), but when the vessel was pre-treated with α1-
adrenoceptor inhibitor prazosin (1 µM) and precontracted with thromboxane 
mimetic U46619, propranolol significantly suppressed the response (n = 6, 
p<0.05). 
B. Similarly, whilst propranolol was ineffective in control (n = 8, p>0.05), it 
affected the relaxation to adrenaline in the presence of prazosin following 
precontraction with U46619 (n = 6, p<0.05). 
 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01 ***p<0.001 vs. 
prazosin. 
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3.2.2. Participation of KATP channels in the relaxation mediated by β-adrenoceptor 
stimulation 
It is known that stimulation of β-adrenoceptor leads to KATP channel-mediated 
hyperpolarization of smooth muscle cells (Hussain et al., 2000; Piascik et al., 1997); 
however, is not clear to what extend this may contribute to the functional response. 
Therefore we decided to establish the role of KATP-channel in the vasomotor responses 
by means of the KATP-channel inhibitor glibenclamide (5 µM). Glibenclamide failed to 
significantly modify both contraction and relaxation to adrenaline (contraction: from 
pEC50 = 6.71 ± 0.06 to pEC50 = 6.5 ± 0.07, n = 6-7, p>0.05; relaxation: from pEC50 = 
6.64 ± 0.05 to pEC50 = 6.59 ± 0.07, n = 3-6, p>0.05) and NA (contraction: from pEC50 = 
5.74 ± 0.03 to pEC50 = 5.61 ± 0.14, n = 6, p>0.05; relaxation: from pEC50 = 6.18 ± 0.08 
to pEC50 = 6.21 ± 0.03, n = 5-6, p>0.05), indicating that the other mechanisms, distinct 
from the hyperpolarization via KATP-channel are responsible for the relaxation to the β-
adrenoceptor stimulation (Figure 3.4A,B). 
3.2.3. Influence of the agonist used to obtain tone on the endothelium-dependent 
relaxation to ACh 
ACh activates endothelial muscarinic M3 receptor in rat mesenteric arteries 
(Fujimoto et al., 1991; Rodriguez-Rodriguez et al., 2009; Wu et al., 1997). Arteries 
precontracted with PE dilated progressively to rising concentrations of ACh (1 nM -      
3 µM; pEC50 = 7.28 ± 0.02, n = 7). Precontraction with NA did not alter the response to 
ACh (pEC50 = 7.3 ± 0.04, n = 6; Figure 3.5A), whereas precontraction with adrenaline 
(pEC50 = 6.72 ± 0.04, n = 5, p<0.05; Figure 3.5A) or U46619 (pEC50 = 6.93 ± 0.02, n = 
6, p<0.05; Figure 3.5B) resulted in the significant inhibition of ACh-induced dilatation.  
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Figure 3.4 Effect of glibenclamide on the concentration-response curves to 
adrenaline and NA in small mesenteric arteries mounted in the wire 
myograph 
A. Summarized data demonstrating contraction and relaxation to rising 
concentrations of NA. In control as well as in the presence of the thromboxane 
mimetic U46619 and the α-adrenoceptor inhibitor prazosin (1 µM), KATP 
channel inhibitor glibenclamide (5 µM) did not alter the response (n = 5 – 6, 
p>0.05). 
B. Glibenclamide was also unable to alter the concentration-response curve to 
adrenaline obtained in control (n = 3 – 6, p>0.05), or following treatment with 
prazosin and precontraction with U46619 (n = 6 – 7, p>0.05). 
 
Results shown are the mean ± s.e.mean. 
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Prazosin
Prazosin+Glibenclamide
Control
Glibenclamide
log [NA] (M)
D
/D
m
ax
(%
)
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Prazosin
Prazosin+Glibenclamide
Glibenclamide
Control
log [Adrenaline] (M)
D
/D
m
ax
(%
)
T/
T m
ax
 (%
) 
T/
T m
ax
 (%
) 
 63
A   
B 
-9 -8 -7 -6 -5
0
20
40
60
80
100
PE tone
U4 tone*
log [ACh] (M)
D
/D
m
ax
(%
)
 
 C  
Figure 3.5 Effects of contractile agonists or glibenclamide on the relaxation 
to ACh in small mesenteric arteries mounted in wire myograph 
A Precontraction of rat mesenteric arteries with the nonselective adrenoceptor 
agonist adrenaline resulted in a rightward shift of the concentration-response 
curve to ACh (1 nM – 3 µM, n = 5, p<0.05), when compared with the tone 
induced by α1-adrenoceptor agonist PE (n = 7, p>0.05), whilst NA (n = 6, 
p>0.05) did not display such an inhibitory effect on the relaxation to ACh.  
B Precontraction with TP receptoragonist U46619 (U4) also suppressed the 
relaxation evoked by ACh (n = 6 – 7, p<0.05).  
C KATP channel inhibitor glibenclamide (5 µM) did not affect the concentration-
response curve to ACh (n = 7, p>0.05).  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01 vs. PE tone. 
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3.2.4. Conducted vasomotor response to adrenaline 
In order to investigate whether adrenergic stimulation is able to evoke a conducted 
vaosdilatation, we infused the adrenoceptor agonist adrenaline (1 µM) into Branch 1 of 
the triple-cannulated pressurized small mesenteric arteries (Figure 3.1). Adrenaline 
constricted the artery at the site of application (to 31.3 ± 10.8% of the maximal tone); 
however, no conducted vasoconstriction was observed in the Feed branch (n = 4; Figure 
3.6C). Interestingly, when the arteries were preconstricted to 58.5% ± 5.3 of the 
maximal tone with the abluminal application of U46619, perfusion of adrenaline into 
Branch 1 resulted in an enhanced local contraction (51.2 ± 5.0%) and appearance of 
spreading dilatation along the Feed branch (n = 5, p<0.05; Figure 3.6A,C). The 
vasodilatation reached 24.5 ± 2.9% at the “zero” point (the nearest point to the Branch 
1) and had little decay at 2.5 mm upstream (17.1 ± 3.9%). The spreading dilatation was 
blocked by propranolol (1 µM), confirming involvement of β-adrenoceptors in the 
observed phenomenon (n = 5, p<0.05; Figure 3.6C).   
3.2.5. Participation of the endothelium in the conducted vasodilatation to 
isoprenaline 
To determine the role of the endothelium in the spreading response to β-
adrenoceptor stimulation we have used β-adrenoceptor agonist isoprenaline (1 µM). In 
arteries preconstricted with U46619, isoprenaline induced a marked local dilatation 
followed by a spreading response along the Feed branch, which was similar to the 
response, induced by ACh (n = 9; Figure 3.7A). Whilst the denudation of the artery 
resulted in the loss of both local and conducted responses to ACh (n = 2, p<0.05; Figure 
3.7B), removal of the endothelium inhibited only the conducted vasodilatation to 
isoprenaline, whereas the local response remained unaltered (n = 4; Figure 3.7C). 
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Figure 3.6 Conducted vasomotor response to adrenaline in triple-
cannulated pressurized small mesenteric arteries  
A. Representative trace illustrating conducted response to luminal perfusion of 
adrenaline (1 µM) into Branch 1. While Branch 1 displayed vasoconstriction, 
conducted dilatation was observed in Feed branch.  
B. Change in intensity of carboxyfluorescein (CF) fluorescence measured in 
Branch 1 correlates with the delivery of adrenaline. 
C. Summarized data showing conucted responses to local application of 
adrenaline at rest (no tone), after pre-constriction with thromboxane mimetic 
U46619 (∼50% of max tone) in control conditions, and after pre-treatment with 
β-adrenoceptor antagonist propranolol (1 µM; n = 3-4, p<0.05). 
 
Results shown are the mean ± s.e.mean;, *p<0.05, **p<0.01vs. ‘no tone’, 
###p<0.001 vs. ‘U4 tone’. 
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Figure 3.7 Endothelium-dependent and –independent conducted dilatation 
in triple-cannulated pressurized small mesenteric arteries  
A. Summarized data illustrating conducted dilatation responses to luminal 
application of muscarinic cholinergic receptor agonist ACh (1 µM) and  
β-adrenergic agonist isoprenaline (1 µM) in arteries preconstricted with U46619 
(n = 9). 
B. Effect of endothelium removal on the conducted dilatation to ACh (n = 2). 
C. Effect of endothelium removal on the spreading dilatation to isoprenaline  
(n = 4).  
Results shown are the mean ± s.e.mean; ***p<0.001 vs. control. 
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3.2.6. Adrenoceptor subtypes responsible for the spreading dilatation 
In this series of experiments prazosin was used to reveal vasodilatation of the 
arteries submaximally preconstricted with U46619, to adrenaline and NA. Perfusion of 
adrenaline (1 µM) and NA (1 µM) into Branch 1 resulted in the local dilatation        
(75.1 ± 6.3% and 56.1 ± 10.8%, subsequently, n = 7) followed by spreading dilatation 
upstream in the Feed branch (Figure 3.8). Inhibition of α2-adrenoceptors with 
yohimbine (1 µM) resulted in an enhanced local response (90.6 ± 7.1%, n = 6 and 72.7 
± 7.1%, n = 7, respectively), whilst its co-application with propranolol inhibited the 
local dilatation (42.5 ± 9.3%, n = 5, and 35.8 ± 6.3 %, n = 6, respectively), which was 
further suppressed by the addition of β3-adrenoceptor antagonist SR 59230A (1 µM, 
16.0 ± 15%, n = 3, and 14.5 ± 7.8%, n = 6, respectively; Figure 3.8B,C). The amplitude 
of the conducted response matched the magnitude local dilatation remained after 
application of adrenergic receptor antagonists (Figure 3.8A,B).  
 
3.2.7. Participation of KATP channels in the conducted dilatation to β-adrenoceptor 
stimulation 
In this section we examined the hypothesis that although KATP channels do not 
play a role in the local dilation they may contribute to the conducted vasodilatation to β-
adrenoceptor stimulation. In the presence of glibenclamide (10 µM) the local dilatation 
to adrenaline (n = 5), NA (n = 5), or isoprenaline (n = 5, not shown) did not spread from 
the site of application more than 0.5-1 mm upstream in the Feed branch (n = 5;       
Figure 3.9A,B), whilst the conducted vasomotor response to ACh was unaffected (n = 
5; Figure 3.9C). 
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Figure 3.8 Effects of adrenoceptor antagonists on the spreading dilatation to 
adrenaline and NA in the triple-cannulated pressurized mesenteric arteries  
A,B. Summarized data showing effects of α2-adrenoceptor inhibitor yohimbine 
(1 µM), β1,2-adrenoceptor antagonist propranolol (1 µM) and β3-adrenoceptor 
antagonist SR 59230A (1 µM) on spreading dilatation responses to luminal 
application of adrenaline (1 µM, A) and NA (1 µM, B) in arteries preconstricted 
with U46619 (1 µM prazosin present). 
C,D. Diagram showing effects of yohimbine, propranolol, and SR 59230A on 
the local (Branch 1) dilatation to adrenaline (C) and NA (D).  
Results shown are the mean ± s.e.mean; *p<0.05 vs. control, #p<0.05, ##p<0.01  
vs. yohimbine. 
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Figure 3.9 Effect of glibenclamide on the conducted dilatation in the triple-
cannulated pressurized small mesenteric arteries 
Summarized data showing effects of KATP channel inhibitor glibenclamide  
(10 µM) on the conducted dilatation responses to luminal application of 
adrenaline (1 µM; n = 5 - 7, A), NA (n = 6 - 7, 1 µM, B) and ACh (1 µM; n = 5 - 
8, C). α1-adrenoceptor inhibitor prazosin (1 µM) was present in the experiments 
with adrenaline and NA. Arteries were preconstricted with U46619 (U4) or 
phenylephrine (PE), as indicated. 
Results shown are the mean ± s.e.mean. 
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3.3 Discussion 
We were interested whether adrenergic agonists could cause a conducted 
vasomotor response and attempted to evaluate the pathway of this response in rat small 
mesenteric arteries. Our results demonstrate that β-adrenoceptor signalling can evoke 
conducted vasodilatation, which relies on the integrity of the endothelial cell layer. 
Moreover, despite a lack of functional involvement of KATP channel in the local 
vasomotor response, this channel was crucial for the conducted dilatation. 
The sympathetic nervous system regulates arterial tone via modulation of the 
release of NA and adrenaline from the sympathetic nerve terminals and adrenal 
medulla, respectively, and their subsequent action on vascular α- and β-adrenoceptors 
(Guimaraes et al., 2001). Constriction in rat mesenteric arteries is mediated mainly by 
activation of α1-adrenoceptors (Hussain et al., 2000), but not α2-adrenoceptors (Silva et 
al., 1996). In our experiments, adrenaline was a more potent vasoconstrictor than NA. 
This observation is consistent with several previous studies, in which adrenaline had a 
greater order of potency towards α1-adrenoceptors than NA. This was demonstrated for 
the canine nasal vasculature (Berridge et al., 1986) and for the human mammary artery 
(Bevilacqua et al., 1991), but not for rat aorta (Buckner et al., 1996).  
Vascular tissue is known to express several subtypes of the β-adrenoceptors, and 
the predominant subtype in rat mesenteric arteries is still a subject of debate. According 
to the experiments recently performed in our lab, using selective agonists and 
antagonists for β-adrenoceptors, it was clearly demonstrated that the main subtype of β-
adrenoceptor responsible for the hyperpolarisation of rat mesenteric arteries was the   
β1-adrenoceptor, whilst the β2-subtype played only a secondary role (Garland et al., 
2011). This evidence supports previously published functional studies, which revealed 
the contribution of both subtypes in the dilatation to β-adrenergic agonists (Zwaveling 
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et al., 1996). Although participation of β3-adrenoceptors was indicated for rat 
mesenteric and coronary arteries (Dessy et al., 2004; Figueroa et al., 2009b), the β3-
adrenoceptor agonist BRL 37344 failed to evoke any significant hyperpolarization in 
experiments performed in our hands (Garland et al., 2011). The competitive antagonism 
of the commonly used β3-adrenoceptor agonist BRL 37344 with the α1-adrenoceptors 
may underlie the observed vasodilatation to this agonist in preparations with PE-
induced tone (Briones et al., 2005), and explain the absence of hyperpolarization from 
resting membrane potential in rat mesenteric arteries (Garland et al., 2011). 
In our experiments we have used the physiological agonists, adrenaline and NA, 
applied in the presence of prazosin on U46619-induced tone. The dilation to adrenaline 
was only slightly greater then that evoked by NA, and the difference did not reach 
statistical significance. The dilatation to the both agonists was augmented by the α2-
adrenoceptor antagonist yohimbine. This correlates with previous studies and may be 
explained by an antagonizing effect of α2-adrenoceptors on β-adrenoceptors in this 
tissue (Kato et al., 2008), probably through the suppressive action of Gi protein on 
adenylyl cyclase. Indeed, the dilatation was dramatically inhibited by β1,2-adrenoceptor 
antagonist propranolol, but, surprisingly, β3-adrenoceptor antagonist SR 59230A further 
inhibited the remaining response. This, however, may be explained by the possibility of 
an additional inhibition of β1,2-adrenoceptors by this antagonist (Hutchinson et al., 
2001; Manara et al., 1996).  
Unlike α-adrenoceptors, activation of β-adrenoceptors generally leads to a 
decrease in vascular tone via stimulation of adenylyl cyclase by Gs protein and 
subsequent enhancement of cAMP production (Guimaraes et al., 2001). First, a rise in 
cAMP leads to hyperpolarization of the smooth muscle via activation of KATP channels 
(Fujii et al., 1999; Nakashima et al., 1995; Quinn et al., 2004; Shi et al., 2007; Somlyo 
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et al., 1970), BKCa channels (White et al., 2001; Zhu et al., 2006), or the delayed-
rectifier voltage-gated K+ channels (Aiello et al., 1998). Second, PKA induces changes 
in the [Ca2+]i  homeostasis through inactivation of store-operated (Liu et al., 2005) and 
L-type Ca2+ channels (Liu et al., 1997; Orlov et al., 1996; Xiong et al., 1994). Finally, 
cAMP signalling involves stimulation of Epac (Gloerich et al., 2010), which was shown 
to antagonise KATP channel activity (Purves et al., 2009). 
Recently, it has been reported for rat mesenteric artery that the β-adrenoceptor-
induced hyperpolarization occurs predominantly via KATP channels. This was 
demonstrated by the inhibitory action of glibenclamide and a lack of the effect of the 
BKCa channel blocker, iberiotoxin (Garland et al., 2011). The hyperpolarization was 
able to evoke vasodilatation through the closure of L-type Ca2+ channels (Ko et al., 
2008; Nelson et al., 1995), and thus it was generally assumed that the activation of KATP 
channel may provide a pathway for the β-adrenoceptor-induced dilation (Quayle et al., 
1997). Our experiments have proved quite the opposite: inhibition of KATP channel 
affected neither contraction, nor dilation, caused by both adrenaline and NA. These data 
agree with a previous report that showed lack of the glibenclamide effect on the dilation 
to isoprenaline (White et al., 2001) and forskolin (Omar et al., 2000). This means that 
other mechanisms, distinct from smooth muscle hyperpolarization, e.g. modulation in 
Ca2+ homeostasis, are underlying the local vasodilatation.  
It is unlikely that such a pronounced hyperpolarization, as occurs in response to β-
adrenoceptor stimulation, has no physiological role. Knowing that hyperpolarisation can 
spread over considerable distances in rat mesenteric arteries (Takano et al., 2004), we 
have hypothesized that although KATP channels appear not to play the main role in local 
dilation, they may contribute to the spreading response. 
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Figure 3.10 Diagram illustrating a pathway for conducted dilatation in 
response to adrenaline 
Rise in smooth muscle cell [Ca2+]i in response to stimulation of α-adrenoceptor 
(α-AR, yellow) leads to a local constriction, whilst stimulation of β-
adrenoceptors (β-AR, green) evokes cAMP production, which could transfer to 
the neighbour non-stimulated cell and  hyperpolarize the cell (EM↑) by opening 
of KATP channels (orange). This hyperpolarization can spread via gap junctions 
(brown) to adjacent endothelial cell and propagate to distant smooth muscle 
cells, leading to their dilatation via closure of LCa channels. 
 
 
Adrenaline applied in the lumen of triple-cannulated pressurized arteries in resting 
conditions, evoked only a local constriction, which did not spread from the site of 
application. This agrees with earlier evidence that in hamster arterioles contraction to 
NA or KCl was constrained to the area of the application (Segal et al., 1999); however, 
when α1-adrenoceptors were suppressed and ∼50% tone was introduced, adrenaline, in 
addition to local vasoconstriction, caused propagated dilatation. This conducted 
dilatation appeared to be a result of β-adrenoceptor signalling, since propranolol 
completely abolished spread. Further, in the presence of β-adrenoceptor blockers, 
NA/adrenaline did not evoke conducted vasoconstriction, suggesting that depolarization 
associated with the α-adrenoceptor-induced vasoconstriction does not spread readily to 
the adjacent cells in these arteries. 
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How the local contraction can be associated with conducted vasodilatation is not 
clear. It is known that smooth muscle [Ca2+]i can spread to the endothelium through the 
myo-endothelial gap junctions, resulting in activation of endothelial NOS and K+ 
channels (Dora et al., 1997; Dora et al., 2000; Kansui et al., 2008); however, this 
mechanism alone is unlikely to explain the vasodilatation, as it was sensitive to 
propranolol or glibenclamide.  
An important observation that cAMP can penetrate through the gap junctions 
(Ponsioen et al., 2007) may help us to explain the phenomenon. Presumably, whilst the 
arterial segment directly exposed to adrenaline develops α1-adrenoceptor-mediated 
vasoconstriction, it produces sufficient cAMP to evoke hyperpolarization in the adjacent 
un-stimulated segment. This hyperpolarization can spread upstream in a pattern similar 
to the hyperpolarization caused by the KATP channel opener levcromakalim (Takano et 
al., 2004) (Figure 3.10). Additionally, the spread of cAMP can be enhanced by its 
downstream effectors, PKA and Epac, which have each been shown to enhance gap 
junctional communication (Duquesnes et al., 2010; Popp et al., 2002).  
Interestingly, immediately after adrenaline was removed, the Feed branch was 
seen to dilate further and Branch 1 dilate beyond the resting level of tone, reaching this 
level in only a few minutes. This may illustrate a faster vessel recovery from the [Ca2+]i 
rise than from the effects of elevated [cAMP]i, however, the precise mechanisms 
responsible for this phenomenon are yet to be determined. 
To elucidate the role of KATP channels in this spreading dilatation, β-adrenoceptor-
mediated dilatation to the physiological relevant catecholamines, adrenaline and NA, 
was unmasked by the α1-adrenoceptor inhibitor prazosin. Whilst having no effect on the 
ACh-mediated response, glibenclamide nearly fully suppressed the conducted dilatation 
to either adrenaline, NA, or isoprenaline. Denudation of the artery abolished both the 
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local and the conducted dilatation to ACh, whilst affecting only conducted dilatation 
evoked by isoprenaline. This finding corresponds to the observation that modulation of 
vascular tone by the endothelium may be carried by a passive spread of 
hyperpolarization through the myo-endothelial gap junctions, independently of changes 
in endothelial cell [Ca2+]i (Takano et al., 2004). 
Finally, during our experiments we have observed an inhibitory effect of U46619 
and adrenaline on ACh-mediated dilation. Whilst U46619 has been reported to inhibit 
SKCa channels during muscarinic receptor signalling (Crane et al., 2004; Plane et al., 
1996), the effects of adrenaline on the ACh response will be elucidated in Chapter 5.  
To summarize, the main finding of the present chapter was the demonstration that 
β-adrenoceptors evoked a conducted dilatator response, able to spread along the 
vascular wall by way of the endothelium. KATP channels appear to play a major role, 
contributing not to the local, initiating dilatation, but to the spreading vasodilatation, an 
important physiological phenomenon that has a significant impact on the regulation of 
vascular blood flow.  
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Chapter 4. Participation of the endothelium in dilatation to                
β-adrenoceptor  stimulation 
 77
4.1 Introduction 
The vascular endothelium lies at the critical interface between the blood and the 
blood vessel wall. It forms a semi-permeable barrier that is particularly important for 
controlling the passage of macromolecules and fluid between the blood and interstitial 
space. However, the endothelium is now known to be more than just a passive barrier 
against the substances dissolved in the blood plasma. It is an important organ that 
regulates a variety of functions including immune defence reactions, angiogenesis, 
thrombogenesis, and vascular smooth muscle tone.  
Vascular tone is also controlled by sympathetic nervous system, through release of 
thcatecholamines, adrenaline and noradrenaline (NA), that target at least nine 
adrenoceptor subtypes, five of these, namely, α2A/D, α2C, β1, β2, and β3, have been 
identified in the vascular endothelium. Activation of these receptors either directly or 
acting through the release of nitric oxide (NO) may participate in the modulation of the 
smooth muscle tone (For review see Guimaraes et al., 2001). 
It is well established that the vascular endothelium has a suppressive effect on 
vasoconstriction (Cocks et al., 1983; Dora et al., 1997; Jin et al., 2008; White et al., 
1986). The main participant in this suppression appears to be endothelial nitric oxide 
synthase (eNOS), since denudation of rat aorta increased sensitivity to adrenergic 
agonists by attenuatign  NO release (Martin et al., 1986). Inhibition of NOS with L-
NAME also enhances the PE contractile response in rat mesenteric arteries (Ben Cheikh 
et al., 2002; Dora et al., 2000). Therefore, it was suggested that activation of eNOS in 
this artery is triggered by endothelial α1-adrenoceptors (Filippi et al., 2001); however, 
stimulation of the smooth muscle α1-adrenoceptors was shown to have an indirect effect 
on the endothelium due to a Ca2+ signal (likely IP3) transferring through the myo-
endothelial gap junctions, leading to an increase of NO synthesis and opening of 
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endothelial KCa channels (Dora et al., 2000; Jin et al., 2008). Furthermore, freshly 
isolated endothelial cells PE does not increase [Ca2+]i (Dora et al., 2000). 
On the other hand, the ability of catecholamines to evoke endothelial NO release 
in response to stimulation of α2-adrenoceptors has also been well described (Guimaraes 
et al., 2001). For example, selective α2-adrenoceptor agonists caused concentration-
dependent vasodilatation of the rat mesenteric arterial bed via NO production by the 
endothelium (Bockman et al., 1996; Figueroa et al., 2001; Pimentel et al., 2007). The 
main subtype that is responsible for this endothelium-dependent NO-mediated 
relaxation is the α2A/D-adrenoceptor, which, surprisingly, did not appear to mediate this 
effect via the cAMP pathway (Bockman et al., 1996). 
It has also been suggested that endothelial β-adrenoceptors may contribute to the 
regulation of vascular tone; however, studies of endothelial participation in the 
relaxation to β-adrenoceptor agonists have given rather contradictory results. Whilst β-
adrenoceptors are generally considered to stimulate eNOS, particularly in cultured 
endothelial cells (Hashimoto et al., 2006; Kou et al., 2007; Zhang et al., 2006b) and 
conduit vessels, such as murine aorta (Akimoto et al., 2002; Ferro et al., 2004; 
Toyoshima et al., 1998) or carotid artery (MacDonald et al., 1999), removal of 
endothelium or eNOS inhibition affected the vasodilatation in rat mesenteric arteries in 
only a fraction of cases (Figueroa et al., 2009b; Graves et al., 1993; Kozlowska et al., 
2003). For example, in perfused mesenteric artery, stimulation of adrenoceptors with 
adrenaline was shown to evoke transient NO release and eNOS phosphorylation at 
serine 1177. Nevertheless, a selective β-adrenoceptor agonist, isoprenaline, failed to 
lead to eNOS phosphorylation (Figueroa et al., 2009b). Others have reported no effect 
of eNOS inhibition on the dilatation responses to isoprenaline (Blankesteijn et al., 1993; 
Briones et al., 2005) or forskolin (Simonsen et al., 1999). Moreover, endothelium 
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denudation or inhibition of eNOS was even shown to augment β-adrenoceptor-mediated 
relaxation in this preparation (Iwatani et al., 2008).  
In the previous chapter (Chapter 3) we demonstrated that the endothelium is 
crucial for the conducted dilatation in response to β-adrenoceptor stimulation. It is not 
clear, however, whether the endothelium contributes to the local dilatation in response 
to β-adrenoceptor signalling in rat small mesenteric arteries. Therefore we decided to 
examine the role of endothelium and endothelium-derived relaxing factors (EDRFs) in 
the local dilatation to adrenaline and NA by means of inhibition of EDRF pathways, 
endothelium removal and comparison of luminal and abluminal applications of the 
adrenergic agonists. 
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4.2 Methods 
4.2.1 Pressure myography 
In order to enable selective application of studied agonists on endothelial or 
smooth muscle cell layers of the artery, the pressure myograph system was used in these 
experiments. For this experiments, segments of arteries free of side branches were cut to 
give a final length of >2 mm, cannulated with two glass pipettes in a bath of the 
temperature-regulated chamber (10 mL, 120CP, Danish Myo Technology, Denmark) 
and pressurized to 70 mm Hg, as described in Section 2.2. A syringe pump system 
(BeeHive syringe pump system, Bioanalytical systems, USA) was connected to one end 
of the artery, whilst the other end was attached to the gravity-fed pressure system allied 
to the open-ended reservoir (5 ml). To obtain denuded arteries, pressure was decreased 
and an air bubble (∼2.5 mm3) was perfused through the artery. The lumen was then 
washed and the pressure was re-introduced. After 20 minutes of equilibration period, 
removal of the endothelium was assessed by loss of the dilatation to ACh (0.1 -10 µM).  
4.2.2 Luminal and abluminal cumulative concentration-response curves 
The studied agonists were added directly to the bath (abluminally) or infused via 
lumen, as described in Section 2.2.1 (Figure 4.1). To obtain abluminal concentration-
response curves, adrenaline or NA were cumulatively applied in bath with time 
increments of not less then two minutes, to allow the response to reach a plateau (Figure 
4.2A). Due to the pipette dead volume, the minimal waiting time between the 
concentrations for luminal infusions was three minutes (Figure 4.2B). Dilatation 
concentration-response curves were obtained following submaximal (70-80% of 
maximal tone) preconstriction with PE or, in the cases when α-adrenergic inhibitors 
were applied, a stable TP receptor agonist U46619. 
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4.2.3 Data analysis  
Data were analyzed as described previously (see Section 2.5). 
4.2.4 Drugs and solutions  
See section 2.6 for the preparation details.  
MOPS buffered solution was used throughout in these experiments. Solutions 
containing L-NAME (100 µM) had their pH additionally adjusted to 7.4±0.02. 
 
 
 
  
 
   
 
 
 
 
Figure 4.1 Diagram illustrating cross-section of the vessel during luminal perfusion 
or abluminal application of studied agonists 
During experiments drugs were either applied directly in bath (abluminally), or infused 
via the lumen by means of syringe pumps (BeeHive syringe pump system). This 
technique allowed the selective application of studied compounds at smooth muscle or 
endothelial cell sides of the artery. 
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Figure 4.2 Constriction of pressurized small mesenteric arteries to NA 
A. Original trace showing concentration-dependent constriction of rat mesenteric 
arteries to abluminal application of NA. 
B. Original trace illustrating concentration-dependent constriction NA perfused 
through the lumen.  
Arrows indicate the timing of NA application. Note that the dead space volume 
of the pipette is causing a delay in the response to luminally perfused NA. The 
muscarinic cholinergic receptor agonist ACh (1 µM) was applied at the end of 
each trace to examine endothelial cell viability. 
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4.3 Results 
4.3.1 Comparison of the constriction responses to luminal and abluminal 
application of adrenergic agonists; effect of NOS inhibition 
To establish the involvement of the endothelium in the dilatation to adrenergic 
agonists, in this section we have examined whether luminal perfusion of adrenaline and 
NA results in reduced contractility due to release of EDRF.  
First, cumulative concentration-response curves to these agonists were obtained 
during luminal perfusion and compared to those obtained by abluminal application. The 
concentration-response curves obtained luminally were significantly shifted to the right 
for both adrenaline (from pEC50 = 7.32 ± 0.06, n = 10, to pEC50 = 6.6 ± 0.07, n = 6, 
p<0.05; Figure 4.3A) and NA (from pEC50 = 6.43 ± 0.04, n = 9, to pEC50 = 5.89 ± 0.05, 
n = 11, p<0.05; Figure 4.3B). Adrenaline was a more potent agonist than NA when 
applied by both methods (p<0.05),  as observed in the wire myograph experiments (See 
Chapter 3, Figure 3.3A). 
Since there was a shift between luminal and abluminal applications of the 
agonists, we have examined whether this shift was mediated by EDRF. For this, we 
have used NOS inhibitor L-NAME (100 µM) and compared its effect on luminal and 
abluminal concentration-response curves. Inhibition of eNOS augmented both 
adrenaline and NA abluminal responses (from pEC50 = 7.32 ±0.06, n = 10, to pEC50 = 
7.74±0.04, n = 6, for adrenaline (p<0.05); and from pEC50 = 6.43±0.04, n = 9, to pEC50 
= 6.79+0.05, n = 7, for NA (p<0.05)); however, constriction to luminal application of 
these agonists was not affected by L-NAME (P>0.05; Figure 4.4 and 4.5), indicating 
that the reduction in the contractile response to lumenally perfused agonists was not 
mediated by eNOS signalling.   
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Figure 4.3 Concentration-response curves of constriction to adrenaline and 
NA applied luminally or abluminally in pressurized small mesenteric 
arteries 
A. Summarized data demonstrating contraction to rising concentrations of 
adrenaline, applied abluminally (in bath; n = 10) or perfused luminally (lumen;  
n = 6, p<0.05). 
B. Summarized data demonstrating constriction to rising concentrations of NA 
applied abluminally (n = 9) or luminally (n = 11, p<0.05). 
 
Results shown are the mean ± s.e.mean, *p<0.05, ***p<0.001 lumen vs. bath. 
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Figure 4.4 The effect of NOS inhibition on the constriction to adrenaline in 
pressurized small mesenteric arteries 
A. Concentration-response curves demonstrate augmented constriction to 
adrenaline applied abluminally after the inhibition of NOS with L-NAME   (100 
µM, n = 6 - 10, p<0.05). 
B. Concentration-response curve to luminal perfusion of adrenaline was not 
modified by L-NAME, (n = 6, p>0.05). 
 
Results shown are the mean ± s.e.mean, *p<0.05 vs. control. 
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Figure 4.5 The effect of NOS inhibition on the constriction to NA in 
pressurized small mesenteric arteries 
A. Concentration-response curves demonstrate augmented constriction to NA 
applied abluminally after inhibition of NOS with L-NAME (100 µM, n = 7-9, 
p<0.05). 
B. Concentration-response curve to luminal perfusion of NA was not modified 
by L-NAME (n = 6 - 11, p>0.05). 
 
Results shown are the mean ± s.e.mean, *p<0.05, vs. control. 
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4.3.2 Dilatation of arteries preconstricted with PE to the luminal application of 
adrenergic agonists 
To establish whether application of adrenergic agonists via lumen can evoke 
endothelium-dependent dilatation, rat small mesenteric arteries were submaximally 
preconstricted with α1-adrenoceptor agonist PE, and then NA and adrenaline were 
luminally perfused. Both NA and adrenaline relaxed arteries to 34.7 ± 10% (n = 9) and 
28.2 ± 12% (n = 7), respectively (Figure 4.6), whilst luminal perfusion of MOPS buffer 
by itself had no significant effect, as it has been shown previously (Rodriguez-
Rodriguez et al., 2009). To elucidate whether EDRFs participated in the adrenaline-
evoked dilatation, the NOS inhibitor L-NAME was applied, and it did not affect the 
dilatation (P>0.05). Application of propranolol (1 µM) alone blocked the dilatation, 
supporting the suggestion of β-adrenoceptors involvement (Figure 4.6).  
4.3.3 Comparison of the dilatation to the luminal and abluminal application of 
adrenergic agonists of arteries preconstricted with U46619 
In order to unmask the relaxation to adrenergic agonists, α1-adrenoceptor 
antagonist prazosin (1 µM) was used and arteries were submaximally preconstricted 
with thromboxane mimetic U46619. Prazosin revealed a nearly maximal dilatation to 
the abluminally applied adrenaline (Emax = 86.1 ±6.7%, n = 4) and NA (Emax = 90.20 ± 
6.4%, n = 6); however, luminal perfusion resulted in a rightward shift of the 
concentration-response curves for adrenaline (from pEC50 = 6.44 ± 0.2, n = 4, to pEC50 
= 5.8 ± 0.3, n = 5; Figure 4.7A) and NA (from pEC50 = 6.22 ± 0.06, n = 8, to pEC50 = 
5.63 ± 0.02, n = 6, p<0.05; Figure 4.7B), but not for a lipophilic adenylyl cyclase 
activator forskolin (from pEC50 = 6.33 ± 0.04, n =11, to pEC50 = 6.36 ± 0.03, n = 5; 
Figure 4.7C).  
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Figure 4.6 The effect of luminal perfusion of adrenaline and NA in 
pressurized small mesenteric arteries preconstricted with PE 
A. Concentration-response curves represent effects of NOS inhibitor L-NAME 
(100 µM; n = 5) and β-adrenoceptor antagonist propranolol (1 µM; n = 3) on the 
dilatation to luminal applied adrenaline (n = 9). 
B. Dilatation to luminally perfused noradrenaline (NA) was also unaffected by 
NOS inhibition (n = 4 - 9). 
 
Results shown are the mean ± s.e.mean. 
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Figure 4.7 Comparison of the dilatation concentration-response curves 
obtained to luminal vs. abluminal application of agonists in pressurized 
small mesenteric arteries  
A. In the presence of the α1-adrenoceptor antagonist prazosin (1 µM), arteries 
preconstricted with U46619 dilated to abluminal application of adrenaline with a 
greater potency than to luminal perfusion (n = 4 - 5). B. Arteries preconstricted 
with U46619 in the presence of prazosin also displayed an enhanced dilatation to 
abluminal applications of NA compared to luminal perfusion (n = 6 - 8, p>0.05).  
C. Concentration-response curves to luminal perfusion of forskolin were not 
different to abluminal application (PE tone; n = 5 - 11, p>0.05).  
Results shown are the mean ± s.e.mean; ***p<0.001 vs. bath. 
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 4.3.4. The role of the endothelium in the dilatation to luminally perfused 
adrenergic agonists   
These experiments were designed to reveal a possible role of the endothelium in 
the dilatation to luminally applied adrenaline or NA. In the presence of prazosin, both 
luminally applied catecholamines evoked concentration-dependent dilatation of 
U46619– preconstricted arteries, which was insensitive to the inhibition of eNOS with     
L-NAME (pEC50 = 5.99 ± 0.39, n = 3, p>0.05, for adrenaline, and pEC50 = 5.71 ± 0.17, 
n = 6, p>0.05, for NA). Denudation of the artery markedly augmented the dilatation, 
with pEC50 values reaching 7.37 ± 0.89 for adrenaline (n = 3) and 6.94 ± 0.09 for NA      
(n = 6) (Figure 4.8). 
 
4.3.5. The role of the endothelium in the relaxation to abluminally applied 
adrenergic agonists   
Arteries preconstricted with U46619 in the presence of prazosin submaximally 
dilated to abluminally applied adrenaline (Emax = 98.3 ± 0.8%, n = 4) and NA (Emax = 
88.1 ± 5.5%, n = 6). This relaxation was insensitive to L-NAME (pEC50 = 6.44 ± 0.04, n 
= 4, p>0.05, for adrenaline, and pEC50 = 6.22 ± 0.06, n = 9, p>0.05, for NA; Figure 
4.9A.B). Additional inhibition of IKCa and SKCa with TRAM-34 (1 µM) and apamin   
(50 nM) resulted in a moderate leftward shift of NA concentration-response curve 
(pEC50 = 6.51 ± 0.04, n = 4, p>0.05; Figure 4.9B). Denudation of the artery has slightly 
augmented the potency to NA (pEC50 = 6.38 ± 0.05, n = 8, p>0.05; Figure 4.9B).  
When a selective β-adrenoceptor agonist, isoprenaline, was used, L-NAME also 
failed to affect the dilatation of the PE-preconstricted arteries (from pEC50 = 7.07 ± 
0.09, to pEC50 = 7.16 ± 0.09, n = 5; p>0.05; Figure 4.9B). These data indicate the lack 
of participation of EDRF in the relaxation to β-adrenoceptor stimulation.  
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Figure 4.8 Involvement of the endothelium and eNOS in the dilatation to 
luminally perfused adrenaline and NA in pressurized small mesenteric 
arteries  
A. Concentration-response curve demonstrating the effect of NOS inhibitor    L-
NAME (100 µM) or endothelium denudation (-EC) on the concentration-
dependent relaxation to lumenally applied adrenaline (n = 3 - 5).  
B. Effect of L-NAME or endothelium denudation on concentration-dependent 
relaxation to lumenally applied noradrenaline (NA; n = 5 - 6). 
Arteries were preconstricted with thromboxane mimetic U46619 in the presence 
of α-adrenoceptor antagonist (prazosin or phentolamine, 1 µM) 
Results shown are the mean ± s.e.mean, *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
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Figure 4.9 Involvement of EDRFs in the dilatation of pressurized small 
mesenteric arteries to abluminal application of adrenergic agonists  
A. Concentration-response curves showing the effect of L-NAME (100 µM) on 
the dilatation to adrenaline, applied in bath (n = 4, p>0.05). B. Effects of 
endothelium denudation (-EC), L-NAME, TRAM-34 (1 µM) and apamin  
(50 nM) on the dilatation to NA (n = 3-9, p>0.05). Arteries were preconstricted 
with U46619 in the presence of the α1-adrenoceptor antagonist prazosin (1 µM; 
A,B). C. Effect of L-NAME on the dilatation of PE-preconstricted arteries to  
β-adrenoceptor agonist isoprenaline (n = 8, p>0.05).  
Results shown are the mean ± s.e.mean. 
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4.4 Discussion 
The vascular endothelium lining blood vessels is known to be a semi-permeable 
barrier that regulates the flux of molecules between the blood and surrounding tissue. 
The permeability of transferred substances depends on their molecular radius (Mehta et 
al., 2006) as well as solubility in lipids (Lew et al., 1989). Endothelial cells are 
therefore the first to be exposed to luminally applied molecules and their action on 
smooth muscle cells will depend on the rate of diffusion through the endothelium.  
In accordance with this, we have tested the hypothesis that luminally applied 
adrenergic agonists may predominantly stimulate endothelial adrenoceptors and lead to 
release of endothelium-derived relaxing factors. Our experiments demonstrated a 
rightward shift of the constriction concentration-response curve for the luminally 
perfused catecholamines in comparison to abluminal application, but this shift was not 
due to release of endothelium-derived relaxing factors, but due to a restricted 
permeability of the endothelial layer to the hydrophilic molecules that may increase 
dilution of the agonist in smooth muscle tissue. This assumption was supported by a 
similar rightward shift of the dilatation concentration-response curve to the luminally 
infused adrenaline and NA that was reversed by removal of the endothelium. 
Interestingly, a lipophilic molecule forskolin, which also activates adenylyl cyclase, did 
not display such rightward shift of the luminally obtained concentration-response curve. 
This agrees with the observation that the endothelial barrier in small arteries is less 
permeable to water soluble molecules than to lipophilic ones (Lew et al., 1989). 
Stimulation of eNOS in rat mesenteric artery has been suggested to be triggered by 
endothelial α1-adrenoceptors (Filippi et al., 2001) α2-adrenoceptors (Bockman et al., 
1996; Figueroa et al., 2001; Pimentel et al., 2007; Rascado et al., 2005), partially β1-
adrenoceptors (Graves et al., 1993; Huang et al., 1998) and all three subtypes of β-
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adrenoceptors (Figueroa et al., 2009b). To clarify the role of eNOS in the dilatation, we 
have examined the effect of NOS inhibition on both constriction and dilatation 
responses to tested catecholamines. During constriction to abluminal application of 
adrenaline and NA, inhibition of eNOS resulted in a leftward shift of concentration-
response curves. A similar effect was already described for both, conduit vessels, such 
as rat aorta (Martin et al., 1986), and resistance vessels, such as rat mesenteric artery 
(Dora et al., 2000), and can be explained by basal activity of eNOS (Martin et al., 1986; 
Simonsen et al., 1999) as well as by an indirect effect of smooth muscle Ca2+ signalling 
through myo-endothelial gap junctions (Dora et al., 2000; Kansui et al., 2008). 
Intriguingly, the shift was present only in case of abluminal applications of 
catecholamines, whereas luminal concentration-response curves remained the same 
after NOS inhibition, as if the NO pathway was already inactivated. This observation 
led us to further experiments, where effects of β-adrenoceptor signalling on 
endothelium-derived relaxation were evaluated (see the results in Chapter 5). 
In contrast to constriction, the dilatation to both luminal and abluminal application 
of adrenaline and NA was not affected by inhibition of eNOS. Since there was evidence 
of EDHF-type responses to β-adrenergic agonists (Dessy et al., 2004; Huang et al., 
1998), we have inhibited EDHF by blocking SKCa and IKCa channels; however this, as 
well as endothelial denudation, resulted rather in slight augmentation of the response. 
Our data therefore support the assumption that the endothelium in rat mesenteric arteries 
regulates and maintains vascular tone via counteracting not only vasoconstriction, but 
also vasodilatation, possibly at least in part by release of endothelium-derived 
contracting factors (Iwatani et al., 2008) (this will be discussed in the Chapter 6 in 
detail). Additionally, the inhibition of the vasodilatation following endothelial 
disruption seen in several studies (Figueroa et al., 2009b; Graves et al., 1993) may be 
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explained by a non-specific constitutive influence of the endothelium on the smooth 
muscle rather than the action of endothelial β-adrenoceptors (Briones et al., 2005). 
Several studies demonstrated that β3 is the adrenoceptor subtype that was 
predominantly involved in activation of eNOS. This was shown for cultured endothelial 
cells (Kou et al., 2007), rat aorta (Trochu et al., 1999), carotid (MacDonald et al., 
1999), and mesenteric arteries (Figueroa et al., 2009b). In these studies, the β3-
adrenoceptor agonist BRL 37344 or antagonist SR 59230A were used to establish an 
involvement of the β3-adrenoceptor in the release of NO; however, other authors 
strongly argue against β3-adrenoceptor-mediated dilatation responses in rat mesenteric 
artery and aorta and point out that both compounds are antagonists of α1-adrenoceptors 
(Brahmadevara et al., 2003; Briones et al., 2005). Notably, in rat mesenteric arteries, β-
adrenoceptor agonists isoprenaline and BRL 37344 were substantially less effective in 
inducing NO release, than the subtype non-selective agonist adrenaline (Figueroa et al., 
2009b). Therefore it could be suggested that activation of α1-adrenoceptors located on 
smooth muscle cells evokes rise in [Ca2+]i that can be transferred to the endothelium, 
leading to activation of eNOS (Dora et al., 2000; Kansui et al., 2008). An additional 
mechanism of NO release may provide neuronal NOS, which also participates in 
responses to β-adrenoceptor stimulation in this tissue (Blanco-Rivero et al., 2006a).  
On the other hand, inhibition of NOS was shown to cause down-regulation of β-
adrenoceptors in anesthetized rats (Whalen et al., 2006), thus, it seems possible that     
L-NAME in some cases attenuated the response to β-adrenergic agonists due to 
enhanced desensitization rather than due to disruption of the dilatation pathway, 
provided by the endothelium.   
Importantly, the non-selective adrenoceptor agonist NA, which has been used as a 
contractile agent in many experiments, was shown to promote NO release in 
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isoprenaline-induced relaxation via stimulation of α2-adrenoceptors in endothelial cells 
(Rascado et al., 2005). In our experiments though, we have used a selective α1-
adrenoceptor agonist PE, which to circumvent the pathway described above (Rascado et 
al., 2005).  
Endothelial denudation was shown to amplify α2-adrenoceptor-mediated 
contraction in rat aorta (Martin et al., 1986) and mesenteric artery (Blanco-Rivero et al., 
2006b; White et al., 1986); it was also reported that eNOS may be involved in the 
dilatation in response to α2-adrenoceptor agonists (Bockman et al., 1996; Figueroa et 
al., 2001; Pimentel et al., 2007; Rascado et al., 2005). On the other hand, the dilatation 
to the commonly used α2-adrenergic agonist clonidine may signal through the activation 
of α1-adrenoceptor (Silva et al., 1996) and lead to a rise in endothelial cell [Ca2+]i. 
Besides that, in our experiments propranolol alone attenuated, whereas yohimbine did 
not suppress, but enhanced the dilatation to adrenaline and NA (see Chapter 3). This 
observation supports the observation that α2-adrenoceptors seem to exert rather an 
inhibitory effect on β-adrenoceptor signalling (Kato et al., 2008), leading to reduced 
dilatation to physiological β-adrenergic agonists. 
A lack of selective β-adrenoceptor antibodies was successfully substituted by the 
β-adrenoceptor fluorescent ligand BODIPY, which confirmed the presence of               
β-adrenoceptors in the adventitia, media and intima of rat small mesenteric arteries 
(Briones et al., 2005). The fact that β-adrenoceptors were not exclusively localized in 
the smooth muscle cells, but also in the endothelium, allows us to suggest that this 
receptor may play as yet unidentified role. Endothelial cell β-adrenoceptors may 
participate in regulation of the intima permeability through their downstream effectors 
PKA and Epac (Birukova et al., 2009), or enhance gap junctional coupling and thereby 
promote conducted vasomotor response (please see Chapter 6) (Duquesnes et al., 2010; 
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Popp et al., 2002). Our preliminary data also demonstrate an increase in the frequency 
and extent of [Ca2+]i events in endothelial cells in response to isoprenaline (see Chapter 
7). Whether this effect is attributed to signalling of smooth muscle cells (SMCs) or 
endothelial cells is the subject of ongoing experiments. 
To summarise, in this chapter we have examined the contribution of the 
endothelium in the dilatation of rat small resistance mesenteric arteries to physiological 
adrenergic agonists, adrenaline and NA. The results of this study demonstrate that the 
endothelium does not seem to play a direct role in the dilatation to β-adrenoceptor 
stimulation. It rather creates a semi-permeable barrier, which prevents luminal 
catecholamines from acting on the smooth muscle cell receptors. However, the 
endothelium is crucial for coordinating the relaxation and as shown in the previous 
chapter, enabling propagated vasodilatation to β-adrenoceptor agonists.  
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Chapter 5. Effects of β-adrenoceptor stimulation on the endothelium-
dependent dilatation 
 99
5.1 Introduction 
The endothelium modulates vascular tone by means of release of vasoactive 
factors as well as by providing a low-resistance pathway for hyperpolarizing currents 
(Dora, 2010; Takano et al., 2004). Dysfunction of this endocrine gland is known to be 
implicated in the development of many cardiovascular diseases, one of which is 
hypertension (Dharmashankar et al., 2010; Feletou et al., 2010b).  
Raised levels of adrenaline and/or NA in blood plasma are associated with 
cardiovascular pathogenesis (Borkowski et al., 1992; Brown et al., 1981; Floras, 1992; 
Gayen et al., 2010; Goldstein, 1983; Grassi et al., 2010; Higashi et al., 2002; Majewski 
et al., 1981; Tung et al., 1981). One of the predictors for a poorer cardiovascular risk 
status is also an increased sympathoadrenal reactivity to stress (Chida et al., 2010; Flaa 
et al., 2008; Lambert et al., 2010), which results in elevated plasma adrenaline 
concentration (Brown et al., 1981; Floras, 1992). Adrenaline may activate 
adrenoceptors expressed on the intima, media and adventitia. Generally, α-
adrenoceptors are mainly involved in vasoconstriction, whilst β-adrenoceptors evoke 
vasodilatation in mesenteric arteries. β-adrenoceptors stimulate adenylyl cyclase to 
elevate cellular cAMP levels, leading to relaxation of the smooth muscle (see Section 
1.2.5 for details). Despite the evidence that β-adrenoceptors are expressed in the 
endothelium and can induce endothelium-dependent relaxation in larger vessels (Ferro 
et al., 2004; Figueroa et al., 2009b; Nishina et al., 1999), our previous investigations 
failed to prove involvement of the endothelium in the local dilatation of rat small 
mesenteric arteries to β-adrenergic agonists (see Chapter 4).   
Activation of healthy endothelium, for example in response to ACh or ATP, is 
associated with a rise in endothelial cell [Ca2+]i (McSherry et al., 2005; Mumtaz et al., 
2010; Rodriguez-Rodriguez et al., 2009; Takano et al., 2004), which stimulates 
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endothelial nitric oxide synthase (eNOS) and cyclooxygenase (COX), leading to release 
of nitric oxide (NO) and prostanoids. It can also stimulate the intermediate and small 
conductance Ca2+-sensitive K+ channels (IKCa and SKCa, respectively); activation of 
these channels causes an efflux of K+ and hyperpolarization of the endothelium (Chen et 
al., 1997; Dora et al., 2008; Edwards et al., 1998; Zygmunt et al., 1996). This 
hyperpolarisation is a key event for the formation of NO- and prostanoid-independent 
endothelium derived hyperpolarization (EDH) of vascular smooth muscle cells (Brahler 
et al., 2009; Garland et al., 1992b; Taylor et al., 1988). EDH can be transferred from 
endothelial cells to smooth muscle cells by two main mechanisms: stimulation of 
smooth muscle Kir channels and the Na+/K+-ATPase with K+ released from endothelial 
IKCa channels (Dora et al., 2008; Doughty et al., 1999; Edwards et al., 1998), and/or 
conduct of the hyperpolarization derived from SKCa channels via myo-endothelial gap 
junctions (Coleman et al., 2002; Dora et al., 2008; Dora et al., 1999; Dora et al., 2003a; 
Figueroa et al., 2009a). Regardless of the mechanism, hyperpolarization of SMC closes 
LCa channels and results in vasodilatation. The vasodilatation can be spatially magnified 
by the ability of EDH to spread both longitudinally and radially through the myo-
endothelial gap junctions (Dora, 2001; Dora et al., 2003b; Segal et al., 1989; Takano et 
al., 2004; Yamamoto et al., 2001). Signalling pathways triggered by many stimuli, such 
as activation of adrenoceptors, involve protein kinases A and C, which can modulate the 
conducted vasodilatation (Bao et al., 2007; Haug et al., 2003; Heyman et al., 2009; 
Inoguchi et al., 1995; Popp et al., 2002) (see Section 1.4 for details). 
Arteries from hypertensive humans and rats were shown to have an impaired 
endothelial function and eNOS activity (Higashi et al., 2002; Li et al., 2007; Linder et 
al., 1990; Wang et al., 2010), supporting a suggestion that deficiency of NO is 
implicated in the pathogenesis of cardiovascular disease (Feletou et al., 2010b; 
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Kedziora-Kornatowska et al., 2006; Kleinbongard et al., 2006; Schulz et al., 2000; 
Wang et al., 2010). There is also a clear link between impairment of the EDH pathway 
and hypertension (Brahler et al., 2009; Feletou et al., 2010b; Figueroa et al., 2009a; 
Grgic et al., 2009); however, despite extensive studies, the precise mechanism linking 
an increased sympathoadrenal reactivity and cardiovascular pathogenesis is still to be 
determined (Lambert et al., 2010). 
Recently, it was shown that activation of adenylyl cyclase leads to suppression of 
the IKCa component of the endothelium-dependent hyperpolarisation to ACh (Dora et 
al., 2008). Therefore, we hypothesized that activation of β-adrenoceptors with 
physiological adrenergic agonists may modulate the endothelium-dependent responses 
in resistance arteries. To confirm this assumption, we investigated the effect of β-
adrenoceptor activation on endothelial-dependent dilatation in small resistance arteries 
from the rat.  
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5.2 Methods 
5.2.1 Rat mesenteric artery isolation and preparation 
See Section 2.1 for methods of artery isolation and preparation. 
5.2.2 Pressure myography 
Arteries were cannulated and pressurized as described in Section 2.2. This method 
was used to study both local and conducted dilatation responses.  
5.2.3 Measurement of local responses 
Local dilatation responses were measured using double cannulated vessels (for 
detailed description see Section 2.2.2). Vessels were preconstricted to 70 - 80% of the 
maximal tone by PE; in experiments, where adrenergic agonists were perfused via the 
lumen (luminally), PE was also used to adjust the tone to the similar level as in the 
control conditions. Cumulative concentration-response curves for ACh (1 nM – 30 µM) 
were performed by addition of rising concentrations of ACh directly into the bath 
(abluminally). To allow predominant action on endothelium, studied substances were 
infused luminally by means of syringe pumps, as described in Section 2.2.1. Adrenergic 
agonists were perfused luminally for 12-15 minutes before starting the ACh 
concentration-response. The KATP channel opener levcromakalim (10 µM) was added at 
the end of experiment, when endothelium-dependent dilatation was impaired. All 
inhibitors were applied both luminally and abluminally. 
5.2.4 Measurement of spreading responses 
Experiments for conducted dilatation studies were performed as described in 
Section 2.2.3.  
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5.2.5 Measurement of endothelial cell [Ca2+]i  
Endothelial cell [Ca2+]i was measured as described in Section 2.4, using a cell-
permeable Ca2+  dye Oregon Green 488 BAPTA-1 AM by means of Olympus IV70 with 
Andor IQ 1.8.1 spinning disc microscope with 40x water immersion objective (UApo 
N340, Olympus, Japan) at 0.1 Hz scan frequency.  
5.2.6 Data analysis  
Data were analyzed as described previously (see Section 2.5). 
5.2.7 Drugs and solutions  
See Section 2.6 for preparation details. MOPS buffered solution was used 
throughout in these experiments. 
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5.3 Results 
5.3.1. Pathways of vasodilatation in response to ACh 
Arteries were initially preconstricted with PE to achieve 70 - 80% of the maximal 
tone, and concentration-dependent dilatation in response to abluminal applications of 
ACh in concentration range from 1 nM to 10 µM was examined (pEC50 = 7.23 ± 0.04, n 
= 6; Figure 5.1A). Denudation of the artery resulted in loss of the dilatation (n = 2-5; 
Figure 5.1B). The dilatation was sensitive to the NOS inhibitor L-NAME (100 µM; 
pEC50 = 6.77 ± 0.08, n = 5, P<0.05), whilst the COX inhibitor indomethacin (10 µM) 
had no effect (pEC50 = 6.74 ± 0.09, n = 6, P>0.05). The inhibitor of SKCa channels 
apamin (50 nM) further attenuated the response (pEC50 = 6.23 ± 0.07, n = 6, P<0.05) 
and addition of the IKCa channel inhibitor TRAM-34 (1 µM) completely blocked the 
remaining vasodilatation (n = 5, P<0.05).  
 
5.3.2 Effect of luminal application of physiological adrenergic agonists on the 
vasodilatation evoked by ACh 
To examine whether activation of the adrenergic pathways affects endothelium-
dependent dilatation, the response to ACh (1nM - 10μM) was explored in the presence 
of physiological adrenergic agonists. Whilst abluminal application of adrenaline at a 
concentration that produced a similar level of tone as the control PE-evoked tone    
(∼0.5 µM of adrenaline) exerted statistically insignificant effect on the ACh-evoked 
dilatation (from pEC50 = 7.1 ± 0.02 to pEC50 = 6.7  ± 0.03, n = 5, P>0.05; Figure 5.2A), 
adrenaline (0.5 µM) and NA (1 µM) perfused luminally significantly shifted the ACh 
CRC to the right (from pEC50 = 7.1 ± 0.02 to pEC50 = 6.6 ± 0.02, n = 6, P<0.05; from 
pEC50 = 7.04 ± 0.03 to pEC50 = 6.42 ± 0.3, n = 6, P<0.05, respectively; Figure 5.2B,C). 
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Figure 5.1 Effects of endothelium denudation, eNOS and KCa channels 
inhibition on the dilatation to ACh of pressurized small mesenteric arteries  
A. Representative trace illustrating responses to cumulative increases of ACh 
concentrations (from 1 nM to 10 µM) after submaximal precontraction with α1-
adrenoceptor agonist PE (0.5 - 2 µM). 
B. Representative trace illustrating the effect of the endothelium denudation on 
the dilatation to ACh. KATP channel opener levcromakalim (10 µM) was added 
at the end of the experiment to evoke endothelium-independent relaxation. 
C. Mean (± S.E.M) CRCs representing dilatation to ACh in the presence of  
L-NAME (100 µM), indomethacin (5 µM), apamin (50 nM) and TRAM-34     (1 
µM). *p<0.05, ***p<0.001 vs. control; #p<0.05, vs. L-NAME, †††p<0.001 vs. L-
NAME+Indo+Apamin. 
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Figure 5.2 Effects of luminal and abluminal application of physiological 
adrenergic agonists on the dilatation to ACh of pressurized small 
mesenteric arteries 
In paired experiments, precontraction of the vessel with adrenaline had a small, 
but insignificant effect on ACh CRC (1nM - 10μM; n = 5, p>0.05; A), whilst 
luminal perfusion of adrenaline (0.5 µM, n = 5, p<0.05; B) or NA (1 µM, n = 6, 
p<0.05; C) significantly attenuated the dilatation evoked by ACh.  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
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5.3.3 Effect of β-adrenoceptor stimulation on the ACh-mediated vasodilatation 
To investigate which adrenoceptor subtype contributes to the inhibition of the 
dilatation to ACh, selective adrenergic agonists were used. Luminal application of the 
β-adrenoceptor agonist isoprenaline (1 µM) reversibly inhibited the dilatation to ACh to 
a similar extent as the nonselective adrenergic agonists adrenaline and NA (from pEC50 
= 7.15 ± 0.01 to pEC50 = 6.44 ± 0.03, n = 6, P<0.05; Figure 5.4A), whilst neither α1-
adrenoceptor agonist PE (0.5 µM; n = 5, P>0.05; Figure 5.3A) nor α2-adrenoceptor 
agonist clonidine (1 µM; n = 5, P>0.05; Figure 5.3B) had a statistically significant 
effect. Moreover, pre-treatment with propranolol (1 μM) eliminated the inhibition of the 
ACh response by luminal application of adrenaline (n = 4, P>0.05) or NA (n = 4, 
P>0.05; Figure 5.5B,C). Finally, activation of the downstream effector of β-
adrenoceptor signalling, adenylyl cyclase by luminal perfusion of forskolin (0.5-1 µM), 
mimicked the inhibitory effect of β-adrenergic agonists on the dilatation to ACh (from 
pEC50 = 7.15 ± 0.02 to pEC50 = 6.48 ± 0.03, n = 5, P<0.05; Figure 5.4B). 
 
5.3.4. Effect of luminally applied β-adrenergic agonists on the eNOS signalling  
To find out whether suppression of eNOS contributed to the β-adrenoceptor-
mediated rightward shift of ACh CRC, the action of NOS inhibition on the remaining 
dilatation was established. Whilst L-NAME (100 µM) attenuated ACh responses in 
control (n = 5, P<0.05; Figure 5.1C) as well as when PE (pEC50 = 6.34 ± 0.02, n = 5, 
P<0.05; Figure 5.6A) or clonidine (pEC50 = 6.18 ± 0.01, n = 6, P<0.05; not shown) 
were luminally perfused, it did not alter the ACh CRC following luminal application of 
adrenaline (n = 6, P>0.05; Figure 5.6B), NA (n = 6, P>0.05; Figure 5.6C), isoprenaline 
(n = 7; P>0.05; Figure 5.7A) or forskolin (n = 4, P>0.05; Figure 5.7B).  
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Figure 5.3 Effects of α-adrenergic agonists on the dilatation to ACh in 
pressurized small mesenteric arteries 
In paired experiments, luminal perfusion of selective α1-adrenergic agonist PE 
(0.5 µM, n = 5, p<0.05; A) or α2-adrenergic agonist clonidine (n = 6, p<0.05; B) 
did not modify the dilatation to cumulative applications of ACh.  
 
Results shown are the mean ± s.e.mean. 
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Figure 5.4 Effects of β-adrenergic agonist and forskolin on the dilatation to 
ACh in pressurized small mesenteric arteries 
In paired experiments, luminal perfusion of selective β-adrenergic agonist 
isoprenaline (1 µM) resulted in inhibition of the dilatation to cumulative 
applications of ACh (n = 5, p<0.05; A). Additionally, the activator of adenylyl 
cyclase forskolin (1 µM) mimicked the inhibitory effect of isoprenaline on the 
dilatation (n = 5, p<0.05; B).  
 
Results shown are the mean ± s.e.mean; ***p<0.001 vs. control. 
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Figure 5.5 Effects of propranolol against the adrenergic agonist-mediated 
inhibition of the dilatation to ACh in rat pressurized small mesenteric 
arteries 
β-adrenoceptor agonist propranolol (1 µM) did not modify the dilatation to ACh 
(n = 4; A), however, it prevented the inhibition of ACh-induced dilatation by 
both adrenaline (n = 4; B) and NA (n = 4; C).   
 
Results shown are the mean ± s.e.mean. 
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On the other hand, when adrenaline and NA were applied together with propranolol, 
inhibition of NOS with L-NAME has been revealed (n = 4; Figure 5.9 A,B).  
As can be seen from Figure 5.1C, dilatation of PE-preconstricted arteries to ACh 
could be blocked only when both eNOS and KCa channels were inhibited. Therefore, in 
the next set of experiments the EDHF pathway was blocked, so the remaining dilatation 
was enabled only by eNOS function (Andrews et al., 2009). Inhibition of IKCa channels 
with TRAM-34 (1 µM) and SKCa channels with apamin (50 nM), resulted in significant 
attenuation of the dilatation to ACh (n = 3, P<0.05). Perfusion of adrenaline (0.5 µM) 
inhibited the remaining dilatation, and addition of L-NAME had no further effect (n = 4, 
P>0.05; Figure 5.7C).  
 
5.3.5. Effect of β-adrenergic signalling on the EDH-mediated vasodilatation  
EDH in rat mesenteric arteries is enabled by opening of IKCa and SKCa channels. 
When the EDH pathway is revealed by inhibition of NOS, perfusion of NA shifted the 
ACh CRC further to the right, showing suppression of KCa channels function (from 
pEC50 = 6.83 ± 0.02 to pEC50 = 6.2 ± 0.03, n = 4, P<0.05; Figure 5.8A). Application 
TRAM-34 did not have an additional effect (pEC50 = 6.17 ± 0.04, n = 4, P>0.05). On 
the other hand, following inhibition of SKCa channels and eNOS with apamin and L-
NAME, respectively, NA, adrenaline or forskolin blocked the remaining dilatation to 
ACh (P<0.05; Figure 5.8B). Application TRAM-34 had an additional effect only at a 
high concentration of ACh (30 µM; n = 8). Importantly, in the presence of propranolol, 
the dilatation remaining after inhibition of NOS and SKCa channels became insensitive 
to adrenergic agonists, but was blocked by TRAM-34 (n = 4; Figure 5.9C). This result 
suggests that the IKCa, but not SKCa, channel is predominantly affected following 
stimulation of β-adrenoceptors.  
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Figure 5.6 Effects of adrenergic agonists on the L-NAME-sensitive 
component of the dilatation to ACh 
In paired experiments, application of L-NAME after luminal perfusion of 
selective α-adrenergic agonist PE (0.5 µM) resulted in inhibition of ACh-
induced dilatation (n = 5, p<0.05; A); however, if applied after perfusion of 
nonselective adrenergic agonists adrenaline (0.5 µM, n = 6, p>0.05; B) or 
noradrenaline (NA; 0.5 µM, n = 6, p>0.05; C), L-NAME was ineffective. 
 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
PE lum+L-NAME
Phenylephrine lum
#
log [ACh] (M)
%
 D
ila
ta
tio
n
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Adrenaline lum
Adrenaline lum
+ L-NAME
log [ACh] (M)
%
 D
ila
ta
tio
n
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Noradrenaline lum
NA lum + L-NAME
log [ACh] (M)
%
 D
ila
ta
tio
n
 113
 
A  
B  
 
 C 
 
Figure 5.7 Effects of adrenergic agonists and forskolin on the L-NAME-
sensitive component of the dilatation to ACh 
NOS inhibitor L-NAME (100 µM) was ineffective after luminal perfusion of 
selective β-adrenergic agonist isoprenaline (1 µM, n = 7, p>0.05; A) or adenylyl 
cyclase activator forskolin (0.5-1 µM, n = 4-8, p>0.05; B). Application of 
adrenaline (0.5 µM), after the inhibition of EDH pathway with apamin (50 nM) 
and TRAM-34 (1 µM), abolished the remaining dilatation to ACh (n = 3,4, 
p<0.05; C).  
 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control, #p<0.05, ##p<0.01 vs. apamin+TRAM-34. 
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Figure 5.8 Participation of K+ channels in the β-adrenoceptor mediated 
inhibition of the dilatation to ACh 
A. Effect of luminal perfusion of NA (1 µM) following NOS suppression with L-
NAME (100 µM) on dilatation to ACh. IKCa channel inhibitor TRAM-34 (1 µM) 
did not affect the remaining dilatation (n = 4, >0.05). B. Suppression of TRAM-34 
-sensitive component of the dilatation by noradrenaline (NA; 1 µM), adrenaline 
(0.5 µM) and forskolin (1 µM).  C. KATP channel inhibitor glibenclamide (10 µM) 
failed to affect suppression of the dilatation to ACh induced by isoprenaline  
(1 µM).  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control,  ###p<0.001 vs. treated (grey circles). 
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Figure 5.9 Effects of propranolol against the β-adrenoceptor mediated 
inhibition of eNOS and KCa signalling  
In the presence of β-adrenoceptor antagonist propranolol (1 µM) applied together 
with the nonselective adrenergic agonists, NOS inhibitor L-NAME (100 µM) lead 
to a rightward shift of the ACh CRC in the presence of both, adrenaline (A) and 
NA (B). Additionally, propranolol prevented the action adrenaline and NA on the 
TRAM-34 (1 µM)-sensitive component of the dilatation (n = 4; C).  
 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control (propranolol), #p<0.05, ###p<0.001 vs. luminally perfused adrenergic 
agonists. 
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5.3.6. Role of KATP channel signalling in the β-adrenoceptor-mediated inhibition of 
the dilatation to ACh  
β-adrenoceptor signalling involves hyperpolarization of smooth muscle cells 
through opening of KATP channels (Fujii et al., 1999; Garland et al., 2011; Nakashima et 
al., 1995). To determine whether the resulting smooth muscle hyperpolarization 
suppressed the EDH-mediated relaxation, we have assessed the effect of the KATP 
channel blocker glibenclamide on the β-adrenoceptor-mediated inhibition of the 
dilatation to ACh. Glibenclamide (10 µM) alone did not affect the dilatation to ACh, 
moreover, it failed to prevent the inhibition by luminal perfusion of isoprenaline (1 µM; 
from pEC50 = 7.13 ± 0.02 to pEC50 = 6.45 ± 0.03, n = 4, P<0.05; Figure 5.8C). 
 
5.3.7. The role of COX in the β-adrenergic inhibition of ACh-mediated 
vasodilatation  
Since β-adrenergic signalling may involve activation of COX (see Chapter 6), an 
effect of COX inhibitor indomethacin (10 µM) on the β-adrenergic inhibition of ACh 
response was established. Indomethacin by itself had no effect on the dilatation (from 
pEC50 = 7.13 ± 0.01 to pEC50 = 7.15 ± 0.01, n = 5-6, P>0.05; Figure 5.10A), and did not 
prevent the attenuation of the dilatation by luminal perfusion of isoprenaline (pEC50 = 
6.7 ± 0.02, n = 5, P<0.05). However, in the presence of indomethacin and isoprenaline, 
NOS inhibition with L-NAME caused further inhibition of the remaining dilatation 
(pEC50 = 6.38 ± 0.02, n = 5, P<0.05). On the other hand, when eNOS and SKCa 
channels were inhibited, indomethacin failed to prevent a significant rightward shift of 
the ACh CRC mediated by forskolin and isoprenaline (pEC50 = 5.95 ± 0.03 and pEC50 = 
5.9 ± 0.1, respectively,  n = 5, P<0.05; Figure 5.10B).    
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Figure 5.10 Participation of COX in the β-adrenergic-mediated inhibition of 
the ACh-mediated vasodilatation  
A. Effect of NOS inhibitor L-NAME (100 µM) on the dilatation to ACh, 
remained after luminally applied β-adrenoceptor agonist isoprenaline (1 µM) in 
the presence of COX inhibitor indomethacin (10 µM). 
B. Effects of luminally applied isoprenaline or forskolin (0.5 µM) on the 
TRAM-34 (1 µM)-sensitive component of the dilatation in the presence of 
indomethacin. 
 
Results shown are the mean ± s.e.mean; ***p<0.001 vs. control, #p<0.05, 
##p<0.01, ###p<0.001 vs. treated (grey circles); †††p<0.001 vs. apamin +  
L-NAME + indomethacin + isoprenaline. 
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Figure 5.11 A role for ROS and PKC in the β-adrenergic inhibition of the 
ACh-mediated vasodilatation  
A. Effect of ROS scavenger tempol (100 µM) on the isoprenaline (1 µM)-
mediated inhibition of ACh dilatation ( n = 3). 
B. Effect of the PKC inhibitor BIS-I (1 µM) on the dilatation to ACh (n = 8, 
p<0.05). 
C. Effect of the NOS inhibitor L-NAME (100 µM) on the dilatation remaining 
after luminally applied adrenaline in the presence of BIS-1.  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01***p<0.001 vs. 
control, #p<0.05, ###p<0.001 vs. treated (grey circles). 
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5.3.8. Participation of PKC and ROS in the β-adrenergic inhibition of ACh-
mediated vasodilatation  
COX signalling is known to involve formation of reactive oxygen species (ROS), 
which can reduce NO availability. To test the hypothesis that ROS are responsible for 
the inhibition of the dilatation mediated by β-adrenoceptors, the ROS scavenger tempol 
(100 µM) was used. However, tempol failed to alter the ACh CRC both in control 
conditions (from pEC50 = 7.09 ± 0.01 to pEC50 = 7.09 ± 0.2, n = 3, P>0.05) and after 
luminal perfusion of NA (1 µM; pEC50 = 6.38 ± 0.1, n = 3, P<0.05; Figure 5.11A). 
It was reported that products of COX can stimulate the TP receptor (Feletou et al., 
2009). One of its downstream signalling enzymes is PKC, which can phosphorylate an 
inhibitory site on eNOS (Matsubara et al., 2003). PKC inhibitor BIS-I (1 µM) exerted a 
slight inhibitory action upon dilatation to ACh (from pEC50 = 6.79 ± 0.02 to pEC50 = 
6.33 ± 0.2, n = 8, P<0.05; Figure 5.11B). When applied together with adrenaline, it 
prevented the rightward shift of the ACh CRC (pEC50 = 6.41 ± 0.2, n = 7, P>0.05), 
moreover, application of L-NAME further attenuated the ACh response (pEC50 = 5.83 ± 
0.3, n = 7, P<0.05; Figure 5.11C). 
 
5.3.9. Effect of isoprenaline on EC [Ca2+]i 
In vascular tissue activation of PKA via the β-adrenoceptor can result in inhibition 
of store-operated channels (Liu et al., 2005) that may cause reduction of [Ca2+]i rise in 
response to ACh, and therefore affect the magnitude of dilatation. Measurement of 
changes in endothelial cell [Ca2+]i in paired experiments revealed an insignificant 
suppression in the response to ACh (0.1-1 µM) in the presence of isoprenaline (1 µM) 
in comparison to the control (n = 3-7, P>0.05; Figure 5.12). 
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Figure 5.12 Effect of isoprenaline on the ACh-mediated rise in EC [Ca2+]i   
A. Representative confocal fluorescence image of endothelial cells loaded with 
Oregon Green 488 BAPTA-1 AM.  
B. Time course of fluorescence intensity changes (F/F0); individual cells are 
shown with grey lines (selected cells are labelled with asterisks in A), average 
intensity is represented by the thick black line.  
C. Summarized data of the endothelial cells [Ca2+]i changes in response to ACh 
(0.1 - 1 µM). After 10 minutes of incubation with isoprenaline (1 µM) there was 
an insignificant reduction of the response (n = 3-7).  
Result shown are the mean ± s.e.mean; ns p>0.05 vs. control. 
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5.3.10. Effect of adrenergic stimulation on the spreading dilatation to ACh  
 Focal application of ACh (1 µM) into the side branch of the triple-cannulated 
artery caused rapid and extended spread of the dilatation that propagated upstream along 
the feed artery against the direction of luminal and abluminal flow. Luminal pre-
application of 0.5 µM adrenaline led to inhibition of the local response to ACh, in a 
similar fashion as was observed in the double-cannulated vessels; however, the spread 
of the dilatation was significantly augmented by adrenaline (n = 8-12; p<0.05; Figure 
5.13A). Abluminal application of NA (0.5-1 µM) resulted in a slight improvement of 
the spreading dilatation, which, however, did not reach significance (n = 4; p>0.05; 
Figure 5.13A).  
To examine the hypothesis that effects of β-adrenergic stimulation on the IKCa- 
and eNOS-dependent components of the dilatation to ACh are responsible for the 
enhancement of the conducted dilatation, we inhibited NOS and IKCa channels with       
L-NAME (100 µM) and TRAM-34 (1 µM). Whilst L-NAME did not modify the 
conducted dilatation (n = 3; p>0.05; Figure 5.13B), TRAM-34 induced a notable 
augmentation of the propagated dilatation within a short proximity from the site of 
application (0.5-1.5 mm), which, however, was not significant and faded with distance 
(n = 3; p>0.05; Figure 5.13C). 
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Figure 5.13 Spreading dilatation responses to the luminal application of 
ACh in the triple-cannulated pressurized small mesenteric arteries  
A. Effect of luminal pre-treatment with adrenaline (0.5 µM, n = 8) or abluminal 
application of noradrenaline (NA; 0.5-1 µM, n = 4) on the spreading dilatation to 
ACh (1 µM). 
B. Effect of NOS inhibition with or L-NAME (100 µM; n = 3) on the spreading 
dilatation response to ACh.  
C. Effect of IKCa channel inhibitor TRAM-34 (1 µM; n = 3) on the spreading 
response. 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01 vs. control. 
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5.4. Discussion 
The main findings of this study are that stimulation of the β-adrenoceptors in 
isolated pressurized small mesenteric arteries of the rat reduces the local dilatation to 
the muscarinic receptor agonist ACh, whilst improves conducted dilatation. The 
impaired local dilatation seems to reflect the loss of eNOS and IKCa components. 
The action of adrenaline as a hypertensive drug is very well known (Floras, 1992). 
Physiologically, adrenaline and NA levels are raised in certain diseases, such as 
hypertension (Berg et al., 2010; Dietz et al., 1982; Grassi et al., 2010; Klemola et al., 
1999; Kuklinska et al., 2010), chronic heart failure (Kubo et al., 1991), primary 
nephrotic syndrome (Xu et al., 2010) or pheochromocytoma (Galetta et al., 2010; 
Higashi et al., 2002), leading to impaired vascular function. The sympathoadrenal 
system is also activated in response to stress (Floras, 1992; Hashiguchi et al., 1997), 
which is linked to a greater cardiovascular risk status (Chida et al.). This creates a basis 
of the association between “stress” and “hypertension”; however, the precise 
mechanisms linking raised sympathetic reactivity and the worsening of cardiovascular 
risk status were not yet determined (Lambert et al., 2010). 
One of the explanations arises from the fact that adrenaline, secreted from adrenal 
medulla and acting on prejunctional adrenoceptors, facilitates release of NA from the 
sympathetic nerve endings. Additionally, adrenaline can be taken up into the nerve 
endings and released together with NA, leading to further augmentation of plasma 
catecholamines concentration and sustained increase in blood pressure (Brown et al., 
1981; Floras, 1992).  
Although, some studies have demonstrated that physiological or pharmacological 
increases in plasma adrenaline/NA concentration affects endothelium-dependent 
responses, in addition to their direct action on smooth muscle α-adrenoceptors. For 
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example, in patients with increased NA levels endothelium-dependent relaxation was 
affected (Higashi et al., 2002). Stressful stimuli lead to elevated blood pressure or 
reduced blood flow and suppression of eNOS function in rats (Bernatowa et al., 2007; 
Gatenbeck et al., 1987; Yoon et al., 2005). Additionally, arteries from hypertensive 
human and rats had an impaired eNOS activity or EDH (Higashi et al., 2002; Li et al., 
2007; Linder et al., 1990). 
Considering this potential physiological relevance, the actions of luminally 
applied catecholamines on endothelium-dependent relaxation were investigated.  We 
used ACh to activate the endothelial muscarinic M3 receptors in rat mesenteric arteries 
(Fujimoto et al., 1991; Rodriguez-Rodriguez et al., 2009; Wu et al., 1997), and found 
that when applied via the lumen, both NA and adrenaline attenuated ACh–evoked 
dilatation through a propranolol-sensitive pathway. In contrast, PE and clonidine did not 
have any effect. Isoprenaline mimicked the inhibitory effect of NA and adrenaline on 
the ACh-mediated relaxation, confirming the involvement of β-adrenoceptors. These 
findings correlate with an earlier observation that raised levels of adrenaline may 
contribute to hypertension via β-adrenoceptors (Borkowski et al., 1985).  
To explain this it has been hypothesized that activation of β-adrenoceptors via Gs 
protein can elevate levels of cAMP and stimulate PKA (Grueb et al., 2008), which, in 
turn, may modulate eNOS or KCa channels. Indeed, application of the adenylyl cyclase 
activator forskolin inhibited the ACh response to a similar extent as isoprenaline 
introduced luminally. Stimulation of the β-adrenoceptor signalling pathway revealed 
attenuated endothelium-dependent relaxation by means of diminishing participation of 
eNOS and IKCa channels in the relaxation.  
There are several possible explanations for the effect of β-adrenergic agonists on 
IKCa channels. Firstly, it has been shown that stimulation of AC inhibits IKCa channels 
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in rat mesenteric arteries (Dora et al., 2008), guinea-pig duodenum ganglia (Vogalis et 
al., 2003), and a direct action of PKA on IKCa was established using Xenopus oocytes 
(Neylon et al., 2004). Secondly, it may also be possible that activation of the smooth 
muscle adenylyl cyclase pathway may lead to a requirement for a higher [Ca2+]i order to 
reach the same level of tone as in control. A rise in smooth muscle cell [Ca2+]i in its turn 
might stimulate Ca2+ efflux from the cell, leading to elevation of Ca2+ in myo-
endothelial space, subsequent stimulation of endothelial CaSR and inhibition of IKCa 
(Dora et al., 2008). Finally, we have also investigated the possible role for KATP 
channels in the observed inhibition of the vasodilatation. Despite the fact that β-
adrenoceptor signalling involves hyperpolarization via KATP channels, activation of 
which might have a suppressive effect on the EDH-mediated relaxation, the effect of 
isoprenaline on the ACh response could not be prevented by KATP channel blocker 
glibenclamide. 
β-adrenoceptors are generally considered to stimulate eNOS, especially in conduit 
vessels and cultured endothelial cells (Akimoto et al., 2002; Hashimoto et al., 2006; 
Huang et al., 1998; Kou et al., 2007; Toyoshima et al., 1998; Zhang et al., 2006b). In 
perfused mesenteric arteries, stimulation of adrenoceptors with adrenaline was shown to 
evoke transient NO release and eNOS phosphorylation at Serine 1177, which was 
sensitive to L-NAME and propranolol (Figueroa et al., 2009b).  
On the other hand, in experimental animal models and humans the opposite is 
true: a chronic increase in  adrenergic tone is associated with a reduction in NO 
availability  (Drexler et al., 1994; Gayen et al., 2010; Higashi et al., 2002). It is 
important to note that in perfused mesenteric arteries NO release in response to β-
adrenoceptors stimulation was transient, and lasted for three minutes only (Figueroa et 
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al., 2009b), so it seems possible, that another, perhaps slower, pathway is activated that 
leads to eNOS inhibition.  
In our experiments pre-treatment with β-adrenergic agonists resulted in loss of L-
NAME-sensitive component in the dilatation to ACh. This would suggest that β-
adrenoceptors cause full activation of eNOS, which could not be further stimulated by 
muscarinic receptor signalling. However, our previous experiments (see Chapter 4) have 
shown a lack of effect of L-NAME on the dilatation to β-adrenergic agonists. This may 
mean that prolonged exposure to β-adrenergic agonists may exert an inhibitory action 
on eNOS activity. In any case, the NO-mediated component of dilation was prevented.   
In the human heart, activation of β3-adrenoceptors was shown to inhibit eNOS 
(Napp et al., 2009), but experiments performed in HUVEC failed to demonstrate any 
changes in eNOS activity after prolonged incubation of the cells with 3 nM of NA 
(Bachetti et al., 1998). However in HUVECs, β-adrenoceptor stimulation induced a 
PKA-mediated inhibition of Rho-kinase, which normally suppresses eNOS, thus β-
adrenoceptor signalling restored NO production (Seya et al., 2006). In our case, 
however, PKC inhibition was sufficient to return the L-NAME-sensitive component of 
the dilatation to ACh, providing evidence for PKC-mediated inhibition of eNOS by 
adrenaline.  
The activity of the endothelial nitric oxide synthase (eNOS) can be upregulated 
independently of an increase in [Ca2+]i by the phosphorylation of Ser1177, but results in 
a low nitric oxide (NO) production (Dimmeler et al., 1999). Recent studies have shown 
that activation of eNOS is associated with dephosphorylation of Thr495 in the 
calmodulin (CaM)-binding domain, whilst PKC phosphorylates this inhibitory site at 
rest (Fleming et al., 2001; Matsubara et al., 2003). Activation of PKC also suppresses 
arginine transport into cells, resulting in reduced NO production (Krotova et al., 2003; 
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Venardos et al., 2009). Interestingly, PKC positively modulates neuronal NOS in rat 
mesenteric arteries (Aras-Lopez et al., 2009). This may explain why stress stimulates 
NO production in the hippocampus (Zhou et al., 2007). 
There is a link between hypertension, PKC-dependent ROS formation and NO 
uncoupling (Li et al., 2006). This link may explain why in a mouse hypertension model 
elevated NA/adrenaline concentrations led to ROS formation and NO depletion (Gayen 
et al., 2010). However, in our experiments the ROS scavenger tempol failed to prevent 
β-adrenergic–mediated inhibition of dilatation to ACh. There is also an evidence that 
EDRF release in response to ATP was attenuated after increase of [cAMP]i due to effect 
on [Ca2+]i in cultured endothelial cells (Luckhoff et al., 1990). However, the hypothesis 
that activation of β-adrenoceptor via PKA can result in inhibition of store-operated 
channels (Liu et al., 2005), which may reduce [Ca2+]i rise in response to ACh, appeared 
not to play a major role in our hands.  
There is a lack of evidence of how β-adrenoceptors can activate PKC. Raised 
cAMP levels were shown to cross talk with PKC through PKA-induced phosphorylation 
of the enzyme (Wooten et al., 1996). The most recent publication supports this cross-
talk by demonstrating the isoprenaline-mediated activation of PKC via the cAMP-
binding protein Epac (Duquesnes et al., 2010). But it may be possible, that PKC 
activation is indirect, and occurs via another pathway. 
In bovine aortic endothelial cells, a rise in cAMP up-regulated COX-2  in a PKA-
dependent manner (Samokovlisky et al., 1999). COX-2 can be upregulated by PKA in 
osteoblasts as well (Choudhary et al., 2004). There is also evidence showing that β-
adrenoceptors can stimulate COX-1,2 in rat aorta and cremaster arterioles (Kang et al., 
2007). On the other hand, exaggerated COX signalling is known to be associated with 
endothelial dysfunction (Bratz et al., 2004; Feletou et al., 2009).  
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Figure 5.14 Diagram illustrating proposed pathway for β-adrenoceptor-
mediated suppression of endothelial cell signalling 
Stimulation of β-adrenoceptors located on smooth muscle or endothelial cell 
promotes cAMP production by adenylyl cyclase. The cAMP can activate both 
PKA (green) and Epac (blue). PKC (pink), which may be upregulated by PKA, 
is able to phosphorylate Thr495 site on eNOS leading to suppression of NO 
production. On the other hand, PKA can phosphorylate thus inhibit IKCa 
channels, affecting the EDHF pathway. COX may also play a role in the eNOS 
inhibition; however, the signalling pathway is not yet determined. 
 
 
 
In some studies, after inhibition of NOS with L-NAME, the ACh-dependent 
response in rat mesenteric arteries was further attenuated by indomethacin (Ben Cheikh 
et al., 2002). Our experiments, though, do not support this evidence. Indomethacin 
failed to inhibit ACh-dependent relaxation; moreover, it reduced the suppressive effect 
of β-adrenoceptor stimulation via revealing a L-NAME-sensitive component. The effect 
on IKCa had a tendency of reduction too, however, both, isoprenaline and forskolin still 
evoked significant suppression of the TRAM-34-sensitive component of the dilatation 
in the presence of indomethacin. 
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COX function has been shown to inhibit NOS signaling in rat mesenteric arteries 
(Bratz et al., 2004; Xavier et al., 2009), but the precise mechanism is still unknown. 
Both COX subtypes participate in production of contractile prostanoids by the 
endothelium; all the prostanoids can bind to TP receptor with different affinities 
(Feletou et al., 2009). TP receptor activation can lead to Rho kinase-dependent 
inhibition of NO production (Liu et al., 2009; Ming et al., 2002), or to PKC-mediated 
uncoupling of eNOS (Perez-Vizcaino et al., 1997; Zhang et al., 2010). Inhibition of 
eNOS in turn triggers release of additional contracting factors from COX, which can 
again activate TP receptor (Ben Cheikh et al., 2002). This mechanism may explain why 
activation of the TP receptor can lead to release of prostacyclin from endothelial cells 
(Hunt et al., 1992), leading to hypertension and atherosclerosis (Feletou et al., 2009). 
This pathological positive feedback loop may be created in response to β-adrenoceptor 
signaling in rat small mesenteric arteries.  
In addition, a stable thromboxane A2 mimetic U46619 has been shown to inhibit 
SKCa channels in rat mesenteric and cerebral arteries (Crane et al., 2004; McNeish et 
al., 2007), when used in high concentrations or following repetitive applications,  the 
whole EDH response to ACh was blocked (Crane et al., 2004; Plane et al., 1996). These 
data support a pathophysiological significance of endothelial TP receptor signalling. 
Whilst attenuating the magnitude of the endothelium-dependent relaxation at the 
site of application, β-adrenergic stimulation had a beneficial effect on the conducted 
dilatation response. The fact that abluminal application was less effective than luminal 
perfusion may be explained by a predominant effect on the endothelial cell layer. This 
goes in accordance with recent evidence that PKA signalling enhances interendothelial 
gap junctional communication (Griffith et al., 2002; Popp et al., 2002). It has also been 
shown that a downstream effector of adenylyl cyclase, Epac, induces connexin 
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phosphorylation and function in rat cardiomyocytes (Duquesnes et al., 2010). On the 
other hand, the effect of β-adrenergic stimulation can be explained by loss of current 
dissipation due to inhibition of IKCa, which was partly confirmed by our observation 
that TRAM-34 tended to augment propagated vasodilatation within a short proximity 
from the site of application (0.5 - 1.5 mm). Conducted dilatation may also be enhanced 
by release of COX products, which can activate TP receptor. As can be seen from 
Chapter 6, precontraction with the TP agonist U64419 also resulted in enhancement of 
the spreading response.  
Lastly, it has been recently shown that treatment with propranolol or subtype 
selective β-adrenoceptor blockers helps to attenuate arterial blood pressure and increase 
NO bioavailability in animals and humans (Buval'tsev et al., 2003; Gupta et al., 2008; 
Priviero et al., 2007; Reiter, 2004; Wenzel et al., 2009); however, the mechanisms 
involved were still poorly understood. We can speculate that the effect of β-adrenergic 
antagonists may at least in part be a result of inhibition of vascular β-adrenoceptors, 
which prevents the blood plasma catecholamine-mediated rise in endothelial cell cAMP 
levels, and may therefore attenuate the inhibition of eNOS and IKCa channels. On the 
other hand, it is worth remembering that intake of β-adrenoceptor blockers may 
diminish the beneficial effect of β-adrenoceptor signalling on the conducted vasomotor 
response. 
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Chapter 6. β-adrenoceptors and a possible endothelium-derived 
contracting influence    
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6.1 Introduction 
Endothelial dysfunction is implicated in various cardiovascular diseases, and is 
particularly important during ageing and development of hypertension. It is generally 
defined as a decrease in the capacity of the endothelium to dilate blood vessels in 
response to physical and chemical stimuli and can be associated with the release of 
endothelium-derived contracting factors (EDCFs), which attenuate the effects of 
endothelium-derived dilatation. The major factors that contribute to the endothelium-
derived contraction are metabolites of arachidonic acid that can activate prostanoid 
receptors expressed in both endothelial and smooth muscle cell layers (Feletou et al., 
2010; Wong et al., 2010b).  
Arachidonic acid is a product of phospholipase A2 (PLA). The Ca2+-dependent 
form of PLA is activated when [Ca2+]i rises in response to cell stimulation, whilst Ca2+-
independent PLA is regulated by phosphorylation. Notably, the Ca2+-independent form 
has been found to be mainly involved in the EDCF release by aortic endothelial cells 
from hypertensive rats (Wong et al., 2010a). Regardless of the source, released 
arachidonic acid can then be metabolized by cyclooxygenase (COX), which produces 
endoperoxide (PGH2) that may undergo further transformations by specific synthases, 
creating a range of prostanoids. Prostacyclin, prostaglandins D, E2, F2α and 
thromboxane A2, all are able to activate TP receptor with different potencies; however, 
although thromboxane A2 is the most potent agonist, prostacyclin seems to be the 
principal metabolite, which acts on the TP receptor and thereby promotes a rise in blood 
pressure and the development of endothelial disfunction associated with numerous 
pathophysoplogical processes in the vasculature of humans and rats (Feletou et al., 
2010; Wong et al., 2010b). 
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On the other hand, β-adrenoceptor-mediated vasodilatation is also known to be 
altered in age and disease. It was therefore proposed that the age-related reduction in β-
adrenoceptor responsiveness may lead to chronic blood pressure elevation and induce 
hypertension development (Blankesteijn et al., 1996; Borkowski et al., 1992). Indeed, 
the reduced vasodilatation to isoprenaline was observed in aorta from old rats 
(Borkowski et al., 1992; Gomez et al., 2008; Kang et al., 2007), as well as in aorta 
(Borkowski et al., 1992; Gomez et al., 2008), femoral and mesenteric arteries (Fujimoto 
et al., 2001) of old spontaneously hypertensive rats (SHRs), but it was almost unaltered 
in mesenteric arteries from young SHRs (Blankesteijn et al., 1996). The decrease in β-
adrenoceptor signalling was proposed to be mediated by reduced receptor density and 
G-protein coupling (Gurdal et al., 1995), attenuated cAMP synthesis or impaired PKA 
function (Deisher et al., 1989), although it might also result from the endothelial 
dysfunction.  
  It is still subject to debate whether the endothelium participates in the dilatation 
in response to β-adrenergic stimulation. Whilst some research groups support the 
involvement of endothelial nitric oxide synthase (eNOS) (Figueroa et al., 2009; Graves 
et al., 1993; Kozlowska et al., 2003), others demonstrate no effect of eNOS inhibition 
on the dilatation to β-adrenergic agonists (Blankesteijn et al., 1993; Briones et al., 
2005a). Intriguingly, removal of the endothelium in our experiments (see Chapter 4) as 
well as in some previous publications (Iwatani et al., 2008) lead not to inhibition, but to 
augmentation of the dilatation in rat mesenteric arteries. This could be explained by 
release of some contractile factors by the endothelium, which may counteract the β-
adrenergic-mediated dilatation (Iwatani et al., 2008). 
Tissue levels of COX metabolites, such as prostacyclin (Kang et al., 2007; 
Numaguchi et al., 1999), PGF2α (Briones et al., 2005c), PGF2 (Matz et al., 2001) and 
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thromboxane A2 (Briones et al., 2005; Garcia-Redondo et al., 2009; Kang et al., 2007; 
Matz et al., 2001) were found to be increased with age or in hypertensive rat models. 
The expression of the enzyme in endothelial cells was enhanced in arteries from SHRs 
(Kang et al., 2007; Numaguchi et al., 1999), not altered (Briones et al., 2005b) or 
augmented (Matz et al., 2000) in normotensive old rats. Recently a role for COX was 
revealed in the aging-related decrease in responsiveness to β-adrenergic agonists in rat 
aorta (Kang et al., 2007); however, the mechanism by which the increased COX 
signalling influences β-adrenoceptor relaxation in small resistance arteries that are 
predominantly involved in the regulation of peripheral blood pressure, is not clear. 
Also, apart from local effects, β-adrenergic signalling can lead to a conducted 
vasomotor response (Garland et al., 2010b), an important event that may significantly 
enhance the effects of physiological regulation of the blood flow (Dora, 2010; Garland 
et al., 2010a). The question of how the conducted vasodilatation can be modulated by 
TP receptor, to our knowledge, has not yet been addressed.  
Therefore, we decided to examine β-adrenergic responsiveness in young (12-14 
weeks) Wistar, old (6 months) Wistar and old spontaneously hypertensive rats, and 
evaluate the role of COX signalling in this dilatation to isoprenaline. We also have 
elucidated the effect of TP receptor stimulation on both local and conducted 
vasodilatation in rat small mesenteric arteries. 
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6.2 Methods 
6.2.1 Rat mesenteric artery isolation and preparation 
In this study, 12 weeks old Wistar, 6 months old Wistar and 6 month old 
spontaneously hypertensive rats (in SHRs, mean blood pressure (MAB) = 171.8 ± 2.8,      
n = 5 in comparison to MAB = 131.8 ± 3.04, n = 3 in the age-matching Wistar rats) 
were used. For the detailed description of how arteries were isolated and prepared, see 
Section 2.1. 
 
6.2.2 Pressure myography 
Arteries were cannulated and pressurized as described in Section 2.2. Pressure 
myography was used to study both local and spreading responses. To obtain denuded 
arteries, pressure was decreased and an air bubble was perfused through the artery using 
the syringe pump system. The lumen was then washed and 70 mm Hg pressure was re-
introduced.  
 
6.2.3 Measurement of local responses 
Local dilatation responses were measured using double cannulated vessels (for 
methods see section 2.2.2). Vessels were preconstricted to 70-80% of maximal tone by 
PE or U46619, where indicated. α1-adrenoceptor inhibitor prazosin was used to reveal 
dilatation evoked by nonselective adrenergic agonists. Cumulative concentration-
response curves (CRCs) to agonists were performed by addition of rising concentrations 
of agonist directly in bath (abluminally) or perfused via lumen by means of syringe 
pumps, as described in Section 2.2.1.  
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6.2.4 Measurement of spreading responses 
Experiments for conducted dilatation studies were performed as described in 
Section 2.2.3.  
 
6.2.5 Data analysis  
Data were collected and analyzed as described previously (see Section 2.5). 
 
6.2.6 Drugs and solutions  
All drugs and solutions were prepared as detailed previously (see Section 2.6). 
MOPS buffered solution was used throughout in these experiments. Solutions 
containing 10 µM indomethacin had their pH additionally adjusted to 7.4 ± 0.02. 
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6.3 Results 
6.3.1 Effect of COX inhibition on the dilatation to ACh 
ACh (1 nM - 10 µM) concentration-dependently dilatated pressurized small 
mesenteric arteries preconstricted with PE from 12 week old (young) Wistar rats,          
6 month old (old) Wistar rats and old SHRs. Arteries from young and old Wistar rats 
fully dilatated with a slight, but significantly greater potency compared to arteries old 
SHRs (pEC50 = 7.13 ± 0.01, n = 6; and pEC50 = 7.37 ± 0.02, n = 4, subsequently; 
p<0.01; Figure 6.1A,B). The Emax to ACh in arteries from SHRs was only 87.3 ± 3.5% 
at 1 µM ACh, and higher concentrations evoked a slight constriction to 78.2 ± 7.7% 
dilatation at 10 µM ACh (pEC50 = 7.0 ± 0.12, n = 4; Figure 6.1C). Whilst indomethacin 
(10 µM) had no effect in both young (pEC50 = 7.15 ± 0.01, n = 5) and old Wistar rats 
(pEC50 = 7.37 ± 0.03, n = 4), it enhanced the dilatation to ACh in arteries from old 
SHRs (Emax = 98.0 ± 1.1%, pEC50 = 7.18 ± 0.04, n = 4; Figure 6.1A,B,C). 
 
6.3.2 Effects of COX and eNOS inhibition on the dilatation to isoprenaline 
The β-adrenoceptor agonist isoprenaline (1 nM- 10 µM) produced different effects 
on each group of rats. Whilst it almost maximally dilatated the arteries from young 
Wistar rats (Emax = 96.6 ± 2.4%; pEC50 = 7.14 ± 0.1, n = 7; Figure 6.2A), the dilatation 
of arteries from old rats was reduced (Emax = 74.4 ± 14.8%; n = 4; Figure 6.2B), and 
there was no notable dilatation to isoprenaline in the SHRs (Emax = 5.9 ± 4.3%, n = 2; 
Figure 6.2C). 
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Figure 6.1 Effect of indomethacin on the concentration-dependent dilatation 
to ACh of rat pressurized small mesenteric arteries 
A. In the presence of tone induced by α1-adrenoceptor agonist PE, arteries of 12 
week old Wistar rats dilated to rising concentrations of ACh (1 nM – 1 µM;  
n = 6). The COX inhibitor indomethacin (10 µM) did not affect the response  
(n = 5). 
B. Dilatation to ACh in arteries from the 6 months old rats was also unaffected 
by indomethacin (n = 4). 
C. High concentrations of ACh (1 µM -10 µM) evoked less dilatation (and even 
contraction) in arteries from 6 month old SHRs (n = 4).  
Results shown are the mean ± s.e.mean. 
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Figure 6.2 Effect of indomethacin on the concentration-dependent dilatation 
to isoprenaline of rat pressurized small mesenteric arteries  
A. Isoprenaline dilated arteries of 12 week old Wistar rats, preconstricted by the 
α1-adrenoceptor agonist PE. The COX inhibitor indomethacin (10 µM) slightly 
enhanced the response (n = 7). 
B. Reduced dilatation to isoprenaline in arteries from 6 months old Wistar rats 
was restored by indomethacin or endothelium denudation (n = 4).  
C. Isoprenaline failed to dilate arteries from 6 months SHRs, and indomethacin 
unmasked the dilatation (n = 2).  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
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Indomethacin had a slight effect on the dilatation to isoprenaline in arteries from 
young Wistar rats (Emax = 99.5 ± 0.3%; pEC50 = 7.38 ± 0.04, n = 7; Figure 6.2A); 
however it improved the response in old Wistar rats (Emax = 99.6 ± 0.4%; pEC50 = 7.25 
± 0.03, n = 4; Figure 6.2B) and fully restored the dilatation in the old SHRs (Emax = 99.5 
± 0.5%; pEC50 = 7.63 ± 0.01, n = 2; Figure 6.2C). Endothelium denudation also 
improved the response to isoprenaline in old Wistar rats (Emax = 99.2 ± 0.8%; pEC50 = 
7.21 ± 0.07, n = 4; Figure 6.2B). 
Whilst the NOS inhibitor L-NAME attenuated the dilatation to ACh (see Figure 
5.1C), it had no effect on the dilatation to isoprenaline (see Figure 4.9C). To elucidate if 
inhibition of COX can unmask the eNOS-dependent component of the dilatation, we 
examined the effect of L-NAME (100 µM) applied together with indomethacin. CRCs 
to isoprenaline remained unmodified after application of L-NAME in all groups, young 
Wistar rats (pEC50 = 7.4 ± 0.04, n = 2; p>0.05; Figure 6.3A), old Wistar rats (pEC50 = 
7.17 ± 0.03, n = 4; p>0.05; Figure 6.3B), and old SHRs (pEC50 = 7.2 ± 0.02, n = 2; 
p>0.05; Figure 6.3C). 
 
6.3.3 Effect of COX inhibition on the dilatation to noradrenaline and forskolin 
In the presence of the α1-adrenoceptor antagonist prazosin (1 µM), L-NAME and 
U46619-induced tone, noradrenaline (NA) applied in the bath concentration-
dependently dilatated arteries of young Wistar rats (pEC50 = 6.11 ± 0.06, n = 8; Figure 
6.4A). The dilatation was not significantly augmented by indomethacin (n = 4; p>0.05) 
or endothelium denudation (n = 8; p>0.05). When NA was perfused through the lumen, 
indomethacin slightly enhanced the response (from Emax = 89.8 ± 6.5%, pEC50 = 5.68 ± 
0.04, n = 6, to Emax = 99.1 ± 0.9%, pEC50 = 6.01 ± 0.02, n = 2; p>0.05; Figure 6.4B). 
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Figure 6.3 Effect of L-NAME on the concentration-dependent dilatation to 
isoprenaline of rat pressurized mesenteric arteries in the presence of 
indomethacin 
A. Dilatation to isoprenaline in arteries from 12 week old Wistar rats was not 
affected by L-NAME (100 µM) in the presence of indomethacin (10 µM; n = 2-
7). 
B. L-NAME did not modify the dilatation to isoprenaline of arteries from 6 
months old Wistar rats (n = 4). 
C. L-NAME also failed to inhibit the dilatation of arteries from 6 month old 
SHRs (n = 2).  
Results shown are the mean ± s.e.mean. 
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Figure 6.4 Effect of indomethacin on the concentration-dependent dilatation 
to NA and forskolin in PE-preconstricted pressurized small mesenteric 
arteries from 12 week old Wistar rat 
A. In the presence of prazosin (1 µM) and U46619-induced tone, abluminal 
application of noradrenaline (NA) revealed dilatation, which was only slightly 
enhanced by indomethacin (10 µM) or endothelium denudation (n = 4-9). 
B. Dilatation to luminal perfusion of NA was moderately augmented by 
indomethacin (n = 2-6). 
C. The adenylyl cyclase activator forskolin (FSK) induced dilatation, which was 
significantly augmented by indomethacin (n = 4, p<0.05).  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
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On the other hand, dilatation to the adenylyl cyclase activator forskolin (FSK) of PE-
preconstricted arteries was significantly enhanced by indomethacin (from pEC50 = 6.02 
± 0.06, to pEC50 = 6.87 ± 0.02, n = 4; p<0.05; Figure 6.4C). 
 
6.3.4 The effect of the agonist used to evoke the tone on the dilatation to 
isoprenaline of rat pressurized small mesenteric arteries  
Dilatation to isoprenaline of arteries from young Wistar rats was dependent on the 
agonist used to evoke the tone. When thromboxane mimetic U46619 was used, it 
significantly shifted the isoprenaline CRC to the right in comparison to PE-induced tone 
(from pEC50 = 7.35 ± 0.06, n = 4, to pEC50 = 6.66 ± 0.1, n = 6; p<0.05; Figure 6.5A); 
similar to those obtained in response to adrenaline and NA with prazosin present 
(Figure 6.5B). Preconstriction with U46619 suppressed the dilatation to isoprenaline of 
the arteries from old Wistar rats to a greater extent (Emax = 47.6 ± 29.2%, n = 4). 
Indomethacin did not modify significantly the dilatation of the arteries from young rats 
preconstricted with U46619 (to pEC50 = 7.1 ± 0.2, n = 4). In contrast, it restored the 
dilatation in arteries from old rats preconstricted with U46619, back to a similar level 
observed in the younger rats (Emax = 97.6 ± 2.4, pEC50 = 7.16 ± 0.16, n = 3).   
  
6.3.5 The effect of the agonist used to induce the tone on the conducted dilatation 
Luminal perfusion of ACh (1 µM) or isoprenaline (1 µM) into a Branch 1 of a 
triple-cannulated artery induced a pronounced local dilatation, that spread upstream into 
the Feed branch. Preconstriction with U46619 markedly enhanced the magnitude of 
spreading for both ACh (from 2.42 ± 1% to 35.36 ± 9.1% at 3 mm upstream, n = 8-21) 
and isoprenaline (from 1.91 ± 2.9% to 35.06 ± 9.4% at 3 mm upstream, n = 6-9) in 
comparison to when PE was used to induce tone. 
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Figure 6.5 Effect of agonist used to evoke the tone on the concentration-
dependent dilatation to isoprenaline of rat pressurized small mesenteric 
arteries  
A. Preconstriction of the arteries from 12 week old Wistar rats with U46619 
attenuated the dilatation to isoprenaline in comparison with the preconstriction 
with PE (n = 4-6). 
B. When compared to the dilatations evoked by adrenaline and NA, dilatation of 
the U46619 preconstricted arteries to isoprenaline was similar (12 weeks Wistar 
rats, n = 4-8). 
C. Preconstriction with U46619 attenuated the dilatation to isoprenaline of the 
arteries from 6 month old Wistar rats even more (n = 4).   
Results shown are the mean ± s.e.mean; ****p<0.01, ***p<0.001 vs. PE. 
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Figure 6.6 Effect of indomethacin on the concentration-dependent dilatation 
to isoprenaline of the U46619-preconstricted rat pressurized small 
mesenteric arteries  
A. Indomethacin (10 µM) did not affect the isoprenaline-induced dilatation in 
arteries from 12 week old Wistar rats (n = 4-6). 
B. Indomethacin restored the isoprenaline-mediated dilatation of the arteries 
from 6 month old Wistar rats to levels observed in younger rats (n = 3-4). 
Results shown are the mean ± s.e.mean. 
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Figure 6.7 Effect of the agonist used to evoke tone on the conducted 
dilatation in triple-cannulated small mesenteric arteries from 12 week old 
Wistar rats  
A. Summarized data illustrating the conducted dilatation responses to luminal 
application of ACh (1 µM) in arteries preconstricted with U46619 (n = 8) or PE 
(n = 21). 
B. Comparison of conducted dilatation responses to luminal application of 
isoprenaline (1 µM) in arteries preconstricted with U46619 (n = 8) and PE  
(n = 9). 
Results shown are the mean ± s.e.mean; ***p<0.001 vs. PE. 
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6.4 Discussion 
It is well known that vascular function is impaired during essential hypertension 
and aging. Our results contribute to and extend this knowledge through a clear 
demonstration that attenuated vasodilatation to endothelium-dependent and -
independent stimuli in old and diseased resistance vessels is attributed to COX 
signaling.  
All major discoveries on the subject of endothelium-derived contracting factors 
(EDCFs) in age and hypertension have predominantly been obtained in conductive 
vessels, mainly aortas from normotensive and hypertensive rats, using the endothelium-
dependent agonist ACh (Feletou et al., 2009). Indeed, COX metabolites were shown to 
significantly attenuate dilatation to ACh of aortas from old (Matz et al., 2000) or 
hypertensive rats (Sekiguchi et al., 2001). However, no effect of nonselective COX 
inhibitor indomethacin was present in our experiments performed on resistance 
mesenteric arteries from young and old normotensive rats. A modest impairment of the 
ACh response due to COX signalling could be seen only in the 6 month old SHRs, 
which supports the evidence that COX metabolites are the EDCFs in this rat model 
(Feletou et al., 2009).  
In contrast, endothelium-independent dilatation evoked by β-adrenoceptor agonist 
displayed a marked reduction in mesenteric arteries from old, and especially from old 
hypertensive rats. This data correlates with several previous publications. Impaired 
dilatation of rat aortae or mesenteric arteries to isoprenaline was shown in old rats 
(Borkowski et al., 1992; Gomez et al., 2008; Kang et al., 2007; Tsujimoto et al., 1986) 
and aorta from young SHRs (Borkowski et al., 1992; Gomez et al., 2008), whilst 
relaxation of the mesenteric arteries from young SHRs were shown to have no 
significant difference in comparison to the control normotensive rats (Blankesteijn et 
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al., 1996). The effect of aging on the isoprenaline-induced dilatation in mesenteric 
arteries from SHRs was not yet described, however, a reduced hyperpolarization was 
shown for both young (Goto et al., 2001) and old (Fujii et al., 1999) animal groups. 
Therefore, it seems possible that impairment of β-adrenoceptor responsiveness of small 
resistance arteries contributes to the age and hypertension-related blood pressure 
elevations to a comparable, if not greater extend than the blunted endothelial cholinergic 
receptor signalling. 
Whilst having a very modest effect on the responses to β-adrenergic agonists in 
young normotensive rats, indomethacin dramatically improved the dilatation to 
isoprenaline in old and hypertensive mesenteric arteries, revealing a similar response 
that was observed in young normotensive animals. These results do not suport the idea 
that impaired receptor density, G-protein coupling (Gurdal et al., 1995), cAMP 
synthesis or PKA function (Deisher et al., 1989) are responsible for the reduced 
response to isoprenaline in age or hypertension, but supports the evidence that COX 
may participate in the attenuation of the relaxation to isoprenaline, which was 
established in aortae from old rats (Kang et al., 2007).  
Removal of the endothelium was shown to augment the endothelium-independent 
dilatation (to isoprenaline, NO donor, 8-bromo-cGMP, calcitonin gene-related peptide) 
in mesenteric arteries from young rats (Iwatani et al., 2008) as well as decrease 
prostanoid levels in aortae from old rats (Kang et al., 2007). In our experiments, the 
dilatation to β-adrenergic agonists of young and old arteries was also improved by 
endothelium denudation, reflecting the possibility of a contractile factor released by the 
endothelium. This may reflect a role for endothelial β-adrenoceptors, which were shown 
to be expressed in the intima, but apparently did not participate in the relaxation to 
isoprenaline (Briones et al., 2005a). On the other hand, it is also possible that cAMP 
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spreads to adjacent endothelial cells from the smooth muscle cells through the gap 
junctions, as was shown for Rat-1 cells (Ponsioen et al., 2007).  
It is not known whether COX is basally releasing prostanoids or is stimulated by 
adrenergic agonists, but the fact that the dilatation to isoprenaline was much more 
attenuted than to ACh, leads us to suggest that isoprenaline may enhance COX 
signaling. Endothelial COX is known to be activated by a rise in [Ca2+]i (Tang et al., 
2007), but how β-adrenergic signaling can stimulate endothelial cell COX is not clear. 
There are several lines of evidence that the cAMP-PKA pathway may enhance COX 
signalling. First, extracellular Ca2+ can mediate PKA-dependent expression of COX-2 in 
osteoblasts (Choudhary et al., 2004). Secondly, in renal tissue the effect of the PKA 
pathway on expression of COX-2 has also been demonstrated (Steinert et al., 2009). 
Further, in bovine aortic endothelial cells, a rise in cAMP up-regulates COX-2 in a 
PKA-dependent manner (Samokovlisky et al., 1999). Finally, another pathway may 
provide stimulation of phospholipase A by β-adrenoceptor, leading to production of 
arachidonic acid (Borda et al., 1998; Neuman et al., 2002), a precursor for COX 
metabolites.  
COX products may underlie a range of pathophysiological processes in the 
endothelium (Feletou et al., 2010a; Wong et al., 2010b). One of the pathways may be 
revealed from the observation that COX signalling or TP receptor activation triggers an 
impairment of eNOS (Bratz et al., 2004; Liu et al., 2009) or guanylyl cyclase function 
(Arshad et al., 2006). Despite some previous publications (Figueroa et al., 2009b; 
Graves et al., 1993), we did not see any eNOS-dependent component to the β-
adrenoceptor-mediated dilatation (see Chapter 4). With the knowledge that β-adrenergic 
signaling may stimulate COX, it seemed therefore possible that this enzyme may 
interfere with a NO-dependent component in response to β-adrenoceptor agonists. If 
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this was the case, indomethacin should reveal an eNOS-dependent dilatation. However, 
in our experiments L-NAME still had no effect in all young, old, and hypertensive 
animals, implying any lack of or a minimal role for eNOS in the vasodilatation to β-
adrenoceptor stimulation, even after COX was inhibited.  
Many prostanoids are able to bind TP receptors, activation of which is a key event 
in triggering cardiovascular pathogenesis (Feletou et al., 2010a; Feletou et al., 2009). 
However, how cross-talk between TP and β-adrenoceptor occurs is not defined. 
U46619 is often used as a contractile agent, especially when α-adrenoceptors are 
inhibited to reveal a β-adrenergic component of the response to NA/adrenaline (Filippi 
et al., 2001; Garland et al., 2010b; Macdonald et al., 1987). β-adrenoceptors are 
coupled to Gs proteins, which stimulate adenylyl cyclase, leading to vasodilatation 
through activity of cAMP-dependent enzymes. The concentration of cAMP is regulated 
by phosphodiesterases, (Boswell-Smith et al., 2006). In rat carotid artery, 
phosphodiesterases were shown to be stimulated by U46619 (Liu et al., 2010), 
suppressing dilatation to isoprenaline. In our experiments, treatment with U46619 also 
resulted in reduced dilatation to β-adrenergic stimulation, indicating that a similar 
pathway may be involved.  
On the other hand, coupling of TP receptor to PKC (Budzyn et al., 2006) may lead 
to a PKC-dependent reduction of KATP channel function in rat mesenteric myocytes 
(Kubo et al., 1997). Although this channel does not play a significant role in the local 
dilatation to β-adrenoceptor agonists (Garland et al., 2011; White et al., 2001), it may 
potentiate a reduction in dilatation when activated together with the inhibitory 
mechanism described above (Liu et al., 2010). 
Importantly, TP receptors by themselves can lead to release of prostanoids from 
cultured endothelial cells and mesenteric arteries (Bolla et al., 2004; Hunt et al., 1992; 
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Nicholson et al., 1984). This may create a negative loop: β-adrenoceptor signalling 
promotes release of prostanoids, which in turn can activate TP receptors to evoke the 
release of more prostanoids and facilitate cAMP breakdown leading to suppression of β-
adrenoceptor signalling. This pathway may be particulary prevelant in 
pathophysiological conditions, explaining why indomethacin dramatically improved the 
dilatation to isoprenaline in U46619-preconstricted arteries from old rats in our 
experiments.  
Despite having a pronounced inhibitory action on the local dilatation, 
precontraction with the TP receptor agonist improved the conducted dilatation to both 
ACh and isoprenaline, when compared to the PE-induced tone. NA, acting on α-
adrenoceptors, was also shown to reduce conducted vasodilatation in hamster feed 
arteries (Haug et al., 2003). The reasons for this may relate to the signalling pathways 
activated by these two receptors. Both activate Gq/11 protein, which is coupled to 
phospholipase C, resulting in breakdown of PIP2 and production of DAG, the 
endogenous activator of PKC. Generally, PKC phosphorylates connexin 43 and reduces 
the intercellular communication via gap junctions (Bao et al., 2007; Heyman et al., 
2009; Inoguchi et al., 1995); however, recent research demonstrated that in cultured 
cardiomyocytes PKC activation enhanced dye transfer through enhanced gap junctional 
permeability (Duquesnes et al., 2010).  
In contrast, TP receptors are also coupled to G-proteins of the G12/13 family, and 
the constriction to U46619, in comparison to PE, relies more on the sensitization 
mechanism through Rho kinase, so dependence on rises in [Ca2+]i is less (Shaw et al., 
2004). This by itself may lead to reduced PKC activity and reduced connexin 
phosphorylation, that together with Rho A -dependent enhancement of gap junctional 
coupling (Derangeon et al., 2008) may increase the spread. Additionally, lack of [Ca2+]i 
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may result in closure of BKCa channels, and, thereby, dissipation of the hyperpolarizing 
current that normally reduces the conducted dilatation in the presence of α1-
adrenoceptor agonist (Beleznai et al., 2011). 
Another explanation may arise from the observation that, in comparison to NA, 
U46619-evoked constriction was accompanied by a smaller depolarization (Plane et al., 
1996). This may mean a smaller increase in membrane potential is effective in 
mediating closure of L-type Ca2+ channels and thus evoking subsequent relaxation. As a 
result, the negative charge produced by stimulated cells dissipates to a lesser extent and 
can reach greater numbers of adjacent cells.  
Taken together, these results demonstrate that stimulation of β-adrenergic 
receptors is associated with the activation of COX, linked to an inhibitory action on 
vasodilatation, especially in old and hypertensive animals. Endothelial denudation 
enhances dilatation to a smilar extent as treatment with COX inhibitors. The enzyme 
activity is not implicated in absence of the L-NAME–sensitive component of the 
dilatation to β-adrenergic agonists. The products of COX may act on TP receptors, to 
suppress the local dilatation to β-adrenergic agonists, whilst in some way enhancing 
conducted dilatation  
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Chapter 7. Nitroxyl anion evokes local and conducted dilatation in rat 
mesenteric resistance arteries; a role for K+ channels 
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7.1 Introduction 
The endothelium participates in the regulation of vascular tone by means of 
electrical coupling via gap junctions and release of various vasoactive agonists and 
gaseous molecules. One of the gaseous molecules, NO, plays a particularly important 
role in vascular physiology (Furchgott et al., 1991; Moncada et al., 2006). 
Activation of the endothelium is usually associated with a rise in [Ca2+]i that 
stimulates eNOS, leading to the release of NO by the mechanisms described in Section 
1.3.2. NO can exist in several different redox forms, among which uncharged free 
radical state of the NO molecule (nitrogen monoxide, NO•) and nitroxyl anion (NO-) are 
present (Hughes, 1999). NO• has been considered to be the main participant in 
vasodilatation responses to different NO donors or after stimulation of endothelium 
(Dierks et al., 1996a; Feelisch, 1993). However, endothelium-dependent relaxation of 
rodent aortas, which mainly goes through NO pathway, was demonstrated to be 
sensitive to both, NO• and NO- scavengers (Ellis et al., 2000; Wanstall et al., 2001).  
It has been shown that NO- can be produced by NOS in the absence of BH4 
(Figure 7.1). Electron donation from BH4 to the heme-bound O2 enables it to be an 
electron acceptor later, during L-arginine oxidation, promoting formation of a ferric 
heme-NO complex, thus ensuring that the enzyme generates NO• instead of NO−. 
However, when BH4 is not available, a ferrous heme-NO complex builds up, resulting 
in formation of NO- (Adak et al., 2000). An additional way of NO- formation is by 
reduction from NO• by mitochondrial cytochrome C (Sharpe et al., 1998). Moreover, it 
has been shown that the initial product of eNOS may be not NO•, but NO- (Schmidt et 
al., 1996), which could be further converted into NO• by means of superoxide dismutase 
(Fukuto et al., 1993; Hobbs et al., 1994; Schmidt et al., 1996), whilst a backward 
conversion of NO• to NO- is highly unfavourable (Bartberger et al., 2002).  
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Figure 7.1 Diagram illustrating the pathway of possible endogenous NO- 
production by NOS  
The heme can react with L-arginine in the presence or absence of BH4. If BH4 is 
present, it provides electron for the heme and, at a later point, the reduced BH4 
can accept the electron from heme-N-hydroxy-L-arginine complex, ensuring 
formation of the NO• (path A). However, if the reductase domain provides the 
electron for the heme, then the reaction can only generate NO− (path B) (Adak et 
al., 2000; Irvine et al., 2008). 
 
Under physiological conditions NO- exists as a conjugated weak acid, HNO 
(nitroxyl). As a donor of nitroxyl species researchers widely use Angeli's salt (sodium 
trioxodinitrate, Na2N2O3), which, after being dissolved in aqueous solution at 
physiological pH, decomposes according to the following equation (Amatore et al., 
2007): 
HN2O3- → HNO + NO2- 
NO-gassed solution is generally used as a source of NO• (Favaloro et al., 2009; 
Rajanayagam et al., 1993; Wanstall et al., 2001), whilst other NO donors, such as 
sodium nitroprusside  can produce both, NO• and NO- (Irvine et al., 2003a).  
By means of pharmacological tools it became possible to distinguish between the 
two main forms of NO. NO• can be inhibited by a free radical scavengers such as 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (carboxy-PTIO) (Irvine 
et al., 2003a; Li et al., 1999b) or hydroxocobalamin (OHCbl) (La et al., 1996; Li et al., 
1999a; Rajanayagam et al., 1993), whilst L-cysteine in millimolar concentrations is 
+BH4 
-BH4 
+ 
+ 
A
B
A
B
NO•
NO-
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widely used to scavenge NO- (Arvola et al., 1992; Ellis et al., 2000; Irvine et al., 2007; 
Pino et al., 1994a; Wanstall et al., 2001). 
In rodent conduit vessels such as aorta (Irvine et al., 2007; Wanstall et al., 2001), 
and resistance arteries such as mesenteric artery (Andrews et al., 2009; Favaloro et al., 
2007; Irvine et al., 2003b), the HNO donor Angeli’s salt was capable to evoke 
functional responses, similar to NO•, via activation of soluble guanylyl cyclase. 
Moreover, NO- was reported to be endogenously generated in response to ACh or ATP 
in sufficient amounts to evoke relaxation of rat arteries (Andrews et al., 2009; Ellis et 
al., 2000). 
However, NO- was found to have even wider target area in the cardiovasculature 
than NO• (Irvine et al., 2008; Martin, 2009). This includes direct activations at 
ryanodine receptors and SERCA (Tocchetti et al., 2007), increases in the myofilament 
sensitivity to Ca2+ by modulation of myofilament proteins that harbour reactive thiolate 
groups (Dai et al., 2007), lack of development of vascular tolerance to NO- (Irvine et 
al., 2007; Irvine et al., 2008), and robust hyperpolarization of smooth muscle (Andrews 
et al., 2009; Favaloro et al., 2009). The latter, which does not occur in response to NO•, 
is achieved by activation of Kv channels (Andrews et al., 2009; Favaloro et al., 2009). 
All previous studies of effects of NO- in rat mesenteric arteries were performed by 
means of wire myography (Andrews et al., 2009; Favaloro et al., 2007; Irvine et al., 
2003b), and whether the results will be confirmed in more physiological conditions is 
unknown. Additionally, hyperpolarizing stimuli can evoke conducted vasodilatation 
(Dora, 2010; Garland et al., 2011; Takano et al., 2004; Winter et al., 2007), and if NO- 
can hyperpolarize vascular smooth muscle, then it may evoke the conducted dilatation. 
Therefore, the aim of this study was to investigate the effects of NO- in the local and 
conducted dilatation in rat pressurized mesenteric arteries. 
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7.2 Methods 
7.2.1 Rat mesenteric artery isolation and preparation 
See Section 2.1 for methods of artery isolation and preparation. 
 
7.2.2 Pressure myography 
Arteries were cannulated and pressurized to 70 mmHg as described in Section 2.2. 
Pressure myography was used to study both local and conducted responses.  
 
7.2.3 Measurement of local responses 
Local dilatation responses were measured using double cannulated vessels, as 
described in the Section 2.2.2. Vessels were submaximally preconstricted with PE, then 
raising concentrations of studied agonist cumulatively or non-cumulatively were applied 
in bath (abluminally). Vasomotion was described as synchronized, if the contraction-
dilatation cycles followed the shape of sigmoid curve with a near equal sizes of the 
pikes and distances between the pikes. 
 
7.2.4 Measurement of conducted dilatation responses 
Experiments for conducted dilatation studies were performed using triple 
cannulated vessels. Agonist together with carboxyfluorescein was perfused via side 
branch (Branch 1), as detailed in section 2.2.3..  
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7.2.5 Data analysis  
Data were collected and analyzed as described in Section 2.5. 
 
7.2.6 Drugs and solutions  
In these experiments, normal MOPS-buffered solution was used, except of L-
cysteine was added into a specially prepared MOPS-buffered solution with a reduced 
amount of NaCl to balance the excess of Na+ incoming with NaOH during adjustment 
of pH (see the method below). In order to prevent decomposition, HNO donor, Angeli’s 
salt, (sodium trioxodinitrate) was dissolved in 10-2 M of NaOH. In aqueous solutions, 
Angeli’s salt exists in a protonated form HNO, and decomposition of 1 M of Angeli’s 
salt gives 0.54 M of NO- (Irvine et al., 2008). In order to obtain a saturated solution of 
NO•, de-gassed MOPS-buffered solution was bubbled with NO gas for 15 min, with the 
final NO concentration of 1.94 mM (Zacharia et al., 2005) (Figure 7.2). pH of solutions 
containing 4-AP (150 µM) and TEA (1 mM) was additionally adjusted to 7.4±0.2. All 
other drugs and solutions were prepared as detailed previously (see section 2.6). 
 
L-cysteine MOPS buffer contains (in mM): NaCl, 135; KCl, 4.7; CaCl2, 2.0; 
MgSO4·7H2O, 1.17; MOPS, 2.0; NaH2PO4·H2O, 1.2; glucose, 5.0; pyruvate, 2.0; 
EDTA, 0.02; NaOH, ∼12.75; L-cysteine, 3; with pH adjusted to 7.40 ± 0.02 (at 37oC). 
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Figure 7.2 Scheme illustrating bubbling cascade for saturated NO• solution 
Step 1. In order to de-gas solutions, argon gas was first bubbled for 30 minutes 
through solution of pyrogallol (5%; yellow circle), then was perfused through 
NaOH solution (10 mM; green circle), MilliQ water for NO saturation (orange 
circle), and buffered saline for NO stock dilutions (blue circle).  
Step 2. NO gas was bubbled through NaOH solution in order to terminate possible 
higher oxides of NO (such as NO2, NO3), then perfused through Milli Q water for 
15 minutes. Dilutions of the saturated NO solution (1.94 mM at room temperature) 
were prepared using de-gassed buffered saline. 
Taps were used to restrict gas to certain solutions during step one and step two. 
 
 
Argon gas 
 (30 min) 
 NO gas 
(15 min) 
Step 1  Step 2 
5% 
pyrogallol 
soln. 
Trap  Trap 
10 mM 
NaOH 
Saline for 
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7.3 Results 
7.3.1 Effect of NO gassed solution on the arterial tone 
To investigate effects of exogenous NO• on tone of pressurized small mesenteric 
arteries we used the NO•-saturated solution (Zacharia et al., 2005). Application of NO• 
(0.1 µM - 300 µM of NO•) evoked concentration-dependent dilatation of rat small 
mesenteric arteries (Emax=98.2 ± 0.6% at 100 µM, pEC50 = 5.3 ± 0.12, n = 7; Figure 
7.3A). Whilst low concentrations of NO• led to a transient dilatation, higher 
concentrations evoked a two-phase response, rapid transient and delayed slow sustained 
dilatation (Figure 7.3A).  
 
7.3.2 Effect of HNO donor on arterial tone 
To establish the effect of NO- on the arterial tone the HNO donor, Angeli’s salt, 
was used in this set of experiments. In PE- preconstricted arteries, bolus application of 
Angeli’s salt (0.1 µM - 300 µM) led to a concentration-dependent dilatation (Emax=98.0 
± 0.5% at 100 µM; pEC50 = 5.05 ± 0.18; n = 3-7), and the degree of the response was 
similar to the evoked by NO• (p>0.05; Figure 7.4A). Bolus addition of submaximal 
concentration of Angeli’s salt (30 µM) evoked a transient response with a maximum at 
∼5 minutes, then the magnitude of the response decreased (Figure 7.3B). Additionally, 
vasomotion induced by PE were stabilized by Angeli’s salt administration (30 µM) in 
21 cases out of 30. 
Since Angeli’s salt was diluted in 10 mM NaOH, the vehicle alone was tested, but  
no significant effect on the arterial tone was observed (p>0.05; n = 2; data not shown).  
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Figure 7.3 Local dilatation to HNO and NO• in small mesenteric arteries 
A. Representative trace illustrating dilatation of the artery in response to 
submaximal concentration of NO• (30 µM) applied as a NO•- saturated solution.  
B. Representative trace showing response to submaximal concentration of HNO 
donor, Angelis salt (AS; 30 µM). ACh (1 µM) was applied at the end of 
experiment to assess arterial viability. 
Time of applications of PE, NO•, AS, and ACh are indicated with arrows. 
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Figure 7.4 Summarized local responses to HNO and NO• of small mesenteric 
arteries  preconstricted with PE 
A. Comparison of non-cumulative concentration responses to HNO donor Angelis 
salt (AS; n = 3-7) and NO•, applied as NO•-saturated solution (n = 7). Values of 
maximal dilatation to each concentration were used in this figure. 
B. Effects of the NO• scavenger carboxy-PTIO (c-PTIO, 200 µM) alone (n = 2) or 
together with the NO- scavenger L-cysteine (3 mM; n = 6) on the dilatation to 
cumulative application of AS. 
 
Results shown are the mean ± s.e.mean; ***p<0.001 vs. control. 
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7.3.3 Effect of L-cysteine on the response to Angeli’s salt 
In order to ensure that the dilatation to Angeli’s salt is mediated by the action of 
NO-, but not NO•, effects of the NO• scavenger, carboxy-PTIO (100 µM), and the NO- 
scavenger, L-cysteine (3 μM), on Angeli’s salt-induced dilatation were evaluated. 
Cumulative applications of Angeli’s salt evoked complete dilatation of the PE- 
preconstricted artery in a concentration range from 100 nM to 100 μM (pEC50 = 4.7 ± 
0.03, n = 8). Whilst carboxy-PTIO did not alter the relaxation to Angeli’s salt (n = 2),  
L-cysteine, applied together with carboxy-PTIO, markedly inhibited this response         
(n = 6; Figure 7.4B), demonstrating that the dilatation occurs mainly due to NO- release 
from Angeli’s salt.  
 
7.3.4 Effect of K+ channel and gyanylyl cyclase inhibition on the responses to 
Angeli’s salt 
 It was suggested that NO- predominantly activates Kv channels in vascular 
smooth muscle and has virtually no effect on BKCa channel activity (Favaloro et al., 
2009; Irvine et al., 2003a). In accordance with this, in our experiment the Kv channel 
blocker 4-aminopyridine (4-AP, 150 µM) also inhibited the response, however, 4-AP 
did not block it completely (Emax = 49.35 ± 13.4% at 5 min, n = 4), also it did not 
prevent the tone oscillations after precontraction with PE (Figure 7.5B). On the other 
hand, incubation with the BKCa inhibitor iberiotoxin (100 nM) evoked contraction of the 
vessel to 35.3±8.4% of the maximum and vasomotion in four cases of seven (n = 7; 
Figure 7.5C); moreover, both iberiotoxin (n = 5) and KCa channel blocker TEA (1 mM; 
n = 6) significantly suppressed the dilatation to Angeli’s salt (Emax = 40.8 ± 14.8% and 
Emax = 46.7 ± 14.2% at 5 min, subsequently; p<0.05).  
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Figure 7.5 Effect of BKCa and Kv channels inhibition on the local dilatation to 
Angeli’s salt 
A. Typical trace illustrating dilatation of the artery to submaximal concentration of 
the HNO donor Angeli’s salt (30 µM) in control.  
B. Representative trace showing a response to Angeli’s salt in the presence of the 
Kv channel inhibitor 4-AP (150 µM).  
C. Effect of the BKCa channel inhibitor iberiotoxin (IbTx, 100 nM) on the 
dilatation to Angeli’s salt.  
ACh (1 µM) was applied at the end of each trace to test endothelial reactivity. 
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Figure 7.6 Effect of high K+ and guanylyl cyclase inhibition on the local 
dilatation to Angeli’s salt 
A. Representative trace illustrating dilatation of the artery to HNO donor Angeli’s 
salt (30 µM), applied in the presence of the BKCa channel inhibitor iberiotoxin 
(IbTx, 100 nM) and the Kv channel inhibitor 4-AP (150 µM).  
B. Typical trace showing dilatation to Angeli’s salt in the presence of high K 
(KCl, 45 mM).  
C. Original trace demonstrating inhibition of the dilatation to Angeli’s salt by the 
guanylyl cyclase inhibitor ODQ (10 µM).  
ACh (1 µM) was applied at the end of each trace to test endothelial reactivity. 
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Figure 7.7 Participation of K+ channels and guanylyl cyclase in the local 
dilatation to Angeli’s salt 
A. Averaged data illustrating effects of the BKCa channel inhibitor iberiotoxin 
(IbTx, 100 nM; n = 6) and the Kv channel inhibitor 4-AP (150 µM; n = 5) on the 
dilatation to the HNO donor Angeli’s salt (AS; 30 µM).  
B. Effects of high K (45 mM) and the guanylyl cyclase inhibitor ODQ (10 µM;  
n = 5).  
C. Summarized data representing effects of IbTx, TEA, 4-AP, high K (KCl, 45 
mM) and ODQ on the dilatation to Angeli’s salt. Values are taken at 5 min after 
the Angeli’s salt was applied. Results are the mean ± s.e.mean. 
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Combination of either iberiotoxin or TEA with 4-AP has almost blocked the dilatation 
(n = 4; Figure 7.7A,C), but failed to prevent vasomotion (Figure 7.6A). High external 
K+ (KCl, 45 mM) constricted the vessel (via depolarization) and suppressed both 
vasomotion and dilatation to Angeli’s salt (n = 5; p<0.05; Figure 7.6B and 7.6B,C). The 
guanylyl cyclase inhibitor ODQ (10 µM) desynchronized vasomotion and abolished the 
response to the HNO donor (n = 5; p<0.05; Figure 7.6C and 7.7B,C). These data 
indicate that dilatation to HNO donor is enabled by opening of both Kv and BKCa 
channels and depends on guanylyl cyclase activity, whilst vasomotion are sensitive only 
to high KCl and guanylyl cyclase inhibition.  
 
7.3.5. Role of NO- in vasomotion observed in PE- preconstricted mesenteric 
arteries 
Since the HNO donor stabilized the vasomotion, whilst NO• did not, we decided to 
elucidate the role of endogenous HNO in the coordination of vasomotion. Submaximal 
preconstriction with PE evoked stable oscillations of tone with a frequency of 0.22 Hz ± 
0.01 (n = 15; Figure 7.3B). Scavenging of NO• with hydroxocobalamin (HXC, 100 µM) 
resulted in a decrease of synchronization of vasomotion, but did not change the 
frequency of tone oscillations (0.22 Hz ± 0.01, n = 5; Figure 7.8A). The NO- scavenger 
L-cysteine applied luminally and abluminally, markedly suppressed the vasomotion (n = 
6; Figure 7.8B). Inhibition of NOS with L-NAME (100 µM) resulted in loss of 
detectable vasomotion in 7 cases from 12, the rest displayed reduced synchronisation 
with a small decrease in frequency of tone oscillations (0.16 Hz ± 0.02, n = 5;        
Figure 7.8C).  
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Figure 7.8 Representative traces illustrating effect of endogenous NO on 
vasomotion in rat small mesenteric arteries preconstricted with PE 
A. Typical trace showing vasomotion in the presence of the NO• scavenger 
hydroxocobalamin (HXC, 100 µM);  
B. The NO- scavenger L-cysteine (3 mM) suppresses the oscillations of tone;  
C. Inhibition of NOS with L-NAME (100 µM) affects vasomotion.  
Application of Angelis salt (30 µM) in the presence of HXC or L-NAME led to 
the dilatation and synchronization of vasomotion, whilst it failed to evoke 
dilatation or tone oscillations in the presence of L-cysteine. 
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7.3.6 HNO donor induces conducted dilatation in the triple-cannulated pressurized 
mesenteric arteries 
It has been earlier demonstrated that hyperpolarizing agents, such as the KATP 
channel opener levcromakalim or the β-adrenoceptor agonist isoprenaline can lead to 
the conducted vasodilatation (Garland et al., 2011; Takano et al., 2004). Since there was 
an evidence that unlike NO•, NO- can robustly hyperpolarize smooth muscle of rat 
mesenteric arteries (Favaloro et al., 2009), we decided to test the hypothesis that NO- 
can also produce a conducted response. In PE- preconstricted arteries, perfusion of the 
HNO donor Angeli’s salt (30 µM) via Branch 1 evoked conducted dilatation along the 
Feed branch (Figure 7.9A), which had a similar magnitude as the response produced by 
the endothelium-dependent agonist ACh (1 µM; n = 5 and n = 6, respectively;        
Figure 7.10A). The K+ channels blockers TEA (1 mM; n = 4) and 4-AP (150 µM; n = 4) 
suppressed the local response, proportionally reducing the conducted response. 
Combination of both (n = 5) or application of KCl (45 mM) as a contractile agent (n = 
3) blocked local and conducted dilatation ( 7.9B). Whilst scavenging of HNO with L-
cysteine resulted in suppression of both local and conducted responses (n = 1), 
endothelial denudation abolished conducted, but not local dilatation (n = 5;             
Figure 7.9C). 
7.3.7 Endogenous NO- induces local and conducted dilatation in the triple-
cannulated pressurized mesenteric arteries of rat 
It was recently demonstrated that eNOS can produce NO- in rat mesenteric arteries 
(Andrews et al., 2009). Therefore, we decided to evaluate whether endogenous NO- can 
produce local dilatation that is able to evoke a similar level of conducted dilatation as 
the HNO donor Angeli’s salt. 
 170
 A     
  
B       
   
  
 
Figure 7.9 Conducted response to HNO donor Angeli’s salt in the triple-
cannulated small mesenteric arteries  preconstricted with PE 
A. Representative trace illustrating conducted dilatation to the HNO donor 
Angeli’s salt (30 µM), perfused via Branch 1.  
B. Averaged data (mean ± s.e.mean) showing effect of the K+ channels inhibition 
with TEA (1 mM, n = 4), 4-AP (150 µM, n = 4) and high K+ (45 mM, n = 3) on 
the conducted response to Angeli’s salt. 
C. Averaged data demonstrating the effect of endothelial denudation (-EC, n = 5) 
or NO- scavenger L-cysteine (3 mM, n = 1) on the conducted response to Angeli’s 
salt. 
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In order to unmask the eNOS-dependent pathway, EDH was blocked by SKCa and 
IKCa channels inhibitors apamin (50 nM) and TRAM-34 (1 µM), respectively, and a 
higher concentration of ACh (10 µM) was perfused via Branch 1. In PE- preconstricted 
arteries, ACh could still evoke a robust dilatation of the Branch 1, which was 
accompanied by a similar degree of spread along the Feed branch, as in control 
conditions (n = 4; p>0.05). NO• scavenger carboxy-PTIO (200 µM) reduced local 
dilatation, but had hardly any effect on the conducted dilatation (n = 5). Unlike carboxy-
PTIO, NO- scavenger L-cysteine not only reduced local, but also abolished conducted 
dilatation (n = 4). Co-application of both scavengers (n = 3, data not shown) or 
inhibition of NOS with L-NAME (100 µM; n = 4) blocked all the responses to ACh 
(Figure7.10B), indicating that eNOS is likely to be the source of NO- in this tissue.  
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Figure 7.10 Conducted dilatation to endogenous NO- in the small mesenteric 
arteries preconstricted with PE 
A. Averaged data demonstrating comparable conducted responses to the HNO 
donor Angeli’s salt (30 µM; n = 6) and acetylcholine (1 µM; n = 5). 
B. Summarized data showing the effect of the NO• scavenger carboxy-PTIO  
(c-PTIO, 200 nM; n = 5), NO- scavenger L-cysteine (3 mM), NOS inhibitor  
L-NAME (100 µM) on the local and conducted dilatation to acetylcholine  
(10 µM), remained after the EDHF pathway was inhibited with the SKCa channel 
inhibitor apamin (apa, 50 nM) and IKCa channel inhibitor TRAM-34 (TR; 1 µM). 
 
Results are the mean ± s.e.mean. 
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7.4 Discussion 
The endothelium-dependent dilatation involves formation of NO in several redox 
forms, among which uncharged free radical state of the NO molecule and nitroxyl anion 
are present (Irvine et al., 2008). This study elucidates the contribution of K+ channels in 
NO- -mediated local and conducted responses in rat pressurized small mesenteric 
arteries.  
The nitroxyl donor, Angeli’s salt, evoked complete vasodilatation of pressurized 
arteries, with a lower pEC50 value than was reported in isometric conditions (in isobaric 
experiments pEC50∼5.1, whilst in wire myography pEC50 was between 7.0 and 7.7 
(Favaloro et al., 2009; Irvine et al., 2003a)). Its concentration-response curve, however, 
exhibited lack of difference to the obtained in response to NO•, which reveal 
comparable effects of both NO forms on the tone of pressurized resistance arteries. 
Despite evidence that NO- can be further transformed to NO• by tissue superoxide 
dismutases (Fukuto et al., 1993; Hobbs et al., 1994; Schmidt et al., 1996), the free 
radical scavenger carboxy-PTIO did not alter the relaxation to Angeli’s salt, whilst 
addition of the NO- scavenger L-cysteine markedly inhibited this response in our 
experiments as well as in previously published results (Ellis et al., 2000; Favaloro et al., 
2009; Wanstall et al., 2001).  
From resting conditions NO• was able to evoke hyperpolarization, which was 
sensitive to inhibition of KATP (Garland et al., 1992a) and KCa channels (Mistry et al., 
1998; Sampson et al., 2001). Although NO• did not repolarize (Garland et al., 1992a), or 
had a very modest repolarization of rat mesenteric arteries preconstricted with the α1-
adrenergic agonist (Favaloro et al., 2009), the NO- donor was able to repolarize PE- 
preconstricted arteries (Favaloro et al., 2009), demonstrating a different mechanism of 
modulation of membrane potential than NO•.  
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A role for endogenous NO- has recently been shown in rat mesenteric arteries, 
where it was able to hyperpolarize smooth muscle via activation of Kv channels 
(Andrews et al., 2009). In accordance to this, in our experiments 4-AP inhibited 
dilatation to the NO- donor, however, the BKCa channel inhibitors iberiotoxin or TEA 
attenuated Angeli’s salt-mediated relaxation to a similar degree as 4-AP. Co-application 
of BKCa and Kv channel inhibitors had an additive effect, whilst ODQ alone fully 
blocked the response. Precontraction (via depolarization) with high K+ also resulted in 
suppression of the dilatation. These results clearly demonstrate that NO- is modulating 
vascular tone via the soluble guanylyl cyclase-mediated activation of BKCa and Kv 
channels (Yuill et al., 2010). 
Apart from releasing EDRF, modulation of tone by the endothelium also occurs 
through providing a low-resistance pathway for a passive spread of hyperpolarizing 
current both longitudinally and radially via the myo-endothelial gap junctions (Dora, 
2001; Dora et al., 2003b; Takano et al., 2004; Yamamoto et al., 2001). This spread of 
hyperpolarization results in coordination of vasomotion over significant distances along 
the artery wall. The essential role for the endothelium in this process is proved by 
denudation, which abolishes both synchronized oscillations of tone (Mauban et al., 
2004) and conducted dilatation in rat mesenteric arteries (Garland et al., 2011; Takano 
et al., 2004).   
In PE- preconstricted arteries, oscillations of tone were markedly synchronized by 
the NO- donor, and this was not mimicked by NO• gas. Under basal conditions, 
vasomotion was also sensitive to NOS inhibition as well as to NO- scavenging, possibly, 
reflecting a modulating effect of basally released endogenous NO (Martin et al., 1986; 
Simonsen et al., 1999) or in response to Ca2+ incoming from smooth muscle cells (Dora 
et al., 2000; Kansui et al., 2008). It was shown that NO- mediates hyperpolarization and 
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relaxation solely via a ODQ-sensitive pathway, whilst NO•-evoked dilatation was less 
dependent on cGMP (Favaloro et al., 2009). This may be of importance since cGMP 
has been demonstrated to coordinate both smooth muscle [Ca2+]i oscillations and 
vasomotion in rat mesenteric arteries (Rahman et al., 2005). The fact that some 
asynchronous vasomotion still occurred during the inhibition of NO-cGMP pathway 
may refer to the importance of cGMP for synchronization of the vasomotion via 
coordination of current movement between the cells (Rahman et al., 2007), but not for 
the initiation of the smooth muscle Ca2+ oscillations (Mauban et al., 2004; Rahman et 
al., 2005). 
A positive effect of endogenous NO on conducted dilatation in response to focal 
application of ACh was shown for hamster cheek pouch arterioles, where inhibition of 
NOS resulted in reduction of the distance of spread (Doyle et al., 1997). Our 
experiments, however, demonstrate that L-NAME had no detectable effect on the 
conducted dilatation in rat mesenteric arteries (Figure 5.11B). Since stimulation of α1-
adrenoceptors (Nilsson et al., 1998) or TP receptors (Fujiwara et al., 1996) may 
moderately depolarize rat mesenteric arteries, this result might indicate that the cGMP 
pathway is amplifying electrical integration in depolarized conditions, whilst playing 
minimal role during spread of hyperpolarization in mesenteric arteries.  
On the other hand, NO•, when when released from an NO• donor, was not able to 
evoke conducted dilatation in both hamster and rat resistance arteries (Doyle et al., 
1997; Winter et al., 2007). In contrast to this, an NO- donor evoked conducted dilatation 
similar to that produced by ACh. Moreover, endogenous NO- was also capable of 
stimulating conducted dilatation. This effect may be explained by the fact that NO- can 
evoke sufficient hyperpolarization of smooth muscle (Favaloro et al., 2009; Irvine et al., 
2003a; Yuill et al., 2010), as other endothelium-dependent and independent stimuli that  
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Figure 7.11 Diagram illustrating signalling of eNOS during the conducted 
dilatation in response to ACh 
Rise in endothelial cell [Ca2+]i in response to stimulation of M3 receptor (yellow) 
evokes NO- production, which hyperpolarize underlying smooth muscle cells via 
soluble guanylyl cyclase (magenta) signalling. This hyperpolarization can spread 
via gap junctions (brown) to adjacent endothelial cell and propagate to the distant 
smooth muscle cells, leading to their dilatation via closure of LCa channels. 
 
led to conducted vasodilatation in this tissue (Garland et al., 2011; Takano et al., 2004; 
Winter et al., 2007). The degree of conducted response was not modified by KV and 
BKCa channels inhibition; however, it was minimised by endothelium denudation. 
Overall, this study demonstrates that NO- targets both KV and BKCa channels via 
activation of guanylyl cyclase in pressurized resistance arteries of rat. Moreover, NO- 
can be endogenously produced in sufficient amounts to modulate synchronization of 
vasomotion and evoke conducted vasodilatation. Despite being crucial for the local 
response, K+ channels do not seem to directly participate in the conducted dilatation to 
NO-, whilst the endothelium is needed to provide a pathway for the conduction of 
hyperpolarization produced by Kv and BKCa channels (Figure 7.11).   
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Chapter 8.  Future directions 
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8.1 Exploring mechanisms for inhibition of endothelium-dependent dilatation  
It is well known that β-adrenoceptors play an important role in the regulation of 
vascular tone (Guimaraes et al., 2001). We have demonstrated that β-adrenergic 
signalling can not only evoke local and distant dilatation, but also interfere with the 
endothelial muscarinic receptor signalling, reducing involvement of eNOS and IKCa 
channel in the dilatation to ACh, an effect that was not mimicked by the α-adrenoceptor 
agonists. This process may contribute towards the development of hypertension, since 
this disease is associated with an increased adrenaline/NA release (Berg et al., 2010; 
Dietz et al., 1982; Klemola et al., 1999; Kuklinska et al., 2010). In accordance to our 
data, it was demonstrated that treatment with β-adrenoceptor blockers helps to attenuate 
arterial blood pressure via reduction of vascular resistance and increase of NO 
availability (Berg et al., 2010; Buval'tsev et al., 2003; Gupta et al., 2008; Priviero et al., 
2007; Reiter, 2004; Wenzel et al., 2009), although the receptor subtype involved is not 
fully determined. Generally, inhibition of both β1 and β2-adrenoceptors has been 
demonstrated to decrease blood pressure in hypertensive rats, whilst β3-adrenoceptor 
inhibition was ineffective (Berg et al., 2010). However, a selective β1-adrenoceptor 
blocker nebivolol has been shown to lower blood pressure, improve endothelial function 
and NO production in human (Buval'tsev et al., 2003) and rat (Wang et al., 2010), 
whilst other β1-adrenoceptor blockers, atenolol and metoprolol reduced blood pressure 
without improving endothelial function (Heffernan et al., 2011). The difference between 
nebivolol and other β-adrenergic antagonists may lay in the ability of nebivolol to 
activate endothelial β3-adrenoceptors that can stimulate eNOS (Dessy et al., 2005). On 
the other hand, not only nebivolol, but also the selective β2-adrenoceptor blocker         
ICI 118 551 reduced pulmonary vasoconstriction via activation of the NO pathway 
(Wenzel et al., 2009). It is important to remember, though, that the effects of β-blockers 
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studied in vivo are attributed not only to the action on vascular adrenoceptors, but also 
on neuronal and cardiac adrenoceptors. Thereby it seems attractive to elucidate the 
effects of subtype-specific β-adrenergic agonists and antagonists on the inhibition of the 
endothelium-dependent dilatation in isolated arteries.  
An important question arises regarding the localization of β-adrenoceptors. The 
fact that abluminal application of adrenaline resulted in a smaller shift of the 
concentration response curve to ACh than luminal perfusion may indicate that β-
adrenoceptors responsible for the inhibition are located close to the arterial intima. 
There are several pieces of evidence demonstrating that of β-adrenoceptors can be 
expressed by endothelial cells (Broeders et al., 2000; Daly et al., 2010), although some 
of these results can be argued due to the poor selectivity of commercially available 
antibodies (Pradidarcheep et al., 2009). A perspective approach of investigation of the 
receptor localization may give an adrenergic ligand labelled with fluorescent dye, such 
as BODIPY TMR-CGP 12177 (Briones et al., 2005),  
Another direction of future studies may lay in the area of establishing of the 
downstream signalling molecules that participate in the inhibition of the dilatation to 
ACh by β-adrenoceptor stimulation. It is clear that adenylyl cyclase is involved in the 
process since forskolin mimicked the effect of the β-adrenergic agonists, however, 
cAMP can activate PKA and Epac, both of which were shown to be capable to stimulate 
PKC (Duquesnes et al., 2010; Wooten et al., 1996), therefore selective PKA and Epac 
antagonist may be employed to examine this pathway. 
We have also shown that the β-adrenergic inhibition of the ACh-mediated 
dilatation partly involves activation of COX. On the other hand, contribution of this 
enzyme in responses to isoprenaline was augmented in old and hypertensive rats. This 
may lead to an enhanced β-adrenergic inhibition of the endothelium-dependent 
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dilatation. In agreement to this hypothesis, our preliminary experiments performed in 
arteries from 6 months old rats revealed a greater isoprenaline-mediated shift of the 
ACh CRC than in 12 week old animals (from pEC50 = 7.23 ± 0.05 to pEC50 = 6.23 ± 
0.05, n = 4; Figure 8.1), although arteries from SHRs were not tested yet. Evidence that 
reduced blood plasma NO levels in SHRs is restored by β-adrenoceptor blockers (Wang 
et al., 2010), whilst COX signalling in this strain is usually increased (Feletou et al., 
2010b), makes it feasible that β-adrenergic inhibition of the endothelium-dependent 
dilatation may be also augmented in hypertensive rats due to enhanced prostanoid 
formation. 
All prostanoids are able to activate TP receptor (Feletou et al., 2010a), and the 
signalling pathway involves PKC (Perez-Vizcaino et al., 1997; Zhang et al., 2010). 
Both TP receptor (Feletou et al., 2010b) and PKC (Johnsen et al., 2005) are implicated 
in cardiovascular pathogenesis; however, whether this receptor is responsible for the β-
adrenoceptor-mediated inhibition of the dilatation to ACh and which prostanoid may be 
involved is not yet known. It is also of interest to elucidate if other agonists that activate 
PKC exhibit similar inhibitory action on the dilatation to ACh, as β-adrenergic agonists 
do. Endothelin-1 and angiotensin II were shown to activate PKC in rat mesenteric 
arteries (Rainbow et al., 2009). So far we have tested endothelin-1, -3, and angiotensin 
II, and discovered a significant shift of the ACh CRC when the agonists were luminally 
perfused (Figure 8.2). Interestingly, whilst endothelin-3 had a similar effect regardless 
luminal or abluminal application, endothelin-1 exhibited a greater inhibition of the 
dilatation when applied in bath, indicating impairment of the smooth muscle reactivity 
rather than endothelial dysfunction in response to endothelin-1. Whether the inhibition 
of the dilatation to ACh by endothelin-1, endothelin-3, and angiotensin II employ 
similar pathway as the β-adrenergic agonists, may be revealed in ongoing studies. 
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Figure 8.1 Effect of luminal isoprenaline perfusion on the dilatation to ACh in 
pressurized small mesenteric arteries from 6 months old rats 
Averaged data demonstrating an effect of luminal perfusion of isoprenaline  
(1 µM; n = 4) followed by NOS suppression with L-NAME (100 µM; n = 3), and 
SKCa channel inhibition by apamin (50 nM; n = 3) on the dilatation to ACh. Whilst  
L-NAME had no effect, apamin suppressed the remaining dilatation. 
 
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
 
 
Anoher endothelium-dependent dilatation pathway, which may be affected by the 
augmented PKC signalling, is the dilatation mediated by purinergic receptor activation. 
We have recently demonstrated that PKC is involved in the desensitization of the 
endothelial P2Y1 receptor, resulting in a decreased amplitude and duration of the 
dilatation (Figure 8.3) (Rodriguez-Rodriguez et al., 2009). Thereby it seems relevant to 
study if β-adrenergic signalling can amplify the desensitization of endothelial purinergic 
receptors.  
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Figure 8.2 Effects of endothelin-1, endothelin-3 and angiotensin II on the 
dilatation to ACh of pressurized small mesenteric arteries of rat 
A. Summarized concentration-response curves representing effects of luminal 
(lum; 10 nM) or abluminal (bath; 1 nM - 10 nM) application of endothelin-1 (ET-
1) on the dilatation to ACh (1 nM-10 µM).  
B. Summarized data showing effects of luminal (100 nM) or abluminal (30 nM -
300 nM) application of endothelin-3 (ET-3).  
C. Summarized data showing effects of luminal application of angiotensin II (Ang 
II; 10 nM).  
Results shown are the mean ± s.e.mean; *p<0.05, **p<0.01, ***p<0.001 vs. 
control. 
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Figure 8.3 Effect of PKC inhibition on the local dilatation to ADPβS in 
pressurized rat mesenteric arteries 
A. Averaged traces illustrating time course of the concentration-dependent 
dilatation to the luminal perfusion of ADPβS (100 nM-3 µM) in control.  
B. Averaged traces demonstrating effect of PKC inhibitor BIS-1 (1 µM) on the 
concentration-dependent dilatation to luminal perfusion of ADPβS.  
C. Summarized data of the effect of BIS-1 on the dilatation to ADPβS taken at 
five minutes after the start of luminal perfusion of ADPβS.  
Results shown are the mean ± s.e.mean; ***p<0.001 vs. control.  
(Data modified from Rodriguez-Rodriguez et al., 2009). 
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8.2 Exploring pathways of the β-adrenergic-mediated COX activation  
Our experiments demonstrated a prominent indomethacin-sensitive component of 
the response to β-adrenergic agonists that led to suppression of the dilatation in old and 
hypertensive rats. Despite the dilatation of the mesenteric arteries from young SHRs did 
not exhibit a significant difference in comparison to control normotensive rats 
(Blankesteijn et al., 1996), membrane potential measurements have shown an impaired 
hyperpolarization to isoprenaline in mesenteric arteries from not only old (Fujii et al., 
1999), but also young SHRs (Goto et al., 2001), demonstrating that β-adrenergic 
hyperpolarization may be defective before the development of altered functional 
response. Therefore it seems worth clarifying whether COX participates in the reduction 
of the hyperpolarization in both age and disease groups.   
The mechanisms of how β-adrenergic signalling can lead to stimulation of COX 
are not yet clarified. Whilst COX is unlikely to be directly phosphorylated by PKC or 
PKA (Vezza et al., 1996), enhanced signalling may result from augmentation of COX 
expression (Choudhary et al., 2004; Steinert et al., 2009) as well as in response to 
[Ca2+]i rise (Tang et al., 2007). We have preliminary data showing that application of 
isoprenaline evoked increase in number of endothelial cells that displayed Ca2+ 
transients (in control, 25.3±3.8%, n = 4, whilst after 10 minutes of isoprenaline pre-
incubation  47.1 ± 7.2%, n = 4, cells had Ca2+ transients; Figure 7.4A). Whether this 
transients were the consequence of endothelial or smooth muscle β-adrenoceptor 
signalling is not clear yet, however, inhibition of phospholipase C by U73122 (1 µM) 
suppressed the response (n = 1), suggesting the involvement of Epac (Schmidt et al., 
2001). Intriguingly, Ca2+ transients in response to isoprenaline were also suppressed by 
the NCX inhibitor benzamil (50 µM; 4.7 ± 4.7% cells had Ca2+ transients, n = 3). This 
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observation may be explained by the observation that NCX can be up-regulated by both 
PKA (Zhang et al., 2009b) and PKC (Harper et al., 2010), enhancing Ca2+ influx.  
It is worth considering also that COX exerts its actions via metabolising 
arachidonic acid, which is produced by phospholipase A. Thereby, we may speculate 
the potential involvement of the arachidonic acid pathway, which is supported by 
several facts. First, it was shown that stimulation of β-adrenoceptors leads to release of 
arachidonic acid in rat hearts (Neuman et al., 2002) as well as in human monocytes 
(Borda et al., 1998); second, PLA can be activated by PKC (Xing et al., 1992), a 
possible downstream enzyme of adenylyl cyclase signalling (Duquesnes et al., 2010; 
Wooten et al., 1996); third, PLA was shown to be overactivated (Kato et al., 1992) and 
participate in the EDCF release in SHRs (Wong et al., 2010). Therefore, it may be 
possible that raised arachidonic acid levels in response to Gs-protein coupled receptor 
stimulation are involved in the release of COX metabolites and development of 
hypertension. 
Apart from COX, arachidonic acid can be metabolized by other enzymes, such as 
cytochrome P450 epoxygenases, which results in generation of EETs. EETs can exert 
diverse actions on vascular function, among which is the action as an endogenous 
antagonist for TP receptor in rat arteries (Behm et al., 2009) as well as inhibition of 
COX-2 in rat monocytes (Kozak et al., 2003). On the other hand, a recent publication 
has highlighted a beneficial effect of cytochrome P450 epoxygenases expression on the 
prevention of hypertension development in hypertensive rat model (Xiao et al., 2010). 
All these lines of evidence may help to explain not only the effect of EETs in the 
reduction of inflammation (Behm et al., 2009), but also contribute to the evaluation of 
pathways that lead to altered COX signalling and may underlay endothelial dysfunction.  
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Figure 8.4 Effects of PLC and NCX inhibition on the isoprenaline -mediated 
rise in the EC [Ca2+]i  of pressurized small mesenteric arteries of rat 
A. Representative trace of fluorescence intensity changes (F/F0) of endothelial 
cells loaded with Oregon Green 488 BAPTA-1 AM in response to isoprenaline 
(1 µM) and ACh (1 µM). Responses of individual cells are shown with grey 
lines; average intensity is represented by a thick black line. 
B. Effect of the PLC inhibitor U73122 (1 µM) on the [Ca2+]i rise in response to 
isoprenaline and ACh. 
C. Effect of the NCX inhibitor benzamil (50 µM) on the [Ca2+]i  changes in 
response to isoprenaline and ACh. 
0 50 100 150 200 250
0.5
1.0
1.5
2.0
1 μM Isoprenaline 1 μM ACh
Benzamil
258 308
Time (s)
F/
Fo
 187
Chapter 9.   Conclusions 
 
The study presented within this thesis aimed to evaluate the role of the 
endothelium in local and distant regulation of vascular tone following activation of 
endothelium-dependent and -independent signalling pathways. 
Firstly, we have examined whether the endothelium participates in the dilatation to 
physiological adrenergic agonists, adrenaline and NA. It has been suggested for several 
arterial beds that β-adrenergic signalling can lead to NO production and thereby the 
endothelium may directly facilitate the resulting dilatory response (Ferro et al., 2004; 
Figueroa et al., 2009b). Our results, however, demonstrate that the endothelium does 
not directly participate in the local dilatation to β-adrenoceptor agonists by release of 
NO or EDHF. Moreover, the endothelium was implicated in the reduction of the 
dilatation, seemingly, by activation of COX. Stimulation of TP receptors also 
suppressed β-adrenoceptor signalling, suggesting that COX products may act on TP 
receptors. Experiments performed on 6 months old and hypertensive animals revealed 
exaggerated COX-mediated inhibition of the dilatation to β-adrenoceptor agonists, 
providing an insight to the possible mechanisms of the vascular dysfunction 
development observed during aging and hypertension.  
It was demonstrated also that the endothelium restricted luminally applied 
adrenergic agonists from acting on vascular β-adrenoceptors, indicating that endothelial 
cells are the first to come into contact with adrenergic agonists carried by blood in vivo. 
The fact that endothelial cells do express adrenoceptors (Briones et al., 2005) may 
provide an additional regulatory mechanism of endothelial cell signalling. One of the 
key findings of this study reveals the pathway of NA/adrenaline-mediated reduction of 
the local dilatation to ACh. The main role seems to belong to β-adrenoceptors, which 
through activation of adenylyl cyclase eliminate eNOS- and IKCa channel-dependent 
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components of the dilatation. Additionally, a role for PKC and COX was suggested. 
This result may be extrapolated to certain cardiovascular diseases associated with high 
plasma NA/adrenaline levels and reduced endothelium-dependent dilatation.  
Activation of endothelial muscarinic receptors by local application of ACh evoked 
prominent conducted dilatation. This phenomenon depended on the integrity of 
endothelium as well as functional K+ channels that were activated during EDHF or NO- 
signalling, indicating that the predominant vasodilator stimuli that propagated along the 
vessel wall, was the hyperpolarization. Additionally, despite attenuating the local 
dilatation, TP and β-adrenergic receptor agonists enhanced the conducted dilatation. 
Another major finding of the present work was the discovery of the ability of 
endothelium-independent agonists, adrenaline and NA, to evoke conducted dilatation 
that spreads along the vessel wall similar to the dilatation in response to endothelium-
dependent agonist ACh. The main role belonged to classical β-adrenoceptors, whereas 
activation of α-adrenoceptors alone did not cause the conducted response. This result 
provides a physiological relevance to the described previously ability of levcromakalim 
to evoke conducted dilatation (Takano et al., 2004): although KATP channels did not 
contribute significantly to the local response, they were essential for the spreading 
dilatation. Importantly, whilst the endothelium served to reduce the β-adrenergic 
dilatation, it was crucial for the propagated response.  
Lastly, it was herein demonstrated that apart from NO•, the endothelium can also 
endogenously produce NO- in amounts sufficient to modulate synchronization of 
vasomotion and evoke conducted dilatation. This dilatation was enabled by guanylyl 
cyclase-mediated opening of KV and BKCa channels, and, again, the endothelium was 
needed to provide a pathway for the hyperpolarization produced by K+ channels.   
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Overall, the results described in this thesis reveal the role of the endothelium in 
regulation of not only local arterial tone, by release of EDCF, EDHF, NO-, and NO•, but 
also tone of remote smooth muscle cells, via providing a pathway for a conducted 
vasodilatory signal (presumably, hyperpolarization). Dysfunction of the endothelium, 
which may develop in response to raised plasma catecholamine levels, may help to 
understand the precursors leading to development of hypertension.  
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